Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

2019

Generating Biologic and Genetic Research Tools to Investigate
Serotype I Feline Coronaviruses
Robert Christian Mettelman

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Virology Commons

Recommended Citation
Mettelman, Robert Christian, "Generating Biologic and Genetic Research Tools to Investigate Serotype I
Feline Coronaviruses" (2019). Dissertations. 3354.
https://ecommons.luc.edu/luc_diss/3354

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2019 Robert Christian Mettelman

LOYOLA UNIVERSITY CHICAGO

GENERATING BIOLOGIC AND GENETIC RESEARCH TOOLS TO
INVESTIGATE SEROTYPE I FELINE CORONAVIRUSES

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

PROGRAM IN MICROBIOLOGY AND IMMUNOLOGY

BY
ROBERT CHRISTIAN METTELMAN
CHICAGO, ILLINOIS
AUGUST 2019

Copyright by Robert Christian Mettelman, 2019
All rights reserved.

ACKNOWLEDGMENTS
I would like to start by thanking my wife, Elizabeth, my parents, Doug and Laura,
my parents-in-law, Jim and Anna, my brothers, William and Matthew, and my sister-inlaw, Mary Catherine. Each of you have given me your own unique support throughout
my education and your continuous encouragement has been a solid foundation to lean
on at difficult steps along the way.
I owe tremendous gratitude to my mentor, Dr. Susan C. Baker, for giving me the
opportunity to learn and develop as a scientist in her lab and for her guidance in all
aspects of science and otherwise. You encouraged me to follow my own scientific
interests, while keeping me focused and productive, and cultivated a collegial and
supportive lab environment. I am so grateful to all members of the Baker lab including
Dr. Anna Mielech, Dr. Xufang Deng, Dr. Amornrat O’Brien, Matt Hackbart, Amani
Eddins, Aaron Volk, and Yazmin Cruz Pulido who have been colleagues, reviewers, coauthors, mentors and friends. All of you helped me develop and refine my technical
skills and showed me new ways of thinking about and approaching scientific questions.
Additionally, I am very grateful to our collaborators including the groups of Drs. Andy
Mesecar, Gary Whittaker, Justin Harbison, Christian Drosten and Gergely Tekes who
opened up new avenues of research and expertise and made this dissertation research
possible.
I would like to thank the individual members of my dissertation committee
including Drs. Francis Alonzo III, Ed Campbell, Tom Gallagher and Seth Robia for your
iii

helpful discussions, guidance and generosity with your time. These sentiments are true
of the greater Loyola community as well, and I would like to thank Dr. Katherine Knight,
all the students, postdocs, technicians, faculty and members of the front office in the
Department of Microbiology and Immunology. The friendly yet academic environment in
the department allowed me to not only develop as an investigator, but also as an
educator and communicator of science. You all made coming to lab a fun, productive
and intellectually rewarding experience.
Furthermore, I would like to thank my previous mentors including Drs. Arijit
Mukherjee, Jean-Michel Ané, Bruce Klein, Tom Sullivan, and Alana Sterkel for
cultivating my interest in scientific research, teaching me how to use a pipette and for
giving me the opportunity to develop as a young scientist.
Finally, I would like to thank all of my funding sources including the Arthur J.
Schmitt Dissertation Fellowship in Leadership and Service, the Winn Feline Foundation
Grant awarded through the Bria Fund for FIP Research, the Intramural Grant awarded
by the Research Funding Committee of Loyola University Chicago, the NIH T32
Training Grant in Experimental Immunology awarded to Dr. Katherine L Knight, and the
NIH R01 awarded to Dr. Susan C. Baker.

iv

For Libby and the tremendous amount of support, patience, and
good humor you sustained to complete this journey with me.

I now have additional questions…
– Sentiment expressed in the Baker Lab

TABLE OF CONTENTS
ACKNOWLEDGMENTS ................................................................................................. iii
LIST OF TABLES ........................................................................................................... xi
LIST OF FIGURES ........................................................................................................ xii
LIST OF ABBREVIATIONS .......................................................................................... xiv
ABSTRACT ................................................................................................................. xxiii
CHAPTER ONE: INTRODUCTION ............................................................................... 24
The Biology of Coronaviruses .................................................................................... 24
Overview and Classification .................................................................................... 24
Genome Organization ............................................................................................. 25
Virion Structure ....................................................................................................... 29
The coronavirus virion .......................................................................................... 29
Spike protein ........................................................................................................ 30
Envelope protein .................................................................................................. 31
Membrane protein ................................................................................................ 32
Nucleocapsid protein ............................................................................................ 33
Hemagglutinin-esterase ....................................................................................... 33
Replication Cycle .................................................................................................... 36
Overview .............................................................................................................. 36
Attachment and entry ........................................................................................... 37
Replicase protein translation, processing and formation of the replicasetranscription complex (RTC) ............................................................................. 39
RNA replication and transcription ......................................................................... 42
Virion assembly and release ................................................................................ 45
Innate Immune Responses to RNA Virus Infection .................................................... 46
Overview ................................................................................................................. 46
Detection of RNA Viruses by Host Sensors ............................................................ 47
Retinoic-acid inducible gene-like receptors (RLRs) ............................................ 48
Toll-like receptors (TLRs) ..................................................................................... 50
NOD-like receptors (NLRs) ................................................................................. 51
Interferons and the Antiviral Effects of Interferon-stimulated Genes ....................... 52
Interferons ............................................................................................................ 52
Antiviral activity of interferon-stimulated genes (ISGs) ........................................ 55
Negative Regulators of Interferon Synthesis and Signaling .................................... 59
Coronavirus-encoded Antagonists of Type I Interferon .............................................. 60
Overview ................................................................................................................. 60
Antagonism of the Interferon Pathway: Synthesis, Signaling and ISG Activity ....... 62
Synthesis .............................................................................................................. 62
Signaling and activity of interferon-stimulated genes (ISGs) ............................... 64
Experimental Examples of Highly Conserved Coronavirus Interferon
vii

Antagonists .......................................................................................................... 66
The feline coronavirus papain-like protease is an IFN antagonist ........................ 66
Nonstructural protein 15 is a potent antagonist of type I interferon ...................... 69
Final section remarks ........................................................................................... 72
Feline Coronaviruses ................................................................................................. 72
Classification and Categorization ............................................................................ 72
Historical Significance ............................................................................................. 74
Biotypes ................................................................................................................... 75
The Internal Mutation Theory .................................................................................. 77
Serotypes ................................................................................................................ 81
FIPV Pathogenesis and FIP Clinical Features ........................................................ 83
T and B Cell Responses and Effects on FIP Progression ....................................... 85
Current Therapeutic Options ................................................................................... 88
The Challenges and Value to Investigating Serotype I Feline Coronavirus ............... 91
Overview ................................................................................................................. 91
Virus Isolation and Strain Variation ......................................................................... 92
Permissive Cell Types ............................................................................................. 97
Objective of Dissertation Research ....................................................................... 100
CHAPTER TWO: MATERIALS AND METHODS ........................................................ 102
Viruses and Cells ..................................................................................................... 102
Viruses .................................................................................................................. 102
HEK 293T and 293T/17 Cells ................................................................................ 102
Felis catus Whole Fetus (Fcwf-4) ATCC Cells ...................................................... 103
Felis catus Whole Fetus (Fcwf-4) Cornell University Cells .................................... 103
Generation and Maintenance of Fcwf-4 CU IRN Cells .......................................... 104
Feline Airway Epithelial (AK-D) Cells .................................................................... 107
Generation and Maintenance of AK-D 2.2 (IFNαR-disrupted) Population............. 108
Felis catus Bone Marrow-derived Macrophages (fBMDMs) .................................. 108
Mycoplasma Detection and Removal from Tissue Culture ................................... 109
FIPV PLP2 Functional Assays ................................................................................. 109
Transcleavage Assay ............................................................................................ 109
Deubiquitinase (DUB) and DeISGylase Assays .................................................... 110
IFN Antagonism Assay .......................................................................................... 111
Plaque Assay ........................................................................................................... 112
Virus Growth Kinetics ............................................................................................... 113
Evaluating Virus Titers from Cell-free and Cell-associated Samples ....................... 113
Type I Interferon Responsiveness Assay ................................................................. 114
Immunofluorescence Detection of FIPV Nucleocapsid Protein ................................ 115
Morphologic Staining ................................................................................................ 115
Cloning and Expression of Feline TMPRSS2 in Fcwf-4 CU IRN Cells ..................... 116
Determining IFNαR2 Expression and Amplicon Melt Temperature.......................... 119
Detecting FIPV N Gene in FIPV-infected Fcwf-4 CU IRN Cells Expressing
TMPRSS2 ............................................................................................................. 120
Reverse Genetics Methods ...................................................................................... 121
Genomic RNA Isolation from FCoV Virions ........................................................... 121
viii

Deep-sequencing, Cloning and Modification of a Laboratory Strain of FIPV
Black ................................................................................................................... 121
Assembly of Full-length FIPV Black Infectious Clone cDNA ................................. 124
Full-length Ligation Junction PCR ......................................................................... 126
In Vitro Transcription and RNA Electroporation .................................................... 126
Detection of FIPV Black N Gene Subgenomic RNA.............................................. 128
Generation of Figures, Graphics, Tables and Reference Management ................... 129
CHAPTER THREE: EXPERIMENTAL RESULTS ...................................................... 130
Section 1: Characterizing Replication Kinetics and Plaque Production of
Serotype I Feline Infectious Peritonitis Virus in Three Feline Cell Lines ............... 130
Rationale ............................................................................................................... 130
Results .................................................................................................................. 131
Type I FIPV Black replication kinetics vary between feline cell types ................ 131
AK-D and Fcwf-4 CU cells facilitate rapid and consistent plaque assays for
FIPV Black ....................................................................................................... 135
Fcwf-4 CU cells are distinct in morphology and IFN-responsiveness ................ 138
Fcwf-4 CU cells replicate both biotypes of type II FCoV .................................... 141
Section 2: Generation of Feline Cell Lines to Study Attenuated or Clinicallyimportant FCoV Strains ......................................................................................... 143
Rationale ............................................................................................................... 143
Results .................................................................................................................. 145
Evaluating the interferon response in AK-D and IFNαR2-deficient AK-D 2.2
cells ................................................................................................................. 145
Evaluating growth kinetics of serotype I FIPV Black in AK-D 2.2 cells ............... 147
Determining the utility of AK-D 2.2 cells in visualizing FIPV Black plaques ....... 149
Evaluating the IFN-responsiveness and FIPV Black replication kinetics in a
clone of Fcwf-4 CU 2.2 Poly cells .................................................................... 152
Determining how IFN signaling is disrupted in Fcwf-4 CU IRN cells .................. 155
Expression of feline TMPRSS2 improves FIPV Black replication ...................... 157
Section 3: Progress Toward Developing an Infectious Clone Reverse Genetics
System of Serotype I FIPV Black .......................................................................... 160
Rationale ............................................................................................................... 160
Results .................................................................................................................. 162
Designing, constructing and evaluating a contiguous plasmid reverse
genetics system of FIPV Black ........................................................................ 162
Generation and detection of a wild-type infectious clone FIPV Black ................ 171
CHAPTER FOUR: DISCUSSION ............................................................................... 173
Summary and Implications ....................................................................................... 173
Overview ............................................................................................................... 173
Characterizing Replication Kinetics and Plaque Production of Serotype I Feline
Infectious Peritonitis Virus in Three Feline Cell Lines ........................................ 174
Summary ............................................................................................................ 174
Implications ........................................................................................................ 174
Generation of Feline Cell Lines to Study Attenuated or Clinically-important
ix

FCoV Strains ...................................................................................................... 178
Summary and implications ................................................................................. 178
Progress Toward Developing an Infectious Clone Reverse Genetics System of
Serotype I FIPV Black ........................................................................................ 186
Summary ............................................................................................................ 186
Implications ........................................................................................................ 187
Final Thoughts .......................................................................................................... 191
APPENDIX A: ANTIBODIES USED TO DETECT FELINE CORONAVIRUS ............. 193
APPENDIX B: PRIMER INDICIES .............................................................................. 196
APPENDIX C: FIPV BLACK LABORATORY SEQUENCE ......................................... 200
APPENDIX D: FELINE IFNAR2 SEQUENCING ALIGNMENT ................................... 211
REFERENCE LIST ..................................................................................................... 213
VITA

......................................................................................................................... 250

x

LIST OF TABLES
Table 1. Coronavirus Entry Receptors. ......................................................................... 32
Table 2. Coronavirus Nonstructural Proteins and Associated Functions. ..................... 41
Table 3. Type I Interferon Stimulated Genes and Antiviral Activities. ........................... 56
Table 4. Coronaviruses and Encoded Antagonists of the Type I IFN System ............. 62
Table 5. Feline Coronavirus Biology. ............................................................................ 73
Table 6. Feline Coronavirus Strains .............................................................................. 94
Table 7. Cell Types Permissive to FIPV Infection ......................................................... 97
Table 8. FIPV cDNA Sub-cloning, Fragments and Restriction Digest Junctions ........ 166

xi

LIST OF FIGURES
Figure 1. Phylogenetic Classification of Orthocoronavirinae Subfamily ......................... 25
Figure 2. Feline Coronavirus Genome Organization, Replicase Processing
and Subgenomic mRNAs ................................................................................ 27
Figure 3. The Coronavirus Virion. .................................................................................. 30
Figure 4. The Coronavirus Replication Cycle ................................................................. 35
Figure 5. Model for Discontinuous Negative-strand Transcription ................................. 44
Figure 6. FIPV PLP2 is a Multifunctional Enzyme and IFN Antagonist .......................... 69
Figure 7. EndoU Mutant MHV Stimulates IFN and Protective Immunity in Mice ........... 71
Figure 8. Fcwf-4 Cornell University (CU) Cells Produce High Titers of Cell-free
Type I FIPV with Rapid Growth Kinetics ....................................................... 133
Figure 9. FIPV Black-induced Cell Cytopathic Effect Varies Between Infected Cell
Types ............................................................................................................ 135
Figure 10. Evaluating FIPV Black Plaque Development and Titer Over Time in
Different Feline Cell Lines ........................................................................... 137
Figure 11. Fcwf-4 CU Cells Differ in Morphology and IFN-responsiveness From
Fcwf-4 ATCC ............................................................................................... 140
Figure 12. Fcwf-4 CU Cells and are Permissive to Both Biotypes of Type II FCoV ..... 142
Figure 13. AK-D 2.2 Cells Exhibit Diminished Response to Type I IFN ....................... 147
Figure 14. Characterization of Replication Kinetics and Cell Association of FIPV
Black in AK-D 2.2 Cells ............................................................................... 149
Figure 15. AK-D 2.2 Cells Can Be Used to Determine Serotype I FIPV Titer .............. 151
Figure 16. Fcwf-4 IRN Cells Have Reduced IFN-responsiveness and Replicate
FIPV Black to High Titer .............................................................................. 154
xii

Figure 17. Fcwf-4 IRN Cells Encode a Shortened, Null Mutant IFNαR Protein ........... 156
Figure 18. Feline TMPRSS2 Improves FIPV Black Replication in Fcwf-4 IRN Cells ... 159
Figure 19. FIPV Black Infectious Clone Reverse Genetics Schematic ........................ 164
Figure 20. Experimental Evaluation of FIPV Reverse Genetics Steps ........................ 168
Figure 21. FIPV gRNA Electroporation Produces Infectious Virus in Fcwf-4 CU
and IRN Cells .............................................................................................. 170
Figure 22. FIPV Infectious Clone Produces Syncytial CPE and N gene
Subgenomic RNA ........................................................................................ 172
Figure 23. Dual Mechanisms of CoV Entry .................................................................. 184

xiii

LIST OF ABBREVIATIONS
(-)

negative-sense

(+)

positive-sense

2.2

second target, second exon of the feline ifnαr2

2.2 Poly

Fcwf-4 CU IFNαR 2.2 polyclonal population

2' 5'-OAS

2'5'-oligoadenylate synthase

3CLpro

3C-like protease

Ac

acidic domain

ACE2

angiotensin converting enzyme 2

ADCC

antibody-dependent cell-mediated cytotoxicity

ADE

antibody-dependent enhancement

AmpR+

ampicillin resistance cassette positive

APN

aminopeptidase N

ATCC

American Type Culture Collection

BAFF

B cell activating factor

BMDM

bone marrow-derived macrophages

bp

base pair

C

capacitance

CARD

caspase activation and recruitment domains

Cardif

CARD adapter-inducing interferon beta

xiv

CCL

chemokine ligand

CCoV

canine coronavirus

cDC

conventional dendritic cell

CI

clinical isolate

CMI

cell-mediated immunity

CoV

coronavirus

CPE

cytopathic effect

CRFK

Crandell Rees feline kidney

Crispr

clustered regularly interspaced short palindromic repeats

CTD

carboxy-terminal domain

CU

Cornell University

CXCL

chemokine CXC-motif ligand

DAMP

danger-associated molecular patterns

DC

dendritic cell

DC-SIGN

dendritic cell-specific ICAM-3-grabbing non-integrin

DMEM

Dulbecco's modified Eagle medium

DMV

double-membrane vesicle

DNA

deoxyribonucleic acid

DPI

days post-infection

DPP4

dipeptidyl peptidase 4

DPUP

domain preceding UBL2 and PLP2

ds

double-stranded

DUB

deubiquitinase

xv

E

envelope

EAV

equine arteritis virus

eIF

eukaryotic initiation factor

EMEM

minimal essential medium Eagle

EndoU

endoribonuclease

ER

endoplasmic reticulum

ERGIC

reticulum-Golgi intermediate compartment

EV

empty vector

ExoN

exoribonuclease

f

feline

FADD

fas-associated death domain

FBS / FCS

fetal bovine serum / fetal calf serum

FCoV

feline coronavirus

FcR

Fc receptor

Fcwf-4

felis catus whole fetus 4

FECV

feline enteric coronavirus

FeLV

feline leukemia virus

FF

firefly luciferase

FIP

feline infectious peritonitis

FIPV

feline infectious peritonitis virus

g

g-force (m/s2)

G2M

coronavirus group 2 marker

GM-CSF

granulocyte monocyte cell stimulating factor

xvi

gRNA

genomic RNA

h

hour

HCoV

human coronavirus

HE

hemagglutinin-esterase

HEK

human embryonic kidney

HEK 293T/17

human embryonic kidney 293T clone 17

HII

hyper interferon-inducing

HIS

hyper interferon-sensitive

HP

high-passage

HPE

hours post-electroporation

HPI

hours post-infection

HR

heptad repeat

HRP

horseradish peroxidase

IBV

Infectious bronchitis coronavirus

ic

infectious clone

IC50

fifty-percent inhibitory concentration

ICTV

International Committee on Taxonomy of Viruses

IFIT

IFN-induced proteins with tetratricopeptide repeats

IFITM

IFN-induced transmembrane proteins

IFN

interferon

IFNαR

interferon alpha receptor

IFNαR2

interferon alpha receptor domain 2

Ig

immunoglobulin

xvii

IL

interleukin

IPS-1

interferon beta promoter stimulator protein 1

IRAK

interleukin 1 receptor associated kinase

IRF

interferon regulatory factor

IRN

IFNα receptor null

ISG

interferon-stimulated gene

ISRE

interferon-stimulated response elements

Jak

Janus kinase

KanR+

kanamycin resistance cassette positive

kb

kilobase

kDa

kilo Dalton

L

leader

LGP2

laboratory of genetics and physiology 2

LP

low-passage

LTR

long terminal repeat

Luc

luciferase

M

membrane protein; molar

M-CSF

monocyte cell stimulating factor

MAVS

mitochondrial antiviral signaling protein

mCEACAM

murine carcinoembryonic antigen-related cell adhesion molecules

MDA5

melanoma differentiation-associated gene 5

MEM

minimal essential medium

MERS-CoV

Middle East respiratory syndrome coronavirus

xviii

MHC

major histocompatibility complex

MHV

mouse/murine hepatitis virus

min

minute

mL

milliliter

mM

millimolar

MOI

multiplicity of infection

Mpro

main protease

mRNA

messenger RNA

MTase

methyltransferase

MyD88

myeloid differentiation factor 88

N

nucleocapsid; amino-terminal

NAB

nucleic-acid binding domain

Neu 5,9 Ac2

5-N-acetyl-9-O-acetylneuraminic acid

NF𝜅B

nuclear factor kappa-light-chain-enhancer of activated B cells

ng

nanograms

NK

natural killer

NLR

nucleotide-binding oligomerization domain like receptors

NPC1

Niemann-Pick C1

nsp

nonstructural protein

nt

nucleotide

NTD

amino-terminal domain

o

degrees Celsius

C

ORF

open reading frame

xix

PAMP

pathogen-associated molecular pattern

PBMC

peripheral blood mononuclear cells

PCR

polymerase chain reaction

pDC

plasmacytoid dendritic cell

PEI

polyethylenimine

PFU

plaque-forming units

PKR

protein kinase R

PLP1

papain-like protease 1

PLP2

papain-like protease 2

pmol

picomole

poly (A)

poly adenosine

poly (U)

poly uridylate

pp

polyprotein

PRR

pattern recognition receptor

qPCR

quantitative PCR

R

Resistance domain

RBD

receptor binding domain

RD

repressor domain

RdRp

RNA-dependent RNA polymerase

Rev Gen

reverse genetics

RFS

ribosomal frameshift

RIG-I

retinoic acid-inducible gene 1

RIP1

receptor interacting protein 1

xx

RL

renilla luciferase

RLR

retinoic acid-inducible gene I-like receptors

RNP

ribonucleoprotein

RT-PCR

reverse-transcription PCR

RTC

replicase-transcriptase complex

S

spike

s

second

SARS-CoV

severe acute respiratory syndrome coronavirus

sgRNA

subgenomic RNA; short-guide RNA

SPF

specific pathogen-free

ss

single-stranded

STAT

signal transducer activator of transcription

STING

stimulator of interferon genes

SUD

SARS-CoV unique domain

TC

tissue culture

TCID50

fifty-percent tissue culture infectious dose

TGEV

transmissible gastroenteritis virus

TIL

toll/interleukin-1 receptor

TLR

toll-like receptors

TMPRSS2

transmembrane serine protease 2

TNF-α

tumor necrosis factor alpha

TP

transducing particle

TRAF

tumor necrosis factor receptor-associated factor

xxi

TRIF

TIR domain-containing adaptor inducing IFN beta

TRS

transcription-regulating sequence

TRS-B

transcription-regulating sequence (body)

TRS-L

transcription-regulating sequence (leader)

ts

temperature-sensitive

Ubl

ubiquitin-like domain

UCD

University of California-Davis

UTR

untranslated region

V

volt

VISA

virus-induced signaling adapter

VLP

virus-like particle

VSV

vesicular stomatitis virus

w/v

weight to volume

WT

wild type; wild-type

Y

coronavirus highly conserved domain

α

alpha; anti-

𝛽

beta

𝛾

gamma

𝜆

lambda

μF

microfarad

μg

microgram

μL

microliter

μM

micromolar

xxii

ABSTRACT
Serotype I feline infectious peritonitis virus (FIPV) is an alphacoronavirus of high
veterinary importance due to the 99% mortality rate observed in cats. Since the 1980s,
robust experimentation on these viruses has been limited by availability of culturable
pathogenic strains, few permissive cell lines, and a lack of standardized methods to
study their basic virology. These complications have resulted in variable and conflicting
literature reports, have slowed study of clinical strains and hindered effective vaccine
design. The goal of this dissertation was to develop a laboratory “toolbox” containing
standardized methods, permissive cell lines and genetic techniques to alleviate some of
the technical barriers to investigating type I feline coronavirus (FCoV). To this end, our
group characterized the replication kinetics of serotype I FIPV Black in three feline cell
lines. From this work, colleagues and I described a new macrophage-like cell line,
termed Fcwf-4 Cornell University (CU), which rapidly grew FCoV to high titer. Using
these cells, we established a standardized plaque assay to accurately determine type I
FCoV titer. To facilitate study of live-attenuated and clinical isolate FCoVs, I used
Crispr/Cas to disrupt IFNαR, the major antiviral signaling component, in two feline cell
lines: AK-D and Fcwf-4 CU. Further, I isolated a clone, termed Fcwf-4 CU IRN, and
demonstrated that expression of a feline protease enhanced FIPV infection in these
cells. Finally, using a deep-sequenced laboratory strain of FIPV Black, we constructed
an infectious clone (ic) reverse genetics system and successfully produced icFIPV.
xxiii

CHAPTER ONE
INTRODUCTION
The Biology of Coronaviruses
Overview and Classification.
Coronaviridae are a family of enveloped, positive-sense RNA viruses that, along
with the Arteriviridae, Mesoniviridae, and Roniviridae, make up the taxonomic order
Nidovirales (Figure 1). Contained within the Coronaviridae are two subfamilies: the
newly defined Letovirinae housing the Alphaletovirus genus, and the much larger
Orthocoronavirinae subfamily composed of four monophyletic genus clusters: Alpha-,
Beta-, Delta- and Gammacoronavirus. The Betacoronavirus genus is further divided into
four lineages, A-D. Together, the Orthocoronavirinae represent the majority of known
and studied coronavirus species and include important animal, human and zoonotic
pathogens (International Committee on Taxonomy of Viruses (ICTV), 2018).
Viruses in the order Nidovirales, including coronaviruses are organized into the
above taxonomic groups based on phylogenetic similarity of the positive-sense RNA
genomes. All Nidoviruses have large RNA genomes, with the Coronaviridae family
boasting the largest known, containing between 27 and 32 kilobases (kb). A unique
feature of Nidovirus genomes, and the one from which the name was derived, is the
expression of genes via the synthesis of a 3’ nested set of 7-9 subgenomic RNAs
(sgRNAs) (Masters, 2006) – nido meaning “nest” in Latin. Other features common to
Nidoviruses include a highly conserved genome organization with a large 5’ replicase,
24

25
arising from ribosomal frameshift translation, which precedes a set of structural and
group-specific accessory genes, as well as a set of viral nonstructural proteins
processed from the replicase polyprotein by replicase-encoded viral proteases. The
major differences between members of the Nidovirus order are morphologic – wide
variations in structural protein type, number and size results in unique virion and
nucleocapsid constructions (Fehr and Perlman, 2015).

Figure 1: Phylogenetic Classification of Orthocoronavirinae Subfamily. The
taxonomic tree depicted here is based on the 2018 report from the International
Committee on Taxonomy of Viruses (ICTV).
Genome Organization.
Coronaviruses (CoVs) carry single copy, non-segmented, single-stranded,
positive-sense RNA genomes, which range in size between 27-32 kb (Figure 2). The 5’
end of the genome is capped with a guanine residue methylated at the N7 position while
the 3’ end terminates with repeating adenosine monophosphate residues, termed the

26
poly (A) tail. These terminal features mimic host messenger (m) RNA thus the CoV
genomic RNA can be directly translated on host ribosomes following membrane fusion.
The 5’ terminal region of the CoV genome is highly structured and contains a
large (210-530 bp) untranslated region (5’ UTR) comprising seven stem-loops (Brown et
al., 2007; Guan et al., 2011; Liu et al., 2009; Yang and Leibowitz, 2015). These stemloops directly associate with host ribosomes as well as the virus-encoded RNAdependent RNA polymerase (RdRp) and are critical to virus replication. The 5’ UTR also
includes a 70-100 nt leader (L) sequence (Lai et al., 1984, 1983), the 3’ end of which
houses the 6-8 nucleotide transcription-regulating sequence (TRS-L [Leader]). Identical
TRS segments are also present on the 5’ end of each of the 7-9 subgenomic mRNAs
(TRS-B [Body]) acting as cis-regulatory elements (Budzilowicz et al., 1985; Masters,
2006) critical for the hallmark discontinuous transcription (Sawicki et al., 2007) observed
during Nidovirus replication (discussed in detail below).

27

Figure 2: Feline Coronavirus Genome Organization, Replicase Processing and
Subgenomic mRNAs. The typical coronavirus genome organization is depicted using
feline infectious peritonitis virus (FIPV) as a model. The replicase, comprising ORF1a
and ORF1b separated by a ribosomal frameshift site (RFS), contain nonstructural
proteins (nsps) 1-16. The two replicase polyproteins (pp1a and pp1ab) are depicted.
Arrows indicate PLP1/2 or 3CLpro cleavage sites; numbers below indicate nsp number.
Specific nsp components: nsp3, papain-like protease 1/2 (PLP1/2); nsp5, 3C-like
protease (3CL); nsp12, RNA-dependent RNA polymerase (RdRp); nsp13, helicase
(HEL); nsp14, exoribonuclease (ExN); nsp15, endoribonuclease (EnU); nsp16, 2-Omethyltransferase (MT). The structural proteins spike (S), envelope (E), membrane (M),
nucleocapsid (N) and accessory protein regions ORF3 (3a, 3bc) and ORF7 (7a, 7b) are
shown. The 5’ leader (L) and body (B) transcription-regulating sequences (TRS-) are
indicated on genomic and subgenomic mRNAs 1-7. Bottom arrow indicates direction of
translation.
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The first two thirds (~20 kb) of the CoV genome downstream of the 5’ UTR is
dominated by the replicase polyprotein coding region. Translation of two open reading
frames, ORF1a and ORF1b produce two replicase polyproteins (pp) 1a and 1ab (Lai et
al., 1994). While pp1a is translated directly from ORF1a, the larger pp1ab is produced
due to a -1 nt ribosomal frameshift (RFS) that occurs at a tandem pseudoknot-slippery
sequence in ORF1 allowing continual translation through ORF1b. Together, the
replicase polyproteins encode 16 nonstructural proteins (nsp1-16) that have wideranging activities including formation of the replicase-transcriptase complex (RTC) and
modulation of innate immune signaling. Downstream of the replicase, the final third (~10
kb) of the CoV genome encodes the structural and accessory genes. CoV structural
proteins include spike (S), envelope (E), membrane (M), and nucleocapsid (N) (de Haan
and Rottier, 2005; Masters, 2006). Several members of the Betacoronavirus genus,
including murine hepatitis virus and bovine coronavirus, also encode a fifth structural
gene, hemagglutinin-esterase (HE) (Cornelissen et al., 1997; Kazi et al., 2005;
Klausegger et al., 1999). Interspersed within the structural proteins are the accessory
genes, which are unique to different CoV subfamilies. Accessory proteins are largely
dispensable for replication but often provide a selective pathogenic advantage (Zhong
et al., 2016) such as antagonism of innate immunity. The genome of the feline
alphacoronavirus FIPV, the focus of this dissertation, contains five such accessory
proteins encoded on two polycistronic gene regions, ORF3 (3a, 3b, 3c) and ORF7 (7a,
7b) (Kipar and Meli, 2014). FIPV 7a, and ORF3, have been implicated in antagonism of
host innate response during infection, however the mechanisms of this activity are not
fully understood (Dedeurwaerder, 2014; Dedeurwaerder et al., 2014, 2013).
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The 3’ terminal end of the CoV genome contains a 270-500 bp untranslated
region (3’ UTR) that directly precedes the poly (A) tail. Like the 5’ end, the 3’ UTR is
also highly structured (Goebel et al., 2004; Yang and Leibowitz, 2015) and contains
several cis-acting elements essential for coronavirus replication [reviewed in (Yang and
Leibowitz, 2015)] as well as a putative molecular switch predicted to be involved in a
transition event during RNA synthesis (Goebel et al., 2004).
Virion Structure.
The coronavirus virion. Coronaviruses are such named due to the solar halo or
corona-like, Latin for crown, pattern of the virion when observed using EM microscopy.
This crown-like appearance is due to the large, trimeric, club-like spike (S) structures,
which jut out from the host membrane-derived lipidic envelope that forms the outside of
the roughly spherical virion (Benjamin W Neuman et al., 2006). Two to three other viral
proteins are also anchored in the envelope: the abundant membrane (M) and the more
sparse envelope (E) proteins are present on all coronaviruses, while the hemagglutininesterase (HE) protein is found on only a subset of Betacoronviruses (de Haan and
Rottier, 2005; Masters, 2006). Coronavirus virions are approximately 100-125 nm in
diameter as determined by studies using cryo-electron microscopy (Benjamin W
Neuman et al., 2006) and cryo-electron tomography (Bárcenaa et al., 2009). Contained
within the virion is the ribonucleoprotein (RNP) core composed of the ~ 30 kb genomic
RNA encased in an oligomer of nucleocapsid (N) protein oriented with helical symmetry.
A typical coronavirus virion is shown in Figure 3.
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Figure 3: The Coronavirus Virion. A schematic of a typical coronavirus virion is
depicted. Trimeric spike (S), dimeric membrane (M) and envelope (E) proteins extend
out from a host-derived membrane and form the outer envelope. The
ribonucleoprotein (RNP), composed of genomic (g) RNA surrounded by nucleocapsid
(N) proteins, forms helical symmetry and associates with M protein dimers. The
approximate virion size in nanometers (nm), measured between opposed spike
exodomains, is indicated below. Hemagglutinin-esterase (HE) membrane proteins are
not shown.
Spike protein. The spike (S) protein is the main determinant of coronavirus hostrange and tissue tropism as it functions to both engage host receptors as well as
mediate the membrane fusion events that deliver the viral RNP to the cell cytoplasm.
For example, small sequence variations of the feline coronavirus spike protein can lead
to drastic changes in cell tropism and virulence (Chang et al., 2012; Licitra et al., 2013;
Rottier et al., 2005). The mature spike is a trimeric type I glycoprotein of approximately
150 kDa. During protein synthesis, the S homotrimer is heavily glycosylated on 21-35 Nglycosylation sites and tethered to the virus envelope outer leaflet via a membraneanchoring sequence and a short hydrophilic CTD tail (de Haan and Rottier, 2005). The
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ectodomain makes up the majority of the S molecule and, for most CoVs, is cleaved into
two polypeptide regions, S1 and S2 by host proteases (Abraham et al., 1990; Luytjes et
al., 1987). The amino-terminal S1 “head” region contains the receptor-binding domain
(RBD), while the carboxy-terminal S2 “stalk” houses the components of a class I fusion
protein (Bosch et al., 2003; Collins et al., 1982; de Haan and Rottier, 2005; Walls et al.,
2019). Many coronaviruses engage host peptidases as entry receptors, although this is
not universally true. A partial list of entry receptors used by alpha- and
betacoronaviruses is provided in Table 1.
Envelope protein. The envelope (E) is a small, 8-12 kDa integral membrane
protein and a minor component of the coronaviral envelope (Raamsman et al., 2000;
Siddell, 1995). The protein has a short hydrophilic amino-terminal end followed by a
hydrophobic membrane domain and a hydrophilic carboxy-terminal domain. The E
protein functions in assembly and release of the virus through potential interaction with,
or modulation of the M protein, or by influencing the curvature of the virion envelope
(Boscarino et al., 2008; Corse and Machamer, 2000; Fischer et al., 1998; Ye and
Hogue, 2007). A portion of the CTD has also been shown to have ion-channel activity,
which has importance in determining SARS-CoV virulence (Nieto-Torres et al., 2014;
Verdiá-Báguena et al., 2012).
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GENUS

AlphaCoronavirus

BetaCoronavirus

SPECIES

RECEPTOR

REFERENCES

HCoV-NL63

ACE2

(Hofmann et al., 2005)

FCoV Serotype I

Unknown

(Dye et al., 2007)

FCoV Serotype II

Feline APN

(Tresnan and Holmes, 1998)
(Tresnan et al., 1996)

CCoV Serotype II

Canine APN

(Benbacer et al., 1997)

TGEV

Porcine APN

(Delmas et al., 1992)

PEDV

Porcine APN

(Li et al., 2007)

HCoV-229E

Human APN

(Yeager et al., 1992)

SARS-CoV

ACE2

(Li et al., 2003)

MERS-CoV

DPP4

(Raj et al., 2013)

MHV

mCEACAM

(Nedellec et al., 1994)
(Williams et al., 1991)

BCoV

Neu 5,9 Ac2

(Schultze and Herrler, 1992)

HCoV-OC43

Neu 5,9 Ac2

(Qian et al., 2015)
(Vlasak et al., 1988)

Table 1: Coronavirus Entry Receptors. Adapted from (Masters, 2006); (Fehr and
Perlman, 2015)
Membrane protein. The membrane (M) protein is a small (25-30 kDa), highly
abundant component of the coronaviral envelope and directs the complete assembly of
mature virion (de Haan and Rottier, 2005; Fehr and Perlman, 2015; Masters, 2006).
Owing to its description as the virion “building block”, the M protein has been shown to
interact with all other structural components via its five, largely hydrophobic domains
[reviewed in (de Haan and Rottier, 2005)]. The amino-terminal ectodomain is
glycosylated and is followed by three hydrophobic transmembrane domains and a large
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carboxy-terminal endodomain (Armstrong et al., 1984; Nal et al., 2005). On the
envelope, the M protein dimer has been shown by cryo-EM and tomography to adopt
two conformations, which influence membrane curvature and interactions with other
virion components including the nucleocapsid (N) protein (Neuman et al., 2011).
Nucleocapsid protein. The nucleocapsid (N) phosphoprotein is the most
abundant viral protein expressed during infection and, together with the CoV RNA
genome, forms the protective and stable ribonucleoprotein (RNP) core (Laude and
Masters, 1995; Narayanan et al., 2003). The N protein ranges in size between 43 and
50 kDa and amino acid identity varies between coronavirus subfamilies. The highlybasic amino-terminal and carboxy-terminal domains of the nucleocapsid associate with
RNA by different mechanisms, possibly utilizing both ends for optimal binding (Chang et
al., 2006; Hurst et al., 2009) and the N protein has been shown to bind specifically to
the TRS and packaging signal of the CoV genome (Molenkamp and Spaan, 1997;
Stohlman et al., 1988). Additionally, phosphorylation of the N protein has been
suggested to impose structural changes that increase affinity for viral, rather than host
RNAs (Stohlman and Lai, 1979). When in complex, the N protein and RNA form a
compact structure with helical symmetry referred to as the ribonucleoprotein (RNP) core
or complex. Other interacting partners include nsp3 (Hurst et al., 2013, 2009), a major
component of the replicase-transcriptase complex (RTC), and the M protein (Sturman et
al., 1980) highlighting potential roles for the N protein in promoting transcription and
packaging newly-synthesized genomic RNAs into virions.
Hemagglutinin-esterase. Several members of the Betacoronavirus genus
cluster encode a fifth structural protein: the hemagglutinin-esterase (HE) (Brian et al.,
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1995). The HE protein is a 60-65 kDa type I transmembrane protein of 424-439 amino
acids that contains an amino-terminal signal peptide ectodomain, a transmembrane
domain and a small, cytoplasmic, carboxy-terminal tail (de Haan and Rottier, 2005;
Hogue et al., 1989). The mature protein is a glycosylated homodimer linked by disulfide
bonds that juts out from the viral envelope, resembling the spike protein (Kienzle et al.,
1990). Much like the hemagglutinin of influenza C virus, the CoV HE protein dimer binds
and cleaves sialic acid residues found on surface glycoproteins (Cornelissen et al.,
1997). HE proteins from specific coronavirus species have also been shown to have
acetyl-esterase activity, a function not present in the HE of influenza C or other CoVs
(Klausegger et al., 1999). Although the exact role of HE during CoV infection and
replication is not fully understood, it has been suggested that HE may enhance Smediated virus entry and/or spread through mucosal tissue, thereby contributing to
pathogenesis (Cornelissen et al., 1997).
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Figure 4: The Coronavirus Replication Cycle. A typical coronavirus replication cycle
is shown in 6 steps: 1) CoV spike engages the host receptor at the cell surface and
membrane fusion, mediated by host proteases at the surface or within endosomes,
allows uncoating and insertion of the RNP into the cytoplasm. 2) gRNA associates with
host ribosomes and translation of the replicase pp1a and 1ab occurs. 3) Pp1a/1ab are
processed by viral proteases (PLP1/2 and 3CLpro) releasing 16 nsps, which form the
RTC on host-derived DMVs. 4) The RTC produces subgenomic RNAs by discontinuous
transcription that are translated into structural and accessory proteins, and replicates
gRNA, which becomes engulfed by N protein to form RNP cores. The structural proteins
traffic from the ER to the ERGIC. 5) RNP cores bud into the ERGIC and are surrounded
by the viral envelope containing the structural proteins to form the mature virion. 6)
Mature virions are released due to vesicle fusion at the cell surface.

36
Replication Cycle.
Overview. Replication of CoVs (Figure 4) is initiated through engagement of the
CoV spike protein with the corresponding target cell receptor. The virus is then taken
into intracellular vesicles through receptor-mediated endocytosis (Gallagher and
Buchmeier, 2001), and following a membrane fusion event (Bosch et al., 2003), the
single-stranded RNA genome is released into the cell cytoplasm (Fehr and Perlman,
2015). In some cases, CoV virions fuse directly at the cell plasma membrane and
immediately release genomic RNP into the cytoplasm (Millet and Whittaker, 2015).
Fusion at the cell surface or within vesicles may be linked to the overall stability of the
virus spike protein, the density or presence of host proteases and/or specific entry cofactors such as tetraspanins involved in promoting membrane fusion (Belouzard et al.,
2012; Earnest et al., 2017; Millet and Whittaker, 2015). In either case, the positivesense genomic RNA enters the cytoplasm and is directly translated on host ribosomes
(Lai et al., 1994), which initiate production of the CoV replicase polyproteins pp1a and
pp1ab (Lai et al., 1994). The large replicase polyproteins are processed through
catalytic cleavage by viral proteases encoded on the replicase (Baker et al., 1993;
Kanjanahaluethai et al., 2003; Masters, 2006) into 16 nonstructural proteins (nsp1-16)
(de Haan and Rottier, 2005). Each nsp has a distinct function that is conserved among
CoV orthologues (Gorbalenya et al., 1989; Su et al., 2014). Of note here are nsp12,
encoding the RNA-dependent RNA polymerase (RdRp), and nsps 3,4 and 6, which
modify host membranes to form the double-membrane vesicles (DMV) that house the
replicase-transcriptase complex (RTC). The RTC has two primary functions: copy the
full-length RNA genome (replication) and transcribe the structural and accessory genes
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(discontinuous transcription) generating a nested set of subgenomic mRNAs. The
structural gene products S, E and M (and HE, if present) are inserted into the
endoplasmic reticulum (ER) and traffic to the endoplasmic reticulum-Golgi intermediate
compartment (ERGIC). In the cytoplasm, the nucleocapsid protein surrounds newlysynthesized genomic RNA then buds into the ERGIC where it becomes enveloped by
the other structural proteins thus forming complete virions. Finally, virions are
transported in smooth-walled vesicles to the cell surface where they fuse with the
plasma membrane and release infectious CoV particles.
Attachment and entry. The coronavirus spike protein is the main determinant of
virus attachment and entry as it possesses both a receptor binding domain (S1) and is a
type I fusion protein via the S2 domain. The interaction between the coronavirus spike
protein and cognate host cell receptor is the first step in initiating the replication cycle.
CoV host range, tissue tropism and zoonotic emergence are largely dependent on the
specificity of the S to a particular receptor, however, may also be determined by the
presence and density of host proteases involved in promoting membrane fusion. These
interactions are highly species specific, but are also mutable as has been shown both
experimentally (Saif, 2004) and naturally with the zoonotic emergence of both SARSand MERS-CoV. The specific location of the receptor binding domain (RBD) varies
along the S1 domain and different CoV species utilize one or both for this function. The
galectin-like amino-terminal domain of S1 binds sialic-acid moieties as observed in
mouse hepatitis virus (MHV) (mCEACAM) (Nedellec et al., 1994) and HCoV-OC43
(Qian et al., 2015). The carboxy-terminal domain of S1 is more commonly utilized and
engages peptidases as identified for HKU1 (Qian et al., 2015), feline CoV (APN)
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(Tresnan et al., 1996; Tresnan and Holmes, 1998), SARS-CoV (ACE2) (Li et al., 2003)
and MERS-CoV (Raj et al., 2013). Interestingly, a neurotropic strain of murine
coronavirus (MHV-JHM) has also been shown to enter cells without specific receptor
engagement (Gallagher et al., 1992) possibly owing to a highly fusogenic, metastable
spike protein.
In all cases, following engagement of the host receptor, the S2 region of S
catalyzes a membrane fusion event, which allows transit of the genomic RNA from
virion to the cytoplasm. This fusion process requires significant structural changes to
spike and has been recently visualized by cryo-EM (Walls et al., 2017). The S
conformational changes are triggered following cleavage by host proteases (in some
cases pH-dependent) and drives the rapid release and insertion of the fusion peptide,
which is located in the center of the pre-fusion spike trimer, into the host membrane. For
most CoV spike proteins, cleavage of S occurs at a defined junction between S1 and
S2; however, certain S proteins have been shown to have alternative or additional
cleavage sites along S1, which can impact cell tropism and pathogenesis (Belouzard et
al., 2012, 2009; Licitra et al., 2013; Millet and Whittaker, 2015). Proteolytic processing of
the spike protein occurs in several locations depending on the CoV, including at the cell
surface (Earnest et al., 2017; Glowacka et al., 2011; Park et al., 2016), within early
endosomes (Millet and Whittaker, 2014) and in complex with lysosomes (Bosch et al.,
2008). This process allows spatiotemporal control of viral entry (Rottier and Bosch,
2008) and has implications in cell tropism, entry efficiency and pathogenicity
(Matsuyama et al., 2005; Park et al., 2016). The membrane fusion event mediated by
the S2 region of the spike is typical of other type I fusion proteins (Harrison, 2015) and
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includes a three step process: i) insertion of fusion peptide into the outer leaflet of the
host membrane; ii) a fold-back event brining the outer leaflets of the host and viral
membranes into close proximity; iii) a hemi-fusion event in which the lipid bilayers of the
host and viral membrane fuse. The end result of this fusion event is the release of the
genomic RNP core into the cytoplasm.
Replicase protein translation, processing and formation of the replicasetranscription complex (RTC). Once within the cytoplasm, translation of the CoV
genomic RNA occurs on host ribosomes (Lai et al., 1994). The 5’ end of the genome is
capped with a methylated guanine residue that precedes a highly-structured
untranslated region containing seven stem-loops (Yang and Leibowitz, 2015). The 5’
structure of the RNA engages host translation machinery components eIF4 and the
ribosomal 40 S subunit to form the pre-initiation complex. The 60 S ribosomal subunit
then associates with this complex and begins translation of the first set of open reading
frames encoding the coronavirus replicase [reviewed in (Nakagawa et al., 2016)].
The replicase region comprises the first two-thirds of the genome and houses all
the components necessary to drive formation of the replicase-transcriptase complex
(RTC), a structure that functions to replicate the full-length genome and transcribe the
downstream structural and accessory genes. The replicase is translated from two open
reading frames, ORF1a and ORF1b that produce two co-terminal polyproteins (pp) 1a
and 1ab (Lai et al., 1994). A large pseudoknot, preceded by a 5’-UUUAAAC-3’ “slippery”
sequence, is present at the junction between ORF1a and ORF1b and directs production
of either pp1a (75%) or pp1b (25%). For production of pp1a, the ribosome translates the
entire ORF1a by unwinding and continuing through the pseudoknot before terminating
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at a downstream stop codon. To produce pp1ab, the pseudoknot causes the ribosome
to temporarily pause at the “slippery” sequence leading to a -1 nt ribosomal frameshift
and subsequent continuation of translation through ORF1b.
The functional components of the ~ 20 kb replicase are a set of 16 nonstructural
proteins, which are released from the co-terminal polyproteins 1a and 1ab through
catalytic cleavage by a set of 2-3 replicase-encoded viral proteases. Contained on nsp3
are one or two papain-like proteases (PLP1; PLP2) (Baker et al., 1993;
Kanjanahaluethai et al., 2003) that process the nsp1/2, 2/3, and 3/4 junctions in trans
through recognition of a conserved LXGG motif. Nsp5 encodes the 3C-like protease
(3CLpro; also termed Main protease or Mpro), a serine protease, which is released by
autocatalytic cleavage and recognizes a conserved LQS motif to release nsps 5-16.
Each nonstructural protein has a distinct function that is conserved among CoV
orthologues (Gorbalenya et al., 1989; Su et al., 2014) and summarized Table 2.
Together, these components mediate the assembly of the cytoplasmic replicasetranscriptase complex (RTC), the site of de novo RNA synthesis and transcription of
subgenomic RNAs. Within hours of infection, nsp3, 4 and 6 (Angelini et al., 2013)
induce large alterations of the cellular reticulovesicular membrane network forming
perinuclear convoluted membranes from which the double-membrane vesicles (DMVs),
the scaffolds of the RTC, are derived (Gosert et al., 2002; Knoops et al., 2008; Prentice
et al., 2004; Shi et al., 1999; van der Meer et al., 1999). Other notable components of
the RTC include nsp12 and 13 that encode the RdRp and helicase, respectively.
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PROTEIN

FUNCTION(S)

REFERENCE

nsp1

Cellular mRNA degradation
Blocks host translation
Innate immune antagonism

(Tanaka et al., 2012)
(Huang et al., 2011)
(Kamitani et al., 2009)
(Kamitani et al., 2006)

nsp2

Not required for replication
Binds prohibitin proteins

(Cornillez-Ty et al., 2009)
(Graham et al., 2005)

nsp3

Multi-domain transmembrane protein; DMV formation
(Ubl1 / Ac) Associate with N protein
(Macrodomain) IFN antagonism, PLP2 interaction
(PLP1/2) LXGG-specific protease (nsp1/2, 2/3, 3/4 junctions)
Deubiquitinase-mediated IFN antagonism
DeISGylase: deconjugates ISG15
(DPUP, Ubl2, NAB, G2M, SUD, Y) unknown functions

(Chen et al., 2015)
(Chatterjee et al., 2009)
(Frieman et al., 2009)
(Serrano et al., 2009)
(Eriksson et al., 2008)
(Neuman et al., 2008)
(Serrano et al., 2007)
(Egloff et al., 2006)
(Ziebuhr et al., 2001)
(Deng et al., 2019a)

nsp4

DMV formation

(Gadlage et al., 2010)
(Clementz et al., 2008)

nsp5

(3CL pro / M pro) RLG-specific protease (nsp4-16 junctions)

(Lu et al., 1995)

nsp6

DMV formation

(Oostra et al., 2008)

nsp7

Forms hexadecameric complex with nsp8
Potential processivity clamp for RNA polymerase (nsp12)

(Zhai et al., 2005)

nsp8

Forms hexadecameric complex with nsp7
Potential processivity clamp for RNA polymerase (nsp12)
Potential primase

(Imbert et al., 2006)
(Zhai et al., 2005)

nsp9

RNA binding protein

(Egloff et al., 2004)

nsp10

Cofactor for nsp14 and nsp16
Promotes 2-O-MT and ExoN activities of nsp14 and nsp16, rsp.

(Decroly et al., 2011)
(Bouvet et al., 2010)

nsp11

Small peptide formed at end of pp1a

(de Haan and Rottier, 2005)

nsp12

(RdRp) RNA-dependent RNA polymerase

(Xu et al., 2003)

nsp13

DNA/RNA helicase; unwinds with 5’ to 3’ polarity
5’ triphosphatase

(Ivanov et al., 2004b)
(Ivanov and Ziebuhr, 2004)

nsp14

(N7 MTase) Addition of 5’ cap to viral mRNAs
(ExoN) exoribonuclease; RNA proofreading activity

(Eckerle et al., 2010)
(Chen et al., 2009)
(Eckerle et al., 2007)
(Minskaia et al., 2006)

nsp15

(EndoU) Endoribonuclease of ss/dsRNAs at uridylate residues
Prevents dsRNA accumulation; strong IFN antagonist

(Deng et al., 2019b)
(Deng et al., 2017)
(Kindler et al., 2017)
(Bhardwaj et al., 2006)
(Bhardwaj et al., 2004)
(Ivanov et al., 2004a)

nsp16

(2’-O-Methyltrasferase); Prevents RNA detection by MDA5

(Züst et al., 2011)
(Decroly et al., 2008)
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Table 2: Coronavirus Nonstructural Proteins and Associated Functions. Included
abbreviations: nsp3, ubiquitin-like domain (Ubl); acidic domain (Ac), papain-like
protease 1/2 (PLP1/2), domain preceding Ubl2 and PLP2 (DPUP), nucleic acidbinding (NAB) domain, coronavirus group 2 marker (G2M) domain, SARS-CoV unique
domain (SUD), coronavirus highly conserved (Y) domain; nsp5, 3C-like protease
(3CLpro), Main protease (M pro); nsp14, methyltransferase (MTase). Adapted from
(Fehr and Perlman, 2015).

Interestingly, several of the nonstructural proteins, including the papain-like
protease (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009; Li et al.,
2011; Mielech et al., 2014; Rose and Weiss, 2009; Sun et al., 2012), and the EndoU
encoded on nsp15 (Deng et al., 2019b, 2017; Deng and Baker, 2018; Kindler et al.,
2017) have been demonstrated to have additional functions and antagonize innate
immunity.
RNA replication and transcription. Within the RTC, replication of the full-length
gRNA occurs and is used as a template to generate of a set of subgenomic (sg)
messenger (m) RNAs that encode the structural proteins, spike (S), envelope (E),
membrane (M), nucleocapsid (N) and hemagglutinin-esterase (HE), if present (de Haan
and Rottier, 2005; Masters, 2006), as well as the group-specific accessory proteins.
Together, the structural and accessory genes comprise the final third of the genome,
downstream of the replicase. The number of sgRNAs differs between coronaviruses but
is typically between 7 and 9. The positive sense (+) sg mRNAs are 5’ capped
(Nakagawa et al., 2016) and contain a 70-100 nt leader (L) sequence downstream of
the cap, which includes a 6-9 nt section called the transcription-regulating sequence
(TRS-B [Body]). The TRS-B is identical to the TRS at the 5’ end of the gRNA (termed
TRS-L [Leader]) and the exact composition of the TRS is highly conserved within each
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CoV subfamily. Additionally, the sgRNAs are 3’ co-terminal with genomic RNA and thus
form the nested-set of subgenomic mRNAs that partly define the Nidovirus order.
The “discontinuous transcription” model (Figure 5) proposed by Sawicki et al.
(Sawicki and Sawicki, 1995) is widely accepted as the mechanism through which sg
mRNAs are produced. In this model, the full-length genomic RNA acts as a template for
the generation of negative-sense (-) sgRNAs, which in turn become templates for
transcription of the positive-sense sg mRNAs. To produce the (-) sgRNAs, the viral
RdRp binds the gRNA at the 3’ poly (A) tail and extension occurs 3’ to 5’ until a TRS-B
is reached. A looping event brings the TRS-B in proximity to the TRS-L located at the 5’
end of the gRNA and here the polymerase strand-switches to produce a complimentary
replicate of the 5’ gRNA leader. When extension terminates, the negative-sense RNAs
possess an anti-sense leader sequence and a poly (U) tail (Sethna et al., 1991). From
the limited population of negative-sense sgRNA templates, the viral RdRp produces
one-hundred times more positive-sense sgRNAs, which are 5’-capped and exit the RTC
to be translated on host ribosomes into S, E, M, N and accessory proteins (de Haan and
Rottier, 2005; Fehr and Perlman, 2015; Masters, 2006; Sawicki et al., 2007).
Owing to the co-terminal nature of the 3’ ends of the sgRNA, the identical TRS
compositions and the strand-jumping tendency of the viral RdRp, CoV genomic
recombination events can occur. Recombination helps drive viral adaptation, evolution,
zoonotic emergence and the generation of quasispecies during an infection. The strain
variation and difficulty in investigating feline coronaviruses, as will be discussed below,
is likely due in large part to recombination.
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Figure 5: Model for Discontinuous Negative-strand Transcription. The viral
RNA-dependent RNA polymerase binds the 3’ end of the positive-strand (solid
black line) RNA and initiates elongation of the negative-strand (red dotted line)
RNAs until a body transcription-regulating sequence (TRS-B) is encountered.
Strand-switching occurs, which pairs the TRS-B with the leader-containing TRS
(TRS-L) on the positive strand. Transcription of the negative strand re-initiates
creating a complement to the TRS-L on the 3’ end and forming a dsRNA
intermediate. The complete negative-strand is used as a template to produce
100-1000 times more positive-sense subgenomic mRNAs. Adapted from
(Masters, 2006).
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As a final note, the formation of double-stranded RNA intermediates in the RTC
during replication presents a unique challenge to coronaviruses as dsRNAs are highly
potent pathogen-associated molecular patterns (PAMP). As mentioned above and will
be discussed below, the activity of at least one nonstructural protein, the EndoU
encoded on nsp15, has been shown to maintain association of dsRNA with RTC
thereby preventing detection of this viral PAMP by cytoplasmic pathogen recognition
receptors.
Virion assembly and release. In addition to the nonstructural proteins, the
structural nucleocapsid (N) protein has also been shown to localize to the replicasetranscriptase complex (Bost et al., 2000; van der Meer et al., 1999). Here, the N protein
binds newly-synthesized, full-length coronavirus genomic RNA through associations
with the 5’ leader, TRS and 3’ UTR to form a ribonucleoprotein (RNP) core (Molenkamp
and Spaan, 1997; Shi and Lai, 2005; Stohlman et al., 1988). The stable RNP core is
maintained by the large number of N-N interactions, which together form a structure
with helical symmetry (de Haan and Rottier, 2005).
Following translation on host ribosomes, the other structural proteins S, E, M and
HE localize to the endoplasmic reticulum (ER) via encoded signal peptides (Fehr and
Perlman, 2015). The proteins are inserted in the ER and oriented such that the protein
ectodomains extend into the ER lumen, then transported via the host secretory pathway
to the ER-Golgi intermediate compartment (ERGIC), the site of mature virion assembly
(Krijnse-Locker et al., 1994; Tooze et al., 1984). Cytoplasmic RNP cores bud into the
ERGIC and become surrounded by host membranes with embedded structural proteins,
thus giving rise to the mature coronavirus virion. The M protein, often referred to as the
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virion “building block” directs the majority of the protein-protein interactions that
necessitate the formation of the mature virion including the accumulation/incorporation
of S into the envelope and directing the RNP core to bud into the ERGIC (de Haan and
Rottier, 2005). However, several groups have shown that M protein alone is not
sufficient to form virions and requires the E protein to form basic virus-like particles
(VLPs), a process that is made more efficient by the N protein (Bos et al., 1996; Siu et
al., 2008). Although the role of E is not fully defined, it may play a role in inducing proper
membrane curvature (Corse and Machamer, 2000; Fischer et al., 1998; Raamsman et
al., 2000), preventing M protein aggregation (Boscarino et al., 2008), altering the host
secretory pathway (Ye and Hogue, 2007), or as is observed with other coronavirus
proteins, may have pleiotropic effects in virion assembly and release. Assembled virions
are transported in smooth-walled exocytic vesicles to the cell plasma membrane where
the vesicles fuse and release the mature, infectious coronavirus particle (de Haan and
Rottier, 2005; Masters, 2006).
Innate Immune Responses to RNA Virus Infection
Overview.
During virus infection, host cells detect extracellular and intracellular products of
virus replication and mount an antiviral response. The so called “antiviral state” limits
virus replication through production of directly-acting antiviral factors, blocking new
infections, stimulation of cellular apoptosis and recruitment of innate and adaptive
immune cells. Interferons (IFNs), host antiviral signaling molecules, are the master
regulators of this antiviral state and are produced in response to detection of viral
pathogen-associated molecular patterns (PAMPs), mainly viral RNAs, by host pattern
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recognition receptors (PRRs). Autocrine and paracrine IFN signaling propagates
through IFN receptors and stimulates expression of hundreds of IFN-stimulated genes
(ISGs) that establish the rapid, pro-inflammatory antiviral state. In addition to interferon,
other PRRs direct the synthesis and release of pro-inflammatory cytokines including
tumor necrosis factor alpha (TNF-α), numerous interleukins (IL’s) and chemotactic
cytokines resulting in an influx of neutrophils, macrophages, natural killer cells,
lymphocytes and plasmacytoid dendritic cells (pDCs) to the sites of infection. Immuneactivated macrophages and pDCs secrete high amounts of type I IFN that significantly
enhance ISG production in surrounding tissue as well as collect viral antigens
necessary to develop long-term immune memory. Together, the pro-inflammatory
antiviral state is intended to limit the spread of the virus and prevent new infections
during an intense yet brief window of time, while recruiting the cells necessary to
generate long-lasting immunologic memory. As prolonged inflammation can lead to
pathology, cells also encode a set of negative regulators to return tissues to
homeostasis.
Detection of RNA Viruses by Host Sensors.
Cells distinguish self from non-self by detecting microbial- and viral-specific
signatures collectively known as pathogen-associated molecular patterns (PAMPs),
which are detected by a set of pattern-recognition receptors (PRRs). Host cells encode
three major classes of PRRs: the cytoplasmic-resident retinoic acid-inducible gene I-like
receptors (RLRs), the surface- and endosomal-resident toll-like receptors (TLRs) and
the cytoplasmic-resident nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs). Together, these PRRs detect virus components and trigger a signal
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cascade to induce production type I and type III interferons and pro-inflammatory
cytokines, which act in concert to orchestrate the “antiviral state” [reviewed in (Koyama
et al., 2008; Loo and Gale, 2011; Takeuchi and Akira, 2009)].
Retinoic-acid inducible gene-like receptors (RLRs). The RLR class of pattern
recognition receptors is the most well-studied and includes three members: retinoic
acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and
laboratory of genetics and physiology 2 (LGP2). RIG-I and MDA5 are highly expressed
in conventional dendritic cells (cDCs), macrophages and fibroblasts, but are also
present in most tissues at a low basal level (Yoneyama et al., 2004). RLR expression is
also tied to IFN signaling as cytoplasmic levels rapidly increase with IFN stimulation
(Kang et al., 2004; Yoneyama et al., 2004; Yount et al., 2007). These two RLRs are
individually or dually responsible for response to numerous RNA viruses [reviewed in
(Loo and Gale, 2011)]. While RIG-I directs responses to Influenza, JapaneseEncephalitis virus and VSV, MDA5 is required for detection of Picornaviruses and,
importantly, Coronaviruses (Deng et al., 2017; Kato et al., 2006; Kindler et al., 2017;
Zalinger et al., 2015). A combined RIG-I and MDA5 response occurs following West
Nile virus, Dengue and Reovirus infections (Fredericksen et al., 2008; Loo et al., 2008).
RIG-I and MDA5 proteins comprise two N-terminal caspase activation and
recruitment domains (CARDs) followed by a DExD/H RNA helicase domain and a Cterminal repressor domain (RD) (Yoneyama et al., 2004). LGP2 does not contain a
CARD domain and is thought to act as a negative regulator of RIG-I and MDA5 through
associations with the RD (Saito et al., 2008). Both RIG-I and MDA5 bind viral RNAs via
the RNA helicase and RD domains, which form a set of RNA-binding loops (Takahasi et
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al., 2009). RIG-I binds short (19-1000 nt), cytoplasmic single-stranded (ss) and doublestranded (ds) RNA species, which are distinguished from host RNAs due to the lack of a
5’ CAP exposing a 5’ triphosphate group (Hornung et al., 2006; Kato et al., 2008;
Pichlmair et al., 2006; Takahasi et al., 2008). MDA5 also binds cytoplasmic RNAs,
however associations are only made with dsRNA species longer than 2 kilobases (Kato
et al., 2008). Additionally, both RIG-I and MDA5 bind the products of the 2’5’oligoadenylate synthase (OAS)-RNaseL system (Malathi et al., 2007), a set of
interferon-stimulated genes that sense cytoplasmic dsRNAs and cleave host and viral
RNA indiscriminately, thus creating a positive-feedback loop to potentiate RLR
signaling. The N-terminal CARDs are held in an inactive “closed” conformation by the
RD and released into an active, “open” conformation following RNA binding allowing
signal propagation (Cui et al., 2008; Saito et al., 2008). Active RIG-I and MDA5 signal
via homotypic CARD-CARD interactions with the mitochondrial antiviral signaling
protein (MAVS) (Seth et al., 2005), also termed IPS-1 (Kawai et al., 2005), VISA (Xu et
al., 2005) or Cardif (Meylan et al., 2005). MAVS is a membrane-associated, CARDcontaining protein essential for RLR-dependent IFN production and resides on
mitochondrial (Seth et al., 2005) and peroxisome (Dixit et al., 2010) membranes. Once
associated, the RLR-MAVS complexes aggregate on host membranes to form the
MAVS “signalome”, an intricate signaling platform modulated by a number of positiveand negative-regulators that functions to activate transcription of interferons and proinflammatory cytokines (Hiscott et al., 2006). Specifically, the MAVS signalome leads to
downstream phosphorylation of interferon regulatory factor (IRF) 3 and IRF7, which
form homodimers that translocate into the nucleus, bind target sequences and drive
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expression of IFN. Interestingly, mitochondrial-associated and peroxisomal-associated
MAVS signalome complexes are thought to differentially stimulate production of type I
and type III interferons, respectively, seemingly by similar activation pathways (Coccia
et al., 2004; Kotenko et al., 2003; Loo and Gale, 2011; Odendall et al., 2014; Onoguchi
et al., 2007; Seth et al., 2005). In parallel, the MAVS signalome also results in the
phosphorylation and subsequent ubiquitin-dependent proteasomal degradation of I𝜅Bα,
releasing active NF𝜅B into the nucleus leading to transcription of pro-inflammatory
cytokines and interferons.
Toll-like receptors (TLRs). Mammalian cells express between 10 and 13 unique
toll-like receptors (TLRs), which specifically associate with a broad range of viral,
bacterial and fungal PAMPs. TLRs are single-span type I transmembrane proteins
containing an N-terminal, leucine-rich ectodomain responsible for binding to PAMPs, a
transmembrane domain, and a C-terminal, cytoplasmic toll/interleukin-1 receptor (TIL)
domain, which allows homo- and heterodimer formation. The endosomal TLRs 3, 7, 8
and 9 are responsible for detection of phagocytosed viral materials or viruses that gain
access to cells via the endosomal network. TLR7 and 9 are highly expressed in
plasmacytoid dendritic cells (pDCs), a specialized innate-immune cell type responsible
for the majority of type I interferon production in mammalian cells and the major
modulator of cell-mediated immunity to coronavirus infection (Cervantes-Barragan et al.,
2006). Within the endosome, TLR7 detects ssRNA species, while TLR9 binds nonmethylated, CpG-containing DNA. TLR3 is more broadly expressed in mammalian
tissues and detects endosomal dsRNA species [reviewed in (Iwasaki, 2012; Iwasaki
and Medzhitov, 2004)]; it has also been shown to be important for appropriate innate
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responses to coronaviruses including the human pathogen SARS-CoV (Totura et al.,
2015).
Following binding to their respective ligands, TLR3 or TLR7 form homodimers
through interactions between the cytosolic TIR domains. For TLR3, the TIR-TIR
interactions form a complex with TIR domain-containing adaptor inducing IFN beta
(TRIF), tumor necrosis factor receptor-associated factor (TRAF) 3, TRAF6, and receptor
interacting protein 1 (RIP1) (Meylan et al., 2004; Oshiumi et al., 2003; Sato et al., 2003;
Yamamoto et al., 2002). NF𝜅B and AP-1 activation occurs via TRAF6/RIP1 resulting in
pro-inflammatory cytokine production, while TRAF3 mediates IRF3 activation through
the kinase activity of TBK1, resulting in type I IFN synthesis. The TLR7 TIR-TIR
interaction forms a more traditional TLR signaling pathway mediated by interaction with
myeloid differentiation factor 88 (MyD88). MyD88 proteins form a signaling complex with
interleukin 1 receptor associated kinase (IRAK) 1, IRAK4, TRAFs 3 and 6 and I𝜅𝜅α to
promote NF𝜅B-mediated cytokine production and IRF-7 mediated IFN synthesis
(Häcker et al., 2006; Kawai et al., 2004; Uematsu et al., 2005).
NOD-like receptors (NLRs). NLRs are a third class of RLRs that detect both
PAMPs and danger-associated molecular patterns (DAMPs), host-derived biomolecules
that propagate pro-inflammatory signals following substantial tissue damage. The NLRs
have a number of functions including the activation of the NLRP3 inflammasome and
production of the pro-inflammatory cytokine IL-1𝛽 (Martinon et al., 2002), regulation of
apoptosis, activation of NF𝜅B and IFN synthesis, and as negative regulators of other
RLRs (discussed below) [reviewed in (Carneiro et al., 2007; Lupfer and Kanneganti,
2013)]. Many of the antiviral NLRs, particularly the NLRP3 inflammasome components,
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are interferon-stimulated geneses and thus are coordinated through the upstream
activation of RLR and TLR signaling. Once formed, the NLRP3 inflammasome can be
activated by a number of cell stresses to produce IL-1𝛽, a highly pro-inflammatory
cytokine with pleiotropic effects. This system is becoming increasingly appreciated in
the antiviral response to RNA and DNA viruses including Orthomyxo-, Paramyxo-,
Picrona-, Flavi-, Pox-, Herpes- and Adenoviridae [reviewed in (Lupfer and Kanneganti,
2013)]. The NLRP3 inflammasome had also been recently shown to be activated by
SARS-CoV (Chen et al., 2019).
Interferons and the Antiviral Effects of Interferon-stimulated Genes.
Pro-inflammatory cytokines and interferons (IFNs) play an integral role in the
innate immune system (de Weerd and Nguyen, 2012; Ivashkiv and Donlin, 2013;
Pestka et al., 2004; Trinchieri, 2010) and are produced through the activity of the
pattern recognition receptors discussed in detail above (Goubau et al., 2013; Iwasaki,
2012; Sen, 2002). These molecules have pleiotropic effects on various cell types and
can direct both local and systemic responses. In most cases, the composition, intensity
and duration of the IFN/cytokine response to viral infection determines if the virus is
cleared, if immune memory is developed and if the host experiences immunopathologic
side-effects. Thus, synthesis and signaling is tightly regulated.
Interferons. Interferons fall into three classes: type I comprising predominantly
IFN-alpha (α) and -beta (𝛽), type II or IFN-gamma (𝛾), and type III or IFN-lambda (𝜆).
These different classes are structurally distinct, and as such, signal through different cell
surface receptors, specific to each class. Type II (gamma) IFN is synthesized by
specialized immune cells such as NK cells, CD4+ Th1 cells and CD8+ T cells and is
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important for immune cell activation and adaptive immunity. Type I and III IFN, the focus
of this discussion, play dominant roles as master regulators of the innate immune
antiviral state. The effects of type I and type III IFN are largely cell-type specific and are
determined both by the level and type of IFN transcription as well as the expression of
the corresponding receptor. Type III IFNs are produced in greater amounts at barrier
tissue sites (pulmonary and intestinal epithelia) and tend to stimulate a mild, localized
response rather than the large, often systemic pro-inflammatory response observed with
type I IFN. It should be noted that tissue-resident macrophages are largely insensitive to
IFN-𝜆 (Zanoni et al., 2017) and therefore, function in an IFN-stimulation paradigm that is
not dependent directly on type III. As a result, IFN-𝜆 is often triggered first in epithelial
cells in an attempt to clear the infection. If the IFN-𝜆 response is insufficient and the
infection persists, then type I IFN, produced predominantly by recruited macrophages
and dendritic cells, takes over. A great example is the relationship between type I and III
interferons in response to influenza infection, which recapitulates the above model
(Galani et al., 2017). Thus, it can be generally stated that IFN-𝜆 is important for antiviral
response at barrier sites, while type I IFN is broadly utilized in antiviral response
[reviewed in (Donnelly and Kotenko, 2010; Lazear et al., 2015)].
The signaling pathways required to trigger synthesis of type I and III IFN
discussed above, converge on the activation of a family of transcription factors termed
interferon regulatory factors (IRFs) (Ito et al., 1999) with IRF3 and IRF7 being of
particular importance to RLR-mediated synthesis of type I / III interferons (Marié et al.,
1998). IRF3 is expressed in a broad range of cell types and low basal levels are present
in the cytoplasm. Activation of IRF3 via the RLR signaling pathways leads to
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homodimerization and translocation into the nucleus where it stimulates production of
mainly IFN-𝛽 (or IFN-𝜆) and several IFN-α subtypes. Following downstream IFN
signaling, IRF7, which is not constitutively expressed and acts as a positive feedback
mechanism for IFN production, is activated by a similar pathway as IRF3 and promotes
transcription of a different set of IFNs than IRF3 [reviewed in (Sen, 2002)]. Together,
active IRF3 and IRF7 promote the synthesis of all type I / III IFNs, which are secreted
from cells and stimulate autocrine (producer cell) and paracrine (surrounding cells)
signal transduction pathways.
Type I and III IFNs signal through distinct receptors, IFNαR and IFNLR1,
respectively, which activate a Janus Kinase / Signal Transducer Activator of
Transcription (Jak/STAT) signal cascade resulting in the transcription of hundreds of
interferon-stimulated genes (ISGs) (Randall and Goodbourn, 2008; Takeuchi and Akira,
2010; Wilkins et al., 2010; Yoneyama and Fujita, 2010). The type I IFN signal cascade
is well defined. Association with type I IFNs causes dimerization of the two IFNαR
component subunits, IFNαR1 and IFNαR2, leading to cross-phosphorylation of two
JAKs associated with the cytoplasmic tail. The Janus Kinases allow association of
STAT1 and STAT2, which are phosphorylated, dimerize and are released to bind
cytoplasmic IRF9 (Meyer, 2009; Samuel, 2001; Yoneyama and Fujita, 2010). This
complex, termed interferon-stimulated transcription factor 3 (ISGF3), enters the nucleus
and binds consensus cis-acting DNA elements (interferon-stimulated response
elements; ISRE) present on several hundred ISG promoters, which enhance
transcription (Liu et al., 2012; Schoggins et al., 2014, 2011). The result is the production
of hundreds of ISGs with a broad-range of antiviral activities.
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Antiviral activity of interferon-stimulated genes (ISGs). The end result of the
intricate interferon signaling cascade is the transcription of hundreds of interferonstimulated genes (ISGs) in both infected and uninfected neighboring cells. These ISGs
range in function from direct antiviral activity, immune cell regulation, negative and
positive- IFN signaling feedback and many more detailed in Table 3. Together, these
responses produce a host antiviral response against a multitude of RNA and DNA
viruses and determine the outcome of infection, degree of associated sequelae and
initiation of immune memory development. Several are discussed here, but please note
that this is by no means an exhaustive list.
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ACTIVITY
TYPE
PRRs

Translation
Inhibition /
Apoptosis

SPECIFIC ISG(S)

FUNCTION(S)

LITERATURE REVIEW

RLRs
(RIG-I, MDA5)

Binding cytoplasmic viral nucleic acids;
IFN I / III stimulation

(Loo and Gale, 2011)

TLRs
(TLR3,7-9)

Binding endosomal viral nucleic acids;
IFN I / III stimulation

(Iwasaki and Medzhitov, 2004)

PKR

(via eIF2a) Translation inhibition
(via FADD and Caspase 8) Apoptosis

(Dauber and Wolff, 2009)

OAS / RNaseL
IFIT Family

Binds dsRNA to induce total RNA
degradation; Substrates for RLRs
Pleiotropic: Reduce cap-dependent
translation; 5’ppp RNA binding; cell-intrinsic
and cell-extrinsic immune responses

(Chakrabarti et al., 2010)
(Diamond and Farzan, 2013)

RNA Mutation

APOBEC

Cytidine deamination

(Stavrou and Ross, 2015)

Host or Viral
Protein
Modulation

ISG15

Pleiotropic regulation of cell processes:
IFN signaling, translation, motility

(Perng and Lenschow, 2018)

Mx

Direct interaction with viral proteins
(e.g. nucleocapsid and polymerase)

(Verhelst et al., 2013)

IFITM Family

Inhibit entry of enveloped viruses

(Diamond and Farzan, 2013)

Tethrin

Binds to virions and prevents virus release
from membranes

(Sauter, 2014)

Viperin

Disruption of lipid rafts and lipid
homeostasis

(Fitzgerald, 2010)

RIG-I-mediated;
NLRp3-mediated

Non-canonical Production of IL-1𝛽;
Modulation of NLRP3 inflammasome

(Kopitar-Jerala, 2017; Poeck et
al., 2010)

IL-12

CD4+ Th1 differentiation;
NK cell production of IFN-𝛾

(Biron et al., 1999)

IL-21

CD8+ / NK cell cytolytic activity

(Strengell et al., 2004)

Perforin and
Granzyme B

CD8+ / NK cell cytolytic activity

(Curtsinger et al., 2014)

IL-15

Proliferation of memory T cells and NK cells

(Verbist and Klonowski, 2012)

IFN-𝛾

Activation of CD8+ T cells and Macrophages

(Samuel, 2001)

CCL3; CCL5;
CXCL10

T cell chemoattractants

(Meager, 2006)

Multiple

Upregulates MHC-I, antigen processing
machinery and co-stimulatory molecules;
dendritic cell expansion, others

(Gessani et al., 2014)

Virus entry
and release

Inflammasome

T Cell and
Cytolytic Cell
Responses

Antigen
Processing /
Presentation

Table 3: Type I Interferon Stimulated Genes and Antiviral Activities.
Multiple ISGs play roles in virus surveillance and inducing drastic cellular
responses including shutdown of protein synthesis and/or programmed cell death
(apoptosis). The importance of pattern recognition receptors cannot be understated as
these allow host cells to determine if a virus is present in the tissue and ultimately
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trigger the interferon signaling cascade. It is not surprising then, that these PRRs,
including the RLRs, TLRs and NLRs, are significantly upregulated in response to
interferon signaling and therefore provide enhanced virus surveillance in infected and
uninfected cells. Additional cytoplasmic RNA binding proteins are also induced by
interferon and include both protein kinase R (PKR) and 2’5’-oligoadenylate synthase
(OAS). Following binding to cytoplasmic dsRNA, PKR has multiple roles in antiviral
response including phosphorylation of eukaryotic initiation factor (eIF) 2a leading to host
translation shutdown and promoting cellular apoptosis via the FADD/caspase8 pathway.
2’5’-OAS also binds cytoplasmic dsRNAs and produces the small signaling molecule
2’5’-oligoadenylate. This activates a second ISG, RNaseL, which non-specifically
degrades host and viral RNAs resulting in a shutdown of protein synthesis and
apoptosis. The products of RNaseL activity are also recognized by RIG-I and MDA5 and
thus represent a positive IFN-signaling feedback loop. Other ISGs including the large
family of cytoplasmic IFN-induced proteins with tetratricopeptide repeats (IFITs) and
ISG15 have been shown to have pleiotropic effects on virus surveillance and
fundamental cell processes. IFIT1 for example, is known to bind 5’-triphosphatecontaining RNAs similar to RIG-I, sequestering viral mRNAs and preventing uncapped
protein translation. IFIT1 has also been shown to inhibit cap-dependent translation
through interaction with eIF3 thereby stalling the translation initiation complex or by
directly preventing association of non-methylated, capped viral mRNAs. ISG15, which is
one of the first and most abundant ISGs produced, is a ubiquitin-like polypeptide and is
post-translationally conjugated to both host and viral proteins. As a result, ISG15 can
caused proteasome-dependent protein degradation, impact the RLR/IFN signaling
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cascades and cell processes such as translation, glycolysis and motility. The full
spectrum of ISG15 activities and the mechanisms through which it acts are not fully
understood, however it can be appreciated as a significant antiviral response mediator.
Another set of ISGs act to inhibit virion entry, maturation and release from cells.
IFN-induced transmembrane proteins (IFITMs), are small host transmembrane proteins
that broadly inhibit the entry of enveloped viruses such as coronaviruses, flaviviruses,
influenza and others. While IFITMs are produced in cells at low basal levels, their
expression increases significantly with IFN stimulation. These proteins appear to more
potently inhibit viruses that fuse in late endosomes and although the exact antiviral
mechanism is not known, they have been predicted to affect the curvature of
endosomes to prevent fusion, alter the composition of lipids and host proteases and
recently, disrupt the vesicular trafficking network completely. Another ISG, Viperin
disrupts lipid homeostasis and lipid raft formation, critical sites for the budding and
release of several host lipid membrane-derived enveloped viruses. Finally, the activity of
an ISG called tetherin, physically binds to budding virions and significantly reduces the
efficiency to release from the cell surface. The activity of these ISGs acts to slow virion
production and help prevent entry of viruses into uninfected cells.
An early and robust interferon response is also important for modulating the
“quality, quantity and balance” of host adaptive responses, a notion our group has
utilized in the design of live-attenuated coronavirus vaccines. Type I interferon
stimulation has been shown to increase surface levels of MHC-I, the machinery required
to process and load antigens on MHC-I as well as and production of co-stimulatory
molecules in, and specific expansion of, antigen presenting cells. Several ISGs have
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also been shown to regulate T lymphocytes, which provide a critical adaptive response
to viral infection and are involved in activating phagocytic cells, antigen-specific killing of
virus-infected cells and cross-talk with B cells to establish humoral immunity. Among the
T cell modulating ISGs are IFN- 𝛾, IL’s -12, -15, -21 and several chemoattractant
cytokines that recruit CD4+ and CD8+ T cells to sites of infection. B cell differentiation
and isotype switching has also been observed, however the relationship between IFN
and these processes is complex and not fully understood. Thus, type I and III
interferons are critical modulators of innate antiviral immunity but are also important
regulators in CMI, humoral and long-term adaptive immunity.
Negative Regulators of Interferon Synthesis and Signaling.
Prolonged inflammation resulting from sustained IFN signaling and ISG activity
can lead to extensive tissue damage and sequelae long after viral clearance. These
immune-mediated complications are collectively referred to as “immune pathologies” or
“interferonopathies” and are observed following infection of multiple viruses including
influenza, West Nile virus and SARS-CoV (Channappanavar et al., 2016; Garcia-Sastre
and Biron, 2006; Le Goffic et al., 2006; Wang et al., 2004). As a result, cells encode a
number of negative regulators that act to suppress IFN signaling at the transcription and
post-transcriptional level [reviewed in (Arimoto et al., 2018)]. IRF2, for example, is a
member of the interferon regulatory factor (IRF) protein family that has been shown to
attenuate type I IFN gene synthesis by preventing transcription in the nucleus (Hida et
al., 2000). Several other ISGs are known to suppress IFN through post-translational
modification or direct interaction with components of RLR signaling pathways. NLRC5, a
NOD-like receptor (NLR) family protein, disrupts RLR-induced antiviral responses
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through direct CARD-CARD sequestration of RIG-I and MDA5, preventing association
with MAVS, while another NLR, NLXR1, disrupts the RLR signaling through competitive
binding to MAVS (Moore et al., 2008). Other proteins affect IFN signaling through
ubiquitin modifications that target RLRs. RNF125 is a K48 ubiquitin ligase that targets
RIG-I and MDA5 causing degradation by the proteasome (Arimoto et al., 2007). CYLD,
a deubiquitinase, removes poly-ubiquitin chains from activated RLRs, preventing
downstream binding to MAVS (Zhang et al., 2008).
Coronavirus-encoded Antagonists of Type I Interferon
Overview.
Establishing successful viral infection is a complex interplay between host and
viral factors. While the host attempts to detect and respond to unique virus signatures,
viruses utilize encoded factors to antagonize these host pathways and establish an
intracellular environment amenable to production of progeny virions [reviewed in (Katze
et al., 2002)]. This competition is often referred to as the “Red Queen Hypothesis”, a
literary allusion to continuous movement without progress, and is the driving force
behind both virus and innate response evolution (Duggal and Emerman, 2012). The
major obstacle to virus replication is the host master antiviral signaling molecule,
interferon. Indeed, all successful viral pathogens, including the coronaviruses discussed
in this dissertation, encode viral proteins that antagonize the synthesis, signaling and/or
effector functions of the host interferon pathway. Importantly, virus strains encoding
mutations in these interferon antagonists, creating so called hyper interferon-inducing
(HII) or hyper interferon-sensitive (HIS) strains, have been shown to attenuate virus
replication and are useful platforms for live-attenuated vaccine design (Deng et al.,
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2017; Du et al., 2018; Kindler et al., 2017). Coronaviruses carry a large, single-stranded
RNA genome, which is replicated in the cell cytoplasm and forms double-stranded RNA
intermediates during the process of discontinuous transcription. These single and
double-stranded viral RNAs are known to be potent triggers of type I / III interferon
synthesis and are detected by cytoplasmic and endosomal PRRs. Interestingly,
coronavirus infection does not result in an early or robust type I IFN response and these
viruses appear to replicate seemingly without innate immune detection by the host. In
fact, this has become a hallmark of coronavirus infection kinetics and is observed in
both human and animal cases (Channappanavar et al., 2016; Kint et al., 2014; Lau et
al., 2013; Menachery et al., 2014). This subversion of the IFN signaling cascade is due
to a complex and coordinated set of CoV-encoded interferon antagonists as well as
several fundamental aspects of coronavirus replication biology. Indeed, over fifteen
unique components of human and animal CoVs have been demonstrated to antagonize
distinct elements of the IFN synthesis and signaling pathways or affect ISG function
(Table 4). From these studies, several key conclusions can be drawn: First, all CoV
have multiple antagonists to delay the IFN response, the majority of which are groupspecific accessory genes, but several, such as the papain-like protease encoded on
nsp3 and the EndoU encoded on nsp15, are highly conserved across all CoVs. Second,
some antagonists are inherent aspects of CoV replication biology and may or may not
have evolved specifically to prevent immune activation. Finally, the ability of CoV
proteins to antagonize IFN may be cell-type specific as observed with MHV ns2 (Zhao
et al., 2012). Together, these mechanisms allow productive replication of coronaviruses
in various mammalian tissues without triggering an early innate immune response.
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ANTAGONIST
TARGET

VIRUS

SARS-CoV

IFN Synthesis
MERS-CoV

ANTAGONIST

ACTIVITY / TARGET

REFERENCE

PLpro

Binds STING and blocks IRF3
translocation

(Sun et al., 2012)

nsp14 and nsp16

RNA capping

(Totura and Baric, 2012)

ORF3b

Binds and blocks IRF3
translocation

(Freundt et al., 2009)

ORF6

Blocks NF-κB signaling

ORF4a

Binds dsRNA; blocks PKR

ORF4b

Prevents MAVS signaling by
binding TBK1
DUB activity prevents IRF3
signaling
Prevents MDA5, OAS and PKR
detection of dsRNAs

PLpro
Nsp15
MHV

(Mielech et al., 2014;
Yang et al., 2014)
(Deng et al., 2017;
Kindler et al., 2017)

DUB activity

(Mielech et al., 2015;
Rose and Weiss, 2009)

Nsp15

Prevents MDA5, OAS and PKR
detection of dsRNAs

(Deng et al., 2017;
Kindler et al., 2017)

nsp1

Decreases STAT phosphorylation

(Wathelet et al., 2007)

PLpro

Interaction with several cell
signaling components

(Clementz et al., 2010;
Devaraj et al., 2007;
Frieman et al., 2009; Li et
al., 2011)

ORF3a

Degradation of IFNαR

(Minakshi et al., 2009)

ORF6

Blocks STAT1 translocation

(Frieman et al., 2007)

ns2

Cleaves 2-5A and prevents
RNase-L activation

(Zhao et al., 2012)

ORF5a

Uncharacterized phenotype

(Koetzner et al., 2010)

Nsp15

Binds dsRNAs and prevents OAS
and PKR activation

MERS-CoV

ORF4a

Binds dsRNA; blocks PKR

(Deng et al., 2017;
Kindler et al., 2017)
(Niemeyer et al., 2013;
Rabouw et al., 2016)

IBV

nsp2

TGEV

ORF7

Overexpress GADD34 to block
PKR
Activates PP1c-mediated
inactivation of PKR and OAS

FIPV

ORF7

SARS-CoV

MHV

ISG Activity

(Yang et al., 2015)

PLP2
HCoV 229E

IFN
Signaling

(Hussain and Gallagher,
2010; Kopecky-Bromberg
et al., 2007)
(Niemeyer et al., 2013;
Rabouw et al., 2016)

Prevents phosphorylation of eIF2α

(Wang et al., 2009)
(Cruz et al., 2013, 2011)
(Dedeurwaerder et al.,
2014)

Table 4: Coronaviruses and Encoded Antagonists of the Type I IFN System.
Antagonism of the Interferon Pathway: Synthesis, Signaling and ISG Activity.
Synthesis. A number of coronavirus factors prevent the synthesis of type I
interferons by preventing detection of cytoplasmic RNAs or by directly targeting
components of the RLR or TLR signaling cascades. One aspect of coronavirus
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replication biology, the formation of host-derived double-membrane vesicles (DMVs), is
an important and well-conserved method to prevent RLR activation. These DMVs,
which are the sites of genomic RNA replication and mRNA transcription, act to
physically separate viral dsRNA replication intermediates from detection by MDA5
(Gosert et al., 2002; Knoops et al., 2008; Prentice et al., 2004; Shi et al., 1999; van der
Meer et al., 1999). Once viral mRNAs are produced within the DMVs, they must enter
the cytoplasm for translation. This is problematic as these viral RNAs contain a 5’
triphosphate, a potent activator of RIG-I. However, the conserved activity of
nonstructural protein (nsp) 13 removes the 5’ triphosphate and further processing by
nsps 10, 14 and 16 adds a methylated guanidine 5’ cap thus preventing the detection of
this viral mRNA by RIG-I and allowing translation (Bouvet et al., 2010; Chen et al.,
2009; Decroly et al., 2008; Ivanov and Ziebuhr, 2004; Züst et al., 2011). Our group and
others have also demonstrated that other highly conserved components of the DMVassociated replicase-transcriptase complex (RTC), the papain-like protease and the
EndoU, are important interferon antagonists. My contributions to determining the IFN
antagonism functions of these proteins will discussed further below.
In many cases, however, DMV formation and viral mRNA capping are not
sufficient to prevent detection of viral PAMPs, thus coronaviruses encode compensatory
mechanisms to directly antagonize components of the RLR or TLR signaling cascades.
The well-studied human coronaviruses, SARS- and MERS-CoV, for example, utilize
several unique accessory proteins for this role. In SARS-CoV, ORF3b binds directly to
IRF3 preventing nuclear translocation (Freundt et al., 2009), while ORF6 blocks NF𝜅B
and downstream STAT1 signaling by impeding protein import into the nucleus (Frieman
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et al., 2007; Hussain and Gallagher, 2010; Kopecky-Bromberg et al., 2007). The MERSCoV accessory protein ORF4a has been shown to bind cytoplasmic dsRNA species
preventing RLR binding as well as PKR-mediated shutdown of host protein synthesis
(Niemeyer et al., 2013; Rabouw et al., 2016). ORF4b, another MERS accessory protein
prevents MAVS signaling by binding to TBK1 and preventing kinase activity (Yang et al.,
2015). Together, these IFN synthesis antagonists represent a small number of studied
viral factors and it is likely that other coronavirus species, including the large number of
SARS-related bat CoVs, encode unique accessory proteins to prevent IFN synthesis.
Signaling and activity of interferon-stimulated genes (ISGs). Following
synthesis, interferons are released and propagate the antiviral signal back to the
producer cell (autocrine) and neighboring cells (paracrine) through engagement of the
IFN alpha-receptor (IFNαR). This triggers the Jak/STAT signal cascade and results in
ISG production. Not surprisingly, coronavirus IFN antagonists also target components of
this signal pathway as well as specific activities of the ISGs produced. To prevent
signaling, SARS-CoV reduces the cell-surface abundance of IFNαR, through the activity
of the accessory protein, ORF3a (Minakshi et al., 2009). Further, SARS-CoV nsp1 and
ORF6 antagonize the host protein STAT by decreasing the phosphorylation required for
STAT activity and blocking STAT1 translocation, respectively (Frieman et al., 2007;
Wathelet et al., 2007).
Further downstream, multiple coronaviruses encode ISG antagonists many of
which target PKR and the 2’5’-OAS / RNaseL system. These two cytoplasmic systems
bind dsRNAs and lead to shutdown of host protein synthesis and apoptosis by
phosphorylation of eIF2α (PKR) or non-specific digestion of host and viral RNAs
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(OAS/RNaseL), thus blocking the activity of these ISGs is critical for virus production.
Several factors including the highly conserved EndoU encoded on nsp15 (Deng et al.,
2019b, 2017; Kindler et al., 2017), and the MERS-CoV accessory protein ORF4a
(Niemeyer et al., 2013; Rabouw et al., 2016) prevent ISG activation by binding and
sequestering cytoplasmic dsRNAs. The MHV hepatocyte-specific accessory protein ns2
cleaves the small signaling molecule 2’5’-oligoadenylate preventing activation of
RNaseL (Zhao et al., 2012). Others, such as MHV ORF5a, are known ISG antagonists
however but their functions have not been fully described (Koetzner et al., 2010).
Generally speaking, coronaviruses that encode these downstream signaling and
ISG antagonists are much more resistant to IFN treatment and are more likely to
prevent de novo interferon activation of infected cells. FIPV, for example, remains highly
resistant to serum IFN as is evident by the inability to treat feline peritonitis with
intravenous IFN after infection is established (Weiss et al., 1990). Several studies
investigating TGEV (Cruz et al., 2013, 2011) and FIPV (Dedeurwaerder et al., 2014,
2013) have determined that 7a, an accessory protein only encoded in several
alphacoronaviruses, antagonizes the activity of ISGs and correspondingly causes
insensitivity to IFN. In TGEV, 7a enhances the specificity of protein phosphatase 1c
(PP1c) for eukaryotic initiation factor (eIF) 2a. This interaction causes increased
dephosphorylation of eIF2a and results in prevention of host translation shutdown. In
FIPV, the activity of 7a is associated with a second unique accessory region, ORF3.
From clinical studies, it was determined that deletion of 7a or ORF3 from WT FIPV
resulted in a significant reduction of FIP severity. Wild-type FIPV and FIPV-∆7a viruses
stimulated similar, increased levels of type I IFN in feline macrophages and serum
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during cat infection. Interestingly, when 7a is expressed alone it not sufficient to
establish IFN resistance during VSV infection, suggesting that 7a requires additional
FIPV components, presumably ORF3 to function. The mechanism of ORF3 activity and
the characterization of other conserved or unique viral components responsible for IFN
antagonism have yet to be evaluated
Experimental Examples of Highly Conserved Coronavirus Interferon Antagonists.
The Baker Lab is interested in understanding how highly conserved nonstructural
proteins contribute to antagonism of interferon. We predict that mutagenesis of these
nsps, leading to a hyper-interferon-inducing (HII) virus phenotype, is a strategy that
could be employed to attenuate most all coronavirus strains and provide a platform on
which to construct live-attenuated vaccines. To test this hypothesis, colleagues and I
studied two CoV factors, the PLP2 encoded on nsp3 and the EndoU encoded on nsp15
and determined if these conserved proteins antagonized interferon. This work laid the
groundwork my dissertation research and formed the long-term goal of developing an
effective vaccine for feline coronavirus.
The feline coronavirus papain-like protease is an IFN antagonist. CoVs
encode one or two multifunctional papain-like protease(s) (PLP1 and/or PLP2), which
catalyze three reactions within the host cell: processing of the nonstructural CoV
replicase polyprotein (protease), cleavage of the host signaling molecule ubiquitin
(DUB), and deconjugation of the antiviral signaling molecule interferon-stimulated gene
(ISG) 15 (deISGylase). While protease activity is required for viral replication, it is
unclear what role DUB or deISGylation play during infection. We and others
hypothesize that PLP2 is an IFN antagonist acting through disruption of ub-dependent
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signaling in the IFN synthesis pathway, and therefore DUB function is an interesting
mutagenesis target for generating live-attenuated vaccine strains. The DUB activity of
MERS-CoV (Bailey-Elkin et al., 2014) and Equine Arteritis Virus (EAV) (van Kasteren et
al., 2013) PLPs have been shown to suppress innate immune responses by targeted
disruption of critical ubiquitination marks of IFN synthesis pathways (Bibeau-Poirier and
Servant, 2008). DUB activity, however, is not the only means by which PLP can
antagonize innate immune responses. Several groups have experimentally determined
that PLPs can indirectly antagonize IFN production through association with different
cell signaling components (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al.,
2009; Li et al., 2011; Mielech et al., 2014; Rose and Weiss, 2009; Sun et al., 2012).
SARS-CoV PLpro stabilizes the NF-𝜅B inhibitor I𝜅Bα, preventing NF-𝜅B nuclear
translocation and subsequent IFN production (Frieman et al., 2009). By a similar
mechanism, the PLPs of HCoV-NL63 and SARS-CoV were shown to associate with and
destabilize stimulator of interferon genes (STING) dimers (Sun et al., 2012). The end
result is disruption of IRF-3 nuclear translocation, a key element of the MAVS-mediated
IFN synthesis pathway. Additionally, SARS-CoV PLpro has been shown to decrease
STAT phosphorylation through proteasome-mediated degradation of ERK1 (Li et al.,
2011), a component of the auto- and paracrine signaling pathways leading to ISG
expression. These studies have largely been done on PLPs from the Betacoronavirus
genus, and I was interested to understand how conserved these functions were in the
alphacoronavirus feline infectious peritonitis virus (FIPV). Therefore, I characterized the
activity of recombinant FIPV PLP2, and demonstrated that it functions as a robust
protease (Figure 6A), deISGylase (Figure 6B) and DUB enzyme (Figure 6C) and is
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able to antagonize MDA5-driven IFN transcription (Figure 6D). Thus, the PLP2 from the
alphacoronavirus FIPV has the same conserved functions as other CoV PLPs, and
therefore generating an FIPV PLP mutant virus may lead to increased IFN stimulation
and virus attenuation.
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Figure 6: FIPV PLP2 is a Multifunctional Enzyme and IFN Antagonist. (A) Ability of
FIPV PLP to recognize and cleave at the predicted LXGG motif shown by trans
cleavage assay. Full-length nsp2/3(GFP) constructs co-transfected with empty vector
(mock), wild-type or catalytic mutant PLP2 in 293T cells. Processed nsp2/3 indicated
by nsp3-GFP cleavage product by western blot. (B-C) Western blot indicates removal
of myc-tagged ISG15 conjugates (B) and flag-tagged ubiquitin (Ub) marks (C)
compared to mock (M) and catalytic (CA) mutant. Cell protein expression (𝛽-actin) and
recFIPV-PLP2(V5) indicated. (D) WT recFIPV-PLP2 at 100 and 200 ng antagonizes
MDA5-mediated IFN promotion from ifn/luc reporter. Values presented as percent total
MDA5-induced ifn/luc promotion. Mean values ±SD from technical triplicate values.
Nonstructural protein 15 is a potent antagonist of type I interferon. Another
effective method used by CoVs to prevent IFN synthesis and ISG activity is to avoid
detection by PRRs entirely. Recently, our group and others demonstrated that the
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endoribonuclease (EndoU) encoded on the highly conserved nonstructural protein 15
acts as a dominant interferon antagonist by preventing detection of dsRNA replication
intermediates (Deng et al., 2019b, 2017; Kindler et al., 2017). In our 2017 study, mutant
mouse hepatitis viruses (MHV) encoding a hexamer-destabilizing mutation (N15m1) or
a catalytic site-inactivating mutation (N15m3) in EndoU stimulated high amounts of type
I IFN during replication in bone marrow-derived macrophages (Figure 7A). The nsp15mutant also promoted rapid macrophage apoptosis (Figure 7B-C) and prevented the
activation of both PKR and the 2’5-OAS / RNaseL systems (data not shown). We
determined that this virus was attenuated in tissue culture and did not cause pathology
in mice (data not shown). Further, vaccination with the N15m1 virus was sufficient to
protect mice from a lethal intracranial challenge of wild-type MHV (Figure 7D)
demonstrating that nsp15 is a valuable target for generation of live-attenuated vaccine
strains of other coronaviruses, such as FIPV.
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Figure 7. EndoU Mutant MHV Stimulates IFN and Protective Immunity in Mice. (A)
MHV expressing mutations in EndoU (N15m1 and N15m3) induce early production of
type I IFN in bone marrow-derived macrophages (BMDMs). BMDMs were infected with
WT or mutant MHV at an MOI of 0.1. At indicated time points, total RNA was extracted
and analyzed for mRNA levels of IFN-α11 by qPCR. The levels of mRNA relative to βactin mRNA were expressed as 2^-ΔCT [ΔCT= CT(gene of interest) −CT(β-actin)]. Values were
analyzed using a two-way ANOVA test by time. (B) Representative electron micrograph
images depicting induction of BMDM cell apoptosis following infection with mutant MHV
or staurosporine positive control. No apoptosis is observed in mock or WT MHVinfected BMDMs. Arrows indicate nuclear chromatin condensation, a hallmark of
apoptosis. (C) B6 BMDMs were infected with WT or mutant MHV at a MOI of 0.1. At
indicated time points, cell lysates were collected for the detection of cleaved–caspase-3
(active form), N protein, and β-actin by Western blotting. (D) Primary challenge of
C57/BL6 mice by N15m1 is protective against secondary challenge with WT virus. For
the primary infection, mice were challenged intracranially (IC) with WT or N15m1 MHV.
Primary WT infection was lethal by 10 days post-infection (DPI), whereas all mice
survived N15m1 infection (data not shown). Surviving mice (N15m1 immunized) were
challenged 7 weeks later with WT virus IC. All N15m1 immunized mice survived
whereas all naïve mice succumbed to infection.
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Final section remarks. From this preliminary work on the IFN antagonism
functions of a highly conserved coronavirus endoribonuclease, EndoU, and defining the
multifunctional activities of FIPV PLP2, it was clear that further investigation of IFN
antagonists encoded by feline coronavirus would positively benefit the field. Feline
coronaviruses (FCoVs) are arguably the most important veterinary infection in young
cats and infections can be highly lethal. However, vaccine design and implementation
has been a perennial challenge and no effective vaccine exists. The long-term goal of
the FCoV research program in the Baker Lab is to develop an effective, live-attenuated
vaccine against feline coronavirus through mutations of encoded interferon antagonists
such as the EndoU and PLP2. The scope of my dissertation, which will be discussed in
detail below, was to establish basic virology techniques to investigate FCoV in the lab
and to design genetic, tissue culture and technical tools to facilitate further study of
these important pathogens.
Feline Coronaviruses
Classification and Categorization.
Feline coronaviruses (FCoV) are members of the Alphacoronavirus genus
(Nidovirales order; Coronaviridae family; Orthocoronavirinae subfamily) (Figure 1) and
are closely related to other important veterinary pathogens, such as canine coronavirus
(CCoV) and transmissible gastroenteritis virus (TGEV), which share relatively high
genetic similarity. The FCoV genome (Figure 2) is single-stranded, non-segmented,
positive-sense RNA comprising approximately 29 kilobases. The genome organization
and predicted RNA structures of a clinical FIPV isolate is described by Dye et al. (Dye
and Siddell, 2007). Contained on the genome are 11 open reading frames, which
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encode the two replicase polyproteins pp1a and pp1ab, four structural protein S, E, M
and N (HE is not present), and two accessory protein regions, ORF3abc and ORF7ab.
Individual strains of feline coronavirus are further defined by two criteria: serotype,
based on antigenicity and sequence of the spike protein, and biotype (often referred to
as “pathotype”) related to cell tropism and the disease characteristics resulting from
infection (Table 5). The two FCoV biotypes include feline enteric coronavirus (FECV),
which causes a mild, often sub-clinical enteritis, and feline infectious peritonitis virus
(FIPV), the etiologic agent of the severe, systemic, immune-mediated disease known as
feline infectious peritonitis (FIP). Both biotypes can encode either serotype I or serotype
II (often referred to simply as “type I” or “type II”) spike proteins. The serotype
designation was initially made on the basis of antibody binding specificity but has
recently been updated to include sequence- and protease-cleavage site-specific
designations (Whittaker et al., 2018).
BIOTYPES

CELL
TROPISM

SEROTYPE

RECEPTOR

I

Unknown receptor;
DC-SIGN co-factor

Subclinical
enteritis; selflimiting;
persistent and
recurrent

Unknown receptor;
DC-SIGN co-factor

Feline infectious
peritonitis (FIP):
high mortality;
systemic;
immunemediated

Feline enteric
CoV (FECV)

II

I
Feline infectious
peritonitis virus
(FIPV)

II

Intestinal, lung
and kidney
Feline aminopeptidase N; epithelia
DC-SIGN co-factor

Myeloid
lineage cells:
monocytes,
Feline aminopeptidase N; dendritic cells,
macrophages
DC-SIGN co-factor

Table 5: Feline Coronavirus Biology.

DISEASE
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Historical Significance.
Feline coronaviruses are the most common pathogen identified in the feces of
domestic cats and are widespread with upwards of 90% seropositivity in certain
domestic feline populations (Hohdatsu et al., 1992; Pedersen, 2009). As a result, feline
coronaviruses, more specifically FIPV, are considered some of the most significant
causative agents of communicable disease in feline medicine. The connection between
a coronavirus and FIP was first suggested by Ward et al. in 1970 (Ward, 1970), and the
first strains were cultured in autochthonous macrophage tissue derived from an infected
cat in 1976-1980 (Black, 1980; N C Pedersen, 1976). A permissive cell type, the
macrophage-like Fcwf-4 cell line, was also described during this time and was used to
isolate several FCoV strains including the serotype I Black strain, the progenitor to the
stain used in this dissertation (Black, 1980; Jacobse-Geels and Horzinek, 1983).
The emergence of FCoV-mediated disease occurred suddenly in the United
States in the 1950-60s as cases of feline infectious peritonitis (FIP), then termed an
“important disorder of cats” (Holzworth, 1963), were increasingly diagnosed by
veterinarians at Angell Memorial Animal Hospital in Boston, MA. Investigators often
speculate on the conditions that led to the emergence of FCoVs during this time and
suggest three, possibly connected factors that may have facilitated the widespread
infection of cats (Pedersen et al., 2009). First is the potential for a speciation event in
which a related coronavirus, such as CCoV or TGEV, which became widespread in the
United States just 10 years prior, jumped into the feline population (Haelterman, 1962).
Indeed, recombination between these related alphacoronaviruses is observed (Benetka
et al., 2006; Herrewegh et al., 1998; Pedersen, 2009; Wesley, 1999). A prime example
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of natural recombination is the serotype II FCoV spike protein, which contains
sequences of both FCoV and CCoV (Herrewegh et al., 1998). Additionally, at least one
CCoV strain has been demonstrated to not only infect cats, but also enhance FIPV
infection (McArdle et al., 1992). A second possibility for emergence of highly pathogenic
FCoVs could stem from an FECV strain variant that is more easily mutable (lower
“mutagenic barrier”) to FIPV that could have arisen during that time. A final theory
involves the changes in feline husbandry in the years following WWII. As purebred cats
became more desirable, the density of mixed-breed cats in animal shelters increased
along with the number of feral cats. The cohousing of large numbers of cats (and dogs
for that matter) increases the chance of virus transmission and recombination between
FCoV strains. Feline leukemia virus (FeLV), another prominent pathogen of cats, also
emerged during this time and may have acted as a cofactor for FIPV: FeLV infection
leads to states of immune suppression, a scenario likely to allow development of a
large, genetically diverse FECV/FIPV quasispecies (Pedersen et al., 2009). It is likely
that multiple factors, possibly all three introduced here, led to the widespread
prevalence of feline coronaviruses within the domestic cat population – a dominance
still observed today.
Biotypes.
Feline coronaviruses are broadly grouped into two biotypes (often referred to as
“pathotypes”), feline enteric coronavirus (FECV) and feline infectious peritonitis virus
(FIPV). Traditionally, the biotype designation is based on several factors including cell
tropism, disease progression or severity, and a collection of genetic markers in the S
and 3c accessory gene (reviewed in Kipar and Meli, 2014; Pedersen, 2014, 2009),
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although the range of disease signs and clinical outcomes are likely to extend beyond
these two basic biotype definitions. Intriguingly, FIPV is not transmissible but rather,
arises directly from FECV during persistent infection of intestinal epithelia.
FECV is endemic in most healthy domestic cat populations. The virus is shed in
the feces and urine of infected cats beginning 1 week after introduction. Shedding can
be transient, recurrent or chronic for months or years. Due to the nature of the
shedding, the virus is transmitted via the fecal-oral route and is carried into the gut
where it replicates in mature apical epithelial cells in the intestine. FECV infection of
cats causes mild enteritis associated with loose stool and diarrhea and commonly leads
to an asymptomatic, persistent infection (Addie, 2011; Addie et al., 2003; Pedersen et
al., 2008). Immunity to FECV is tenuous and felines that clear the virus are often reinfected with the same FECV or a strain with high genetic similarity. Additionally,
antibody titers to FECV positively correlate with increased virus shedding in the feces,
and it thought that cell-mediated rather than antibody-mediated immunity is important to
clear FECV infection. A subset of FECV infections (3-10%) result in progression to
lethal feline infectious peritonitis (FIP) (Kipar and Meli, 2014; Pedersen, 2014a, 2009), a
systemic, immune-mediated disease with high mortality rates (Addie and Jarrett, 1992;
Niels C. Pedersen, 1976). This rapid-onset disease is due to genotypic and phenotypic
changes in a subpopulation of FECV virions resulting in infection of myeloid-lineage
cells. The infection of myeloid cells and the onset of FIP defines the second FCoV
biotype, FIPV.
FIPV is the second FCoV biotype and is not horizontally transmitted despite
being highly infectious if isolated and artificially introduced. The lack of transmission is
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likely due to the shift in tropism away from intestinal epithelia resulting in little to no
detectable FIPV shed in the feces. Rather, FIPV specifically infects myeloid lineage
cells including monocytes, macrophages and dendritic cells leading to systemic,
immune-mediated disease pathology and mortality rates close to 99% (Pedersen,
2014a).
The Internal Mutation Theory.
Characterizing the genotypic and phenotypic requirements for FECV to FIPV
progression is one of the more well-studied aspects of feline coronavirus biology as it
has such dramatic effects on disease and mortality. To date, the most widely-accepted
model is known as the “internal mutation theory” (Poland et al., 1996; Vennema et al.,
1998), which proposes that, within an individual animal, FIPV arises directly from FECV
due to non-synonymous mutations in spike (S) and the group-specific protein 3C. These
mutations accumulate and arise independently, not as a “set” and therefore, the
phenotype resulting from these mutations is critical – mainly productive infection of
myeloid-lineage cells.
Numerous factors can contribute to the accumulation of mutations in the FCoV
genome during infection. All coronaviruses encode both an RNA-dependent RNA
polymerase (nsp12), which has an error rate of 1 per 10,000 nucleotides, and an ExoN
(nsp14) with proofreading activity to ensure sequence fidelity. Despite this, when one
group compared 11 genomes each of FECV and FIPV obtained during natural
infections, they found that approximately 10% of the FIPV nucleotide identity was
unique, and did not occur across the FECV genomes tested (Chang et al., 2012;
Pedersen, 2014a). Further, over half of these mutations occurred in spike while others
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accumulated in ORF1ab and the accessory genes. The high rate of substitution
suggests that advantageous mutations accumulate over the course of multiple
replication cycles and, therefore, both acute and persistent FECV infection can increase
the density of mutations. A second factor is immune suppression, which can allow
mutations to arise that would normally be selected against due to a loss of fitness. FIP
rates are higher in kittens and likely result during the primary FECV infection when virus
titers are higher, and mutations are tolerated due to a less developed immune system.
In adult cats with recurrent or persistent FECV infection, perturbations of the host feline
immune state leading to immune deficiency can allow virus replication to flare up
(Pedersen, 2009; Poland et al., 1996; Tekes and Thiel, 2016), resulting in the formation
of a quasispecies and the genetic sampling required for progression to FIPV. Genetic
recombination amongst co-infecting FECV is the final component that leads to
accumulation of mutations. This can occur between members of a quasispecies or if a
cat becomes infected with a different strain of FECV.
Mutations that accumulate specifically within spike and accessory protein 3c are
thought to be the determinants of myeloid cell infection and progression to FIPV (BankWolf et al., 2014; Cham et al., 2017; Chang et al., 2012; Licitra et al., 2014, 2013;
Regan et al., 2008). The spike protein is the major determinant of cell tropism and
critical for infection of myeloid cells. This was first demonstrated using FCoV
recombinants where investigators determined that regions of the FIPV spike were
absolutely required for macrophage replication (Rottier et al., 2005). Further studies
done using serotype I laboratory strains determined that spike cleavage can be variable
between biotypes. FECV-UCD strain recovered from experimentally-infected cats
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maintained the S1/S2 furin cleavage site, while an FIPV strain, UCD1, lost this furin
cleavage site exposing a heparan sulfate binding motif allowing spike interaction with
polysaccharide residues (de Haan et al., 2008), which may impact cell tropism. In
parallel using serotype II FCoVs, Regan et al. identified differential roles for pH and
cathepsin cleavage during entry of FECV compared to FIPV (Regan et al., 2008). This
study demonstrated that specific S cleavage site sequences and, by extension, specific
host proteases are necessary to FCoV tropism. In an important study, another group
compared the genomic sequences of 11 FECV-FIPV pairs as well as 100s of individual
strains and found two mutations in the fusion peptide of spike S2, which were present in
96% of FIPV and none of the FECV strains (Chang et al., 2012). The following year,
Licitra et al. identified that 66% of FIPV strains evaluated carried unique mutations in
the S1/S2 cleavage site, which altered the efficiency of cleavage by host furin (Licitra et
al., 2013). Interestingly, several of these mutations at or around the S1/S2 cleavage site
were also observed in non-pathogenic strains of FECV suggesting that this may be an
early step in acquiring myeloid tropism. Together, these reports demonstrate that
mutations to S that alter either spike cleavage or fusion are associated with or directly
lead to myeloid cell tropism.
In approximately 20% of FECV primary infections, FECV replication in
macrophages is observed without severe disease progression (Pedersen, 2009; Poland
et al., 1996). This indicates that other mutations need to occur in order to cause FIP and
simple infection of macrophages is not sufficient. The accessory protein 3C, produced
from the polycistronic ORF3 region, is the second component that contributes to FCoV
biotype transition, although the exact function of 3c is unknown. Across several studies
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investigators determined that approximately two-thirds of sequenced FIPV strains have
mutations resulting in a truncated 3C protein, with the other one-third carrying extensive
mutations at the 3’ end (Bálint et al., 2012; Chang et al., 2012, 2010, Pedersen et al.,
2012, 2009). The authors collectively suggested that truncation of the 3C protein (or
significant mutation) is critical for macrophage tropism as truncated 3c coding
sequences were only observed in myeloid cell-isolated strains and not in strains derived
from fecal or intestinal materials. Further, Hsieh et al. demonstrated that expression of
full-length 3C in feline macrophage-like Fcwf-4 cells significantly reduced the titers of
FIPV strains encoding truncated 3c genes (Hsieh et al., 2013). Interestingly, FECV
intestinal isolates have been identified with collections of mutations at the 3’ end of the
full-length 3C protein coding sequence and may represent a transition-state virus
population.
Collectively, the comparative studies of FCoV spike and 3C support the original
proposal of the “internal mutation theory” in which FIPV arises directly from FECV: i)
perturbations of feline immune competency lead to bursts of FECV quasispecies
replication allowing new mutations to be sampled without negative selection; ii) spike
mutations accumulate in a subset of FECV virions, allowing attachment and entry into
myeloid cells; iii) truncations of the 3C protein enhance replication within these myeloid
cells providing a competitive advantage; iv) infected myeloid cells traffic to various
tissue sites leading to systemic infection and progression to FIP.
Interestingly, following transition, the FIPV genome is relatively stable with an
observed mutation rate of 5-6x10-6 over 50 passages (Phillips et al., 2013). This
demonstrates that not only are large numbers of mutations tolerated (relative to the
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parental FECV), but also illustrates the large degree of genetic disruption that can occur
to the FCoV genome before significant disruptions to virus fitness occur. Finally, this
observation underscores the high degree of genetic plasticity and variability observed
between FCoV isolates and the various states of transition isolates may exist in.
Serotypes.
The feline coronavirus spike (S) glycoprotein is largely responsible for
determining host range and cell tropism as it mediates both receptor binding and
membrane fusion. These large, trimeric structures have extensive ectodomains, which
represent the main surface antigen and binding target of FCoV-specific antibody
responses. As a result, characterizing FCoVs based on antigenicity of the spike protein
was an early method used to group new strains, and has revealed the existence of two
such serotypes: serotype I and serotype II (Hohdatsu et al., 1991a; Pedersen et al.,
1984). Thus, FECV and FIPV strains can be defined as either serotype I or serotype II.
Serotype I FCoVs, which utilize an unknown host receptor for entry, are widespread and
are responsible for the majority (70-90%) of natural infections. Serotype II FCoV strains,
which round out the other 10-30% of infections, express a naturally-occurring
recombinant of feline and canine coronavirus type I S proteins (Addie et al., 2003;
Benetka et al., 2004; Herrewegh et al., 1998; Hohdatsu et al., 1992; Kennedy et al.,
2002). Serotype II viruses use feline aminopeptidase N (fAPN), a cell-surface
metalloprotease distributed in intestinal, lung and kidney epithelia, as an entry receptor.
Both serotypes are known to use dendritic cell (DC)–specific intercellular adhesion
molecule (ICAM) grabbing nonintegrin (DC-SIGN), a C-type lectin, as an entry co-factor
enabling entry into macrophages, however this factor is not sufficient for entry (Regan et
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al., 2010). A commendable number of studies focus on type II FCoV as these viruses
are much more easily propagated in cell culture than serotype I FCoVs. However, it is
difficult to know how accurately type II laboratory strains reflect natural infections with
type I viruses given that the bulk of what is known about type I is extrapolated from
studies using a type II virus.
With the advent of inexpensive high-throughput sequencing and FCoV strain
isolation it has become increasingly clear that the traditional serotype designation is not
sufficient to describe the large amount of FCoV strain variation. Recently, a new method
to classify FCoV strains has been proposed to update the serotype designations and
improve the taxonomy of alphacoronaviruses (Whittaker et al., 2018). Whittaker et al.
argue that grouping FCoV based on spike antigenicity alone inappropriately implies that
only minor biologic differences separate these viruses. However, it is now widely
appreciated that major biologic differences do exist between serotypes including
severity of associated pathogenesis (Pedersen, 2014a) and usage of cellular
components, such as cholesterol, for replication (Takano et al., 2016). Additionally,
serotype I and II FCoV spike proteins engage different host cell entry receptors (Dye et
al., 2007; Tresnan et al., 1996), contain unique cleavage sites on S that require different
host proteases for cleavage, and can even differ in the site of virus membrane fusion:
surface versus endosomal. (Licitra et al., 2013; Whittaker et al., 2018). Therefore, rather
than defining FCoV simply on antigenicity of S, Whittaker et al. propose to further
categorize FCoVs into two clades by combining function-based data (e.g. receptor
binding; protease cleavage) with S-protein sequencing (Whittaker et al., 2018). Although
this method of categorizing FCoV strains is objectively more accurate, for the sake of

83
continuity, this dissertation will refer to strains based on their original serotype
designations.
FIPV Pathogenesis and FIP Clinical Features.
FIPV primarily infects myeloid cells such as monocytes, macrophages and
dendritic cells. During artificial infection, FIPV replication in macrophages progresses
slowly over 2 weeks and is critical for determining disease progression. In rare cases,
the feline mounts a strong, rapid cell-mediated immune (CMI) response, containing the
virus within the mesenteric lymph nodes and eventually clearing it. However, in the
majority of cases the CMI is not strong enough and the virus titer, distribution and naïve
macrophage infection rate increase dramatically. Coincident with the rise in FIPV viral
load is the onset of detectable viruses-specific antibody titers in the blood between 1021 days post-infection. Although antibodies have been shown to neutralize virus in vitro,
during natural infection, antibody-dependent enhancement (ADE) of disease is
observed. In this case, antibodies specific to S (and commonly the E protein) prevent
engagement of the virus receptor; however, these large antibody-virus complexes are
endocytosed via FcR-mediated uptake and accumulate in the late endosome and virus
replication proceeds.
FIP can present in two forms depending on the dominant immune response to
infection. The more common “wet” disease occurs when humoral immunity is strong and
CMI is absent. This wet disease is effusive and results in inflammation of the visceral
serosa and omentum with exudation into the abdomen. This is visualized by significant
enlargement of the body cavity due to intestinal distension and ascites fluid buildup. The
wet systemic disease results from the development of so-called pyogranulomas, a
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collection of protein-rich edema fluid containing T and B lymphocytes and neutrophils
that surround a large number of FIPV-infected macrophages, around different organ
venules. In response to pyogranuloma formation, additional macrophages are recruited,
which exacerbate inflammation with the release of cytokines and the activation of the
classical complement cascade. Prolonged inflammation and complement activation
cause microhemorrhages and red blood cell lysis. Infected cats usually succumb to FIP
several days after the development of pyogranulomas.
The rarer form of FIP, known as “dry” disease occurs when humoral immunity is
strong and CMI is present, but weak. In this case, the initial infection is more contained,
but not completely eliminated thus the disease progresses more slowly over weeks to
years. The dry disease presents with more traditional granuloma formation and
involvement of parenchymatous organs such as the kidneys, mesenteric lymph node,
bowel wall, liver and most commonly the eyes and central nervous system. Granulomas
form when B and T lymphocytes surround around a small number of macrophages with
little to no replicating virus. Unlike the wet disease, the inflammation is low-intensity and
chronic rather than massive and acute. Complications due to prolonged inflammation
occur in multiple organ systems and usually involve paralysis and seizure. Although the
dry form progresses more slowly, the mortality rate is the same as the wet form – nearly
99% fatal.
Due to the degree of immune suppression during FIPV infection, co-infections
are common and lead to additional complications, accelerated disease and enhanced
transmission of FECV. Feline leukemia virus (FeLV) infection is observed in one-half to
one-third of FIPV cases and other coinfections include opportunistic bacterial pathogens
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and parasites such as Toxoplasma gondii. Several groups have suggested that these
co-infections, specifically of FeLV, which can induce immune suppression, can enhance
progression to FIPV in co-housed cats.
T and B Cell Responses and Effects on FIP Progression.
FIP is defined as an “immune-mediated” disease meaning that the degree of
associated pathology is largely due to differences in the timing strength and type of the
immune response. Significant imbalances between intrinsic, T and B cell immune
responses is the most widely accepted reason for the inability of cats to resist FIPV
infection and the resulting > 90% mortality rate (de Groot-Mijnes et al., 2005; Kipar and
Meli, 2014; Pedersen, 2014a, 2009).
Although rare, positive FIP outcomes are associated with rapid cell-mediated
immunity (CMI) involving cytotoxic T lymphocytes and natural killer (NK) cells. A strong
CMI-response limits virus growth through direct killing of virus-infected cells, mostly
macrophages, in the mesenteric lymph node and prevents the massive upregulation of
pro-inflammatory cytokines and granuloma formation that mediate disease (Pedersen,
2014a). Increased IFN-𝛾 production, a major product of activated CD8+ T cells and NK
cells, is associated with protection in cats with natural FIPV infection and was observed
in peripheral blood mononuclear cells (PBMCs) taken from experimentally-infected cats
that survived FIPV challenge (Satoh et al., 2011). Surviving cats were also found to
have high levels of IL-10, an important immune-suppressing cytokine produced by T
regulatory cells. Additional evidence supporting the importance of CMI comes from
examination of cats that succumb to FIPV infection. In these cases, CD4+ and CD8+ T
cells and NK cells were found to be depleted in peripheral blood of moribund cats with
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natural FIPV infections (Vermeulen et al., 2013). T regulatory cells, which produce IL-10
and function to regulate the degree of inflammation in response to infection, were also
found to be depleted suggesting that elimination of these cells may significantly
contribute to unregulated inflammation associated with severe pathology (Vermeulen et
al., 2013). Finally, transcriptional profiling of PBMs recovered from FIPV-infected
animals demonstrated enrichment of the PD-1 / PD-L1 factor pair (Harun et al., 2013),
which is involved in repression of cytotoxic T cell responses, further highlighting the
importance of cell-mediated immune responses in controlling FIPV.
The majority of FIPV infections result in death of the infected animal and are
associated with depletion of T cells resulting in inefficient CMI, systemic virus replication
and unrestricted inflammation (Kipar et al., 2006; Pedersen, 2014a). Indeed, moribund
cats naturally infected with FIPV were found to have a higher proportion of activated
macrophages and neutrophils (Kipar et al., 2006; Takano et al., 2009b), increased
serum levels of macrophage differentiation / stimulation factors including IL-6, GM-CSF,
M-CSF and IL-1𝛽, and reduced immune regulatory factors such as IL-10 and IL-12
(Kipar et al., 2006). Macrophages from moribund FIPV-infected animals also expressed
high levels of B-cell activation markers including IL-6, CD40 and B cell activating factor
(BAFF), suggesting that B cells are somehow involved in FIP progression (Takano et
al., 2009a). Indeed, activation of B cells and production of FIPV-specific antibodies
(humoral immunity) is strongly associated with rapid disease progression though a
process called antibody-dependent enhancement (ADE) (Pedersen and Boyle, 1980;
Takano et al., 2008; Weiss and Scott, 1981). FCoV-specific antibodies are observed
during both FECV and FIPV infections (Pedersen, 2009) and are directed against
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surface epitopes on the FCoV S and E proteins. In tissue culture, these antibodies lead
to virus neutralization; however, these same neutralizing sites were also responsible for
directing ADE in animals – a fact that has complicated vaccine design for decades
(Takano et al., 2011). One group demonstrated the negative impact of these antibodies
experimentally by injecting subclinically-infected cats with serum obtained from cats fully
infected with either FECV or FIPV (Takano et al., 2008). This passive immunization led
to serotype-matched-specific ADE and rapid disease progression compared to control.
Several groups have proposed models of how ADE of FIP occurs. Studies by
Dewerchin and colleagues determined that macrophages infected with FIPV expressed
viral antigens on the cell surface (Dewerchin et al., 2008). When antibodies bound these
antigens, the antigens were rapidly internalized (Dewerchin et al., 2008, 2006). The
internalization of these cell surface antibody-antigen complexes reduces to chance of
virus-infected macrophages to undergo antibody-dependent cell-mediated cytotoxicity
(ADCC), a process in which infected cells are actively killed by surveying NK cells
through interactions between NK cell Fc receptors (FcR) and a cell-bound antibody.
Thus, FIPV-infected macrophages survive and continue to produce virus. A second,
more traditional model of ADE was also proposed by this group (Dewerchin et al.,
2008). During in vivo infection, it was observed that large antibody-virus complexes
were endocytosed by macrophages, accumulated in mature endosomes and led to
productive infection. This internalization process was dependent on FcR-𝛾 on the
surface of the macrophage, which allows internalization of viruses by CoV-receptor
independent process. This provides some clarity on how the same virus epitope could
lead to virus neutralization in tissue culture, but ADE in vivo – likely these “neutralized”
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viruses do not require surface-level spike-receptor engagement, but rather gain entry
through endocytosis of the entire complex. By either method, FIPV is able to enhance
access to macrophages and maintain productive infection without triggering targeted
cell death.
The complex relationship between innate and adaptive responses and the
immune-consequences that lead to FIP development need to be strongly considered
during vaccine design. For this reason, vaccine development had been slow and viewed
more as a pipedream, and much more emphasis has been placed on development of
therapeutics (see below). However, new studies from our group on generating liveattenuated CoV vaccines through generation of hyper-interferon inducing (HII) strains,
and the research presented in this dissertation may overcome some of the previous
challenges to designing an effective FIPV vaccine.
Current Therapeutic Options.
A large number of studies have looked at the efficacy of various therapeutic
compounds in treating FIP. These compounds fall into three main categories: i) immune
modulatory compounds targeting the rapid systemic inflammation arising during FIPV
infection; ii) compounds targeting cellular pathways usurped by the virus during
replication; iii) direct-acting antiviral inhibitors that specifically block virus replication.
As pathology associated with FIPV infections is mediated by an overactive
inflammatory response, it is reasonable to predict that targeting these immune
responses may decrease disease severity. Reduced levels of TNF-alpha, a
proinflammatory host factor, were shown to be associated with positive outcomes in
cats with natural FIPV infections (Kipar et al., 2006), however, treatment with the anti-
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TNF-alpha inhibitor Pentoxifylline failed to reduce FIP-associated mortality (Fischer et
al., 2011). Another group pre-treated cats with type I IFN, which has pleiotropic antiviral
effects, in an attempt to prime antiviral innate immune responses. This prophylactic
administration of type I IFN was also ineffective at reducing mortality rates following
FIPV infection (Weiss et al., 1990), an observation consistent with the presence of IFN
signaling and ISG antagonists present in FCoVs (Dedeurwaerder et al., 2014, 2013).
Interestingly, combining IFN treatment with peptides mimicking the FIPV spike heptad
repeat (HR)-domain (predicted entry inhibitors) had a synergistic antiviral effect on
reducing serotype II FIPV infection (Liu et al., 2013) suggesting that type I may be
effective as a treatment supplement. These experiments, however, were performed in
tissue culture and it is unclear if the tandem IFN/HR-peptide treatment would be
effective in vivo.
Several groups have demonstrated effective FIPV treatment by employing
compounds that target cellular processes. Takano and colleagues observed that type I,
but not type II FIPV replication requires the presence of plasma-membrane cholesterol
(Takano et al., 2016) and predicted that this may be a cellular target of antiviral
treatment. Indeed, a follow-up study demonstrated that pre-treatment of cells with
U1866A, an inhibitor of cholesterol transport, caused intracellular cholesterol
accumulation and strong inhibition of type I FIPV replication (Takano et al., 2017). This
study also reported that the antiviral activity of U1866A was reversed by the HDAC
inhibitor Vorinostat, which reverses the negative effects of U18666A on the host protein
Niemann-Pick C1 (NPC1) suggesting a possible role of NPC1 in type I FCoV
replication. Further evidence for the role of NPC1 was recently demonstrated (Takano
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et al., 2019). This study determined that therapeutic treatment of infected cats with the
antifungal drug Itraconazole, which blocks NPC1, had significant antiviral activity
against serotype I, but not serotype II FIPV. These studies represent exciting new
avenues of drug development and treatment of cats with FIPV; however, as they target
cell-intrinsic properties, further investigation will be needed to determine the long-term
safety of these drugs.
The most promising anti-FIPV therapeutics are the class of small-molecule
inhibitors with direct-acting antiviral activities. Several of these compounds have been
developed and specifically inhibit the FIPV 3C-like protease (3CLpro), a viral enzyme
absolutely required for CoV replication. St. John et al. investigated the inhibitory
potential of several peptidomimetic compounds, which impersonate the natural peptide
cleavage target and non-covalently associate with the active site of 3CLpro (St. John et
al., 2015). Two such compounds were found to inhibit purified recombinant FIPV
3CLpro with 50% inhibitory concentration (IC50) values in the sub-micromolar range. An
exciting study was recently published by Kim et al., which demonstrated near-full
reversal of FIP upon treatment with another 3CLpro inhibitor, GC376 (Kim et al., 2016).
Investigators experimentally infected cats with serotype I FIPV (m3c-2 strain) and
administered doses of GC376 after development of clinical signs of FIP and observed
recovery of treated cats after several weeks. It should be noted that GC376 is a small,
dipeptidyl compound containing a catalytic warhead, which covalently binds the catalytic
cysteine reside in the active site of 3CLpro and may have unintended off-target effects
on cellular proteases. Additionally, the compound has reduced access to the CNS due
to the blood-brain barrier and therefore may be ineffective at treating the dry form of
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disease. Although exciting, further investigation of this inhibitor will be needed before
wide-spread use is adopted by veterinary professionals.
Much progress has been made in developing effective therapeutics to treat cats
infected with FIPV. However, realistic and effective treatment of sick cats would likely
require near-immediate recognition of FIP-like disease symptoms, multiple injections
and a substantial investment by drug companies to synthesize large quantities of
compounds, all factors that drive up the total cost of treatment. Additionally, these
methods do not address the high seroprevalence of FECV in domestic cat populations
and cannot prevent new infections with subclinical strains. The gold standard in the field
remains the development of an effective vaccine against serotype I FCoV allowing longterm and widespread immunity. Such a vaccination would be effective at preventing the
spread of the virus, decrease global seroprevalence and allow maintenance of isolated
FCoV disease using the more expensive antivirals. Over the decades, however,
developing a vaccine for serotype I FIPV has been a significant challenge to the field
and as a result of numerous factors, discussed in the following section, no such vaccine
exists…yet.
The Challenges and Value to Investigating Serotype I Feline Coronavirus
Overview.
Serotype I viruses account for the bulk (80-90%) of naturally occurring FCoV
infections in domestic cats and are considered one of the most important veterinary
animal pathogens. Investigating type I FCoV in a controlled laboratory setting is
required to understand the basic virology of natural infection, characterize clinical
isolates, test novel therapeutics, and develop effective feline vaccines. Additionally,
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serotype I FCoVs provide an important model system in which to study the
pathogenesis, immune regulation, and basic virology of the Alphacoronavirus genus,
which comprises several under-studied yet economically-important animal
coronaviruses such as TGEV and PEDV. However, a number of challenges to studying
serotype I FCoVs have burdened the field for decades and include inefficient methods
of virus isolation and growth in tissue culture, limited permissive cell types, the lack of a
known receptor and significant variation between clinical and lab-adapted virus strains.
As a result, many groups have focused on the less prevalent (<10%) type II FCoV as
these viruses are much more easily propagated. However, despite the utility of the type
II FCoVs it is difficult to know how accurately type II laboratory strains reflect natural
infections with type I viruses given that the bulk of what is known about type I is
extrapolated from studies using a type II virus. Thus, more needs to be done to facilitate
research of serotype I feline coronavirus in order to overcome the challenges described
in this section.
Virus Isolation and Strain Variation.
Since the early 1980’s, a number of groups have isolated feline coronavirus
strains representing both bio- and serotypes (Table 6). As mentioned, most groups
study serotype II strains due to their rapid growth in tissue culture (TC). For example,
the widely used FECV 79-1683 and FIPV 79-1146 viruses have been TC-adapted and
readily propagate in cell lines expressing feline APN, such as Crandell Rees Feline
Kidney (CRFK) cells (Miguel et al., 2002). Although there is debate on how “natural”
these strains are, TC-adaptation does not appear to effect the patho-biology of the
serotype II viruses as strains lead to the same illness in cats from which they were
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derived (Pedersen, 2014a, 2009). In addition, several serotype II FCoV including the
C1Je and NTU156 strains, have been maintained as primary clinical isolates (CI) by
passage in felines (Dye and Siddell, 2007; Lin et al., 2013). This technique preserves
the natural “clinical” virus phenotype, avoids any tissue-culture adaptations and allows
experimental control of natural serotype II infection.
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BIOTYPE

FECV

TYPE

I

II

I

FIPV

II

STRAIN

VIRULENCE

SPECIMEN

ACC #

REFERENCE(S)

UCD

Avirulent

CI

-

(Pedersen et al., 1981b)

RM

Avirulent

CI

-

(Hickman et al., 1995)

Felix

Avirulent

Rev Gen

MG893511.1

(Ehmann et al., 2018)

79-1683

Avirulent

TC Adapt

JN634064.1

(McKeirnan et al., 1981)

TN406-LP

High

CI

-

(Black, 1980)

TN406-HP

Avirulent

TC Adapt

Black
(TN406)

Avirulent

Rev Gen

EU186072

(Tekes et al., 2008)

UCD1

High

Cat Tissue

-

(Pedersen et al., 1981a)

UCD2

Avirulent

TC Adapt

-

(Pedersen and Floyd, 1985)

UCD3

-

TC Adapt

-

(Pedersen and Floyd, 1985)

UCD5

-

CI

-

(Herrewegh et al., 1995)

UCD8

FIP (+)

CI

-

(Hickman et al., 1995)

UCD9

FIP (+)

-

UCD10

FIP (+)

CI; FECVRM infected
cat with FIP

Wellcome

-

TC Adapt

-

(O’Reilly et al., 1979)

KU-2

-

-

D32044

(Hohdatsu et al., 1991b;
Motokawa et al., 1995)

m3c-2

FIP (+)

Cat Passed

-

(Kim et al., 2016)

79-1146

High

TC Adapt.

DQ010921.1;
NC002306

(Dye and Siddell, 2005)

79-1146

High

Rev Gen

-

(Tekes et al., 2012)

UCD4

Moderate

TC Adapt

-

(Pedersen and Floyd, 1985)

UCD6

-

CI

-

(Herrewegh et al., 1995)

NOR15

High

TC Adapt

-

(Evermann et al., 1981)

DF2

-

Rev Gen

JQ408981

(Bálint et al., 2012;
Christianson et al., 1989;
Evermann et al., 1981)

DF2 (ts)

Avirulent

Vaccine

DQ286389.1

(Taboni et al., 2007) unpub

C1Je

FIP (+)

CI

DQ848678.1

(Dye and Siddell, 2007)

NTU156

FIP (+)

CI

GQ152141

(Lin et al., 2013)

(Pedersen and Black, 1983)

(Poland et al., 1996)
-

Table 6: Feline Coronavirus Strains. Abbreviations: GenBank accession number (Acc
#); TN406-Low Passage (LP), TN406-High Passage (HP), DF2-temperature- sensitive
strain (ts); Causes FIP without indicated severity [FIP (+)]; Clinical isolate (CI), Reverse
genetics strain (Rev Gen), Tissue culture adapted strain (TC Adapt); Unpublished
sequence submitted to GenBank [(Taboni et al., 2007) unpub].
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The same cannot be said of serotype I FCoV strains, however. Serotype I FCoVs
do not readily adapt to growth in cell culture and the few strains that have been
successful isolated, required either numerous rounds of passage before cytopathic
effects were observable [e.g.(Amer et al., 2012; Black, 1980)] or use of entryenhancement techniques such as spinoculation (Hohdatsu et al., 1995) or addition of
DEAE-dextran or trypsin during virus adsorption (Jacobse-Geels and Horzinek, 1983).
As a result of forcing virus growth in an atypical environment, TC-adapted type I FIPV
strains lose in vivo pathogenicity and do not cause FIP in experimentally-infected cats
(Pedersen and Black, 1983; Thiel et al., 2014). This suggests two things: first– that the
current isolation techniques used to obtain serotype I viruses likely select for a subset of
virus genotypes that do not represent the majority; and second– significant genomic
mutations must be obtained in order for serotype I FCoVs to adapt to growth in the
currently available feline cell lines. Both of these factors distance the lab-adapted
strains from the parental clinical isolates and therefore complicate controlled
investigations of virus attenuation, vaccination and evaluation of therapeutics. At least
one type I FIPV strain, mc3-2, has maintained a virulent phenotype by continuous
passage in cats (Kim et al., 2016) suggesting that preserving the genotype of FIPV is
achievable of cultured appropriately.
The issues surrounding type I FCoV isolation are exemplified by the prototypic
serotype I FIPV strain Black, also referred to as TN406– one of the first type I FIPV
isolated (Black, 1980). As this virus was derived from a cat with FIP, the low-passage
(LP) Black strain remains highly pathogenic when introduced back into an animal
(Black, 1980). However, as is observed with all TC-adapted type I FIPV strains, the
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high-passage (HP) Black virus lost all pathogenicity following TC-adaptation (Pedersen
and Black, 1983). More recent studies using variants of FIPV Black produced by
reverse genetics further demonstrated that this virus was avirulent and had acquired
numerous mutations in the spike and accessory genes (Thiel et al., 2014). Interestingly,
all known serotype I FCoVs that replicate in TC lose in vivo virulence and accumulate
significant mutations in spike and the ORF7 accessory protein region (Kipar and Meli,
2014; Pedersen, 2014a, 2009). While mutations in the spike likely affect receptor or
host-protease usage, it is unclear how these and the ORF7 mutations affect
pathogenesis. At least one group has suggested that ORF7 is an antagonist of type I
interferon (Dedeurwaerder et al., 2014), indicating that TC-adaptation may result in
viruses that are less resilient to innate immune responses.
As a final note, it is well known that natural FIPV infection produces a viral
quasispecies in feline tissues comprising numerous genetic variations and stages of
progression from FECV to FIPV. As a result, virus isolation offers only a fraction of the
total FIPV strain diversity and, further, results in large strain-to-strain variation between
isolates. This, paired with the mutations required for TC-adaptation, make investigating
type I FCoV complicated and ultimately inconsistent. Thus, better isolation techniques
and permissive cell types need to be identified in order to replicate clinical serotype I
FIPV isolates without the requirements of TC adaptation.
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CELL NAME

CELL TYPE

TYPE I
FIPV

TYPE II
FIPV

REFERENCES

Crandell Rees
Feline Kidney
(CRFK)

Immortalized feline
kidney

No

Yes

(Miguel et al., 2002)

AK-D

Feline airway epithelia

Yes;
Low titer

-

(Millet and Whittaker,
2015; Benjamin W.
Neuman et al., 2006;
Pedersen, 2009)

Fcwf-4

Feline macrophage-like

Yes;
Low titer

Yes

(Alazawy et al., 2011;
Jacobse-Geels and
Horzinek, 1983)

Peripheral blood
mononuclear
cells (PBMCs)

Feline Primary cells;
monocytes, lymphocytes,
macrophages, others

Yes

Yes

(Harun et al., 2013)

Macrophages

Feline Primary;
Bone-marrow isolated or
stem cell-derived

Yes

Yes

(Gow et al., 2013;
O’Brien et al., 2018;
Rottier et al., 2005;
Sprague et al., 2005)

Dendritic Cells

Feline Primary;
Bone-marrow isolated or
stem cell-derived

Yes

Yes

(Bienzle et al., 2003;
van Berne, 2008)

Table 7: Cell Types Permissive to FIPV Infection.
Permissive Cell Types.
The cell types available to study serotype I FCoV are limited and this has been
one of the biggest hurdles to studying these viruses in the lab (Table 7). Unlike serotype
II FCoV, which replicate in cells that naturally or ectopically express feline APN, the
receptor for type I FCoVs is not known, thus permissive cell types are difficult to identify,
and the receptor cannot be simply expressed in common cell lines such as BHK or HEK
293Ts. Several TC-adapted strains of type I FIPV, particularly the Black strain, replicate
in two continuous cell lines, the feline airway epithelial cell line, AK-D, and the feline
macrophage-like cell line felis catus whole fetus 4 (Fcwf-4). As epithelial cells are an
unnatural replication site for FIPVs, the immediate issue with AK-D cells is that they do
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not reflect a normal infection route and it is likely that TC-adaptations that allow type I
viruses to replicate in these cells have adverse effects on virus pathology and shift
viruses away from a clinically-important phenotype. Fcwf-4, another other permissive
cell line, was originally isolated from the peritoneal cavity of a cat infected with FCoV.
This continuous cell line was further characterized as “macrophage-like” due to active
phagocytic activity, and the presence of Fc receptors and non-specific esterases
(Jacobse-Geels and Horzinek, 1983). Compared to AK-Ds, Fcwf-4 cells represent a
more biologically-relevant cell type in which to study serotype I FCoVs. Indeed, many
groups have used these cells to study both type I and type II FCoVs and they have
been an important tool for recovering type I FIPV strains and modeling feline
coronavirus infection in macrophages. The type I FIPV Black strain, for example, was
originally isolated using Fcwf-4 cells (Black, 1980), and others, such as strain DF2,
replicate in Fcwf-4 cells as well. However, these cells have been used to study type I
FCoVs more out of necessity than utility and have a number of associated issues. First,
previous studies report that type I FIPV grows to low titers (104 - 105 pfu/mL) in these
cells relative to type II (>106 pfu/mL) (Tekes et al., 2012) and can be measured by
determining either the 50% tissue culture infectious dose (TCID50) (Ramakrishnan,
2016; Reed and Muench, 1938) or by plaque assay (Takano et al., 2017; Tekes et al.,
2012, 2010). Second, type I virus growth kinetics are variable in Fcwf-4 cells, requiring
between 15-96 h to achieve maximum titer (Jacobse-Geels and Horzinek, 1983; O’Brien
et al., 2018; Tekes et al., 2012, 2008)). Third, some reports suggest that type I viruses
produced in Fcwf-4 cells are highly cell-associated (Jacobse-Geels and Horzinek, 1983;
Pedersen et al., 1984) and multiple freeze-thaw cycles may be required to recover virus,
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which further reduces the overall titer. Finally, Fcwf-4 cell doubling time is slow (>31 h)
(American Type Culture Collection, 2013), cells do not grow to high density and begin to
die after several passages. These growth issues make advanced genetic techniques
such as Crispr/Cas gene editing, which will be critical to evaluating attenuated FCoV
strains, unrealistic. Thus, although serotype I FCoVs grow in Fcwf-4 cells, additional cell
types are needed that grow viruses to high titer and are amenable to genetic
manipulation.
Feline primary cells including total PBMCs, macrophages, and dendritic cells are
the most natural cell types in which to grow and isolate serotype I FIPV strains. As
these are a natural cell type, limited TC adaptations are required for sustained virus
replication and the high virulence FIPV genotype is maintained. Certain type I strains
such as UCD1, -2, and -3 have been successfully cultured in these ex vivo feline tissues
and re-introduced into cats to cause FIP (Pedersen et al., 1981a; Pedersen and Floyd,
1985). However, use of these cells is limited by several factors: first, due to high
seroprevalence, acquiring FCoV-free tissue samples is challenging without an
established colony of specific pathogen (SPF)-free cats and deriving immune cells from
bone marrow can take up to two weeks; second, primary cells usually cannot be
passaged and new cells need to be plated for each experiment leading to increased
variability, and finally, many genetic techniques such as gene expression or Crispr/Cas
gene editing cannot be performed in primary cell further limiting the scope of available
experiments.
While each cell type discussed here is important for different aspects of FCoV
research, ultimately a biologically-relevant, genetically tractable, continuous cell line that
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replicates high titers of type I FCoVs is needed. Although this seems like a lofty
challenge, such a cell line is critical for the discovery of the type I FCoV entry receptor,
recovery of clinical isolates without TC-adaptation, determining the function of FCoV
proteins that antagonize innate immunity and for intensive study of vaccine strains
developed through rational design. One of the goals of this dissertation was to identify
and characterize such a cell line to enable future research of these important animal
pathogens.
Objective of Dissertation Research.
Since the 1980’s FCoVs have been predominantly studied in veterinary settings
where the focus was on diagnosis of sick cats and describing the pathogenesis of
strains isolated in-house using any cells available. In this environment, researchers
emphasized use of protocols and cells that allowed growth of the virus and as a result,
the nearly three decades of reports and reviews contain a high degree of variability
amongst the basic virology techniques, cell lines and virus strains characterized. This
issue of variability has led to much confusion and over-complication of the literature
making study of serotype I FCoVs an exercise in extrapolation of data collected from
either highly-diverged type I lab strains or serotype II viruses rather than well-controlled
experimentation of biologically-relevant type I viruses in a natural environment.
The long sought-after goal of FCoV research is the development of a broadlyeffective type I vaccine to protect young kittens from developing FIP. Immunization
against serotype I FIPV is likely to be the most effective method to prevent this disease
as this represents the majority of circulating virus (Pedersen, 2009), but due to the
issues discussed in this section, development of a type I FIPV vaccine has been
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challenging and ultimately unsuccessful (Kiss et al., 2004; Pedersen, 2014b, 2009).
Furthermore, conventional vaccination methods using inactivated, high-passage or
temperature-sensitive viruses have been restricted to serotype II FCoV [e.g. (Haijema et
al., 2004)]. Indeed, Felocell® FIP, the only currently available FIP vaccine, contains a
temperature-sensitive version of the serotype II virus, DF2. However, this vaccine fell
out of favor as it failed to protect against the dominant, circulating serotype I virus. Thus,
the challenge posed to researchers in the field, and the ultimate goal of this dissertation,
is to develop a set of “tools” – methods, reagents, genetically-tractable cell types, that
will facilitate efficient investigation of serotype I FCoV. Here, I describe my efforts to i)
characterize a new variant of Fcwf-4 cells that rapidly produce high-titers of cell-free
FCoVs comprising both bio- and serotypes and use these cells to establish a uniform
plaque assay to determine cell titer; ii) demonstrate the genetic malleability of these
new Fcwf-4 cells through Crispr/Cas guided disruption of the type I IFN receptor and the
expression of a feline surface protease, TMPRSS2. The ultimate goal of this
dissertation is to facilitate the generation of live-attenuated type I FCoV vaccine strains
through investigation and mutagenesis of IFN antagonists. Thus, in the final section, I
describe iii) establishing a reverse genetics system to produce a lab-sequenced strain
of FIPV Black, which can be specifically attenuated through direct mutation. Together,
the contribution of this dissertation is to provide several basic virology tools to bolster
basic science research of type I FCoVs and help develop an effective type I FIPV
vaccine.

CHAPTER TWO
MATERIALS AND METHODS
Viruses and Cells
Viruses.
Feline coronavirus strains including type I feline infectious peritonitis virus (FIPV)
Black (TN406), type II FIPV WSU 79-1146, and type II feline enteric coronavirus (FECV)
WSU 79-1683 were kindly provided by Dr. Fred Scott, Cornell University College of
Veterinary Medicine, Ithaca, NY. Viruses were propagated in Fcwf-4 Cornell University
(CU) cells and recovered from supernatants for stock virus preparation. Briefly, subconfluent T-75 flasks of Fcwf-4 CU cells were infected with virus at 1 multiplicity of
infection for 1 hour in 2 mL serum-free media at 37oC and 5% CO2. Infectious media
was replaced with 8 mL EMEM (see below) containing 5% FCS, and the monolayer was
incubated at 37oC and 5% CO2. After 24 hours, supernatants were collected and
clarified by centrifuging at 1,000 xg for 10 minutes at 4oC. Virus-containing cell-free
supernatants were then aliquoted (100 – 300 μL) and stored at -80oC. Titers of stock
virus were determined by plaque assay on AK-D or Fcwf-4 CU cells. Virus aliquots that
were thawed more than twice were pooled and a new titer was determined.
HEK 293T and 293T/17 Cells.
Human embryonic kidney (HEK) 293 T cells were maintained in DMEM (#10017-CV, Corning) containing 10% FCS, supplemented with 1% nonessential amino
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acids, 1% HEPES, 1% L-glutamine, 1% sodium pyruvate, and 1% pen/strep
(penicillin/streptomycin). For generation of lentivirus transducing particles, a second line
of HEK 293T/17 (ATCC® CRL-11268TM) was purchased from ATCC and maintained in
the same media formula. When cells were confluent, the monolayer was washed with
PBS, then cells were removed by addition of 1.5 mL 0.25% trypsin-versene solution for
1-2 min at room temperature. For routine passaging, cells were transferred (1:10 split)
to a new T-75 flask every 2 days.
Felis catus Whole Fetus (Fcwf-4) ATCC Cells.
Fcwf-4 cells were purchased from the ATCC (ATCC® CRL-2787TM), and
designated Fcwf-4 ATCC cells. Fcwf-4 ATCC cells were maintained in Minimal
Essential Medium Eagle (EMEM) (Sigma, #M0268) containing 10% FBS, supplemented
with 1.5 g/L sodium bicarbonate, 1% non-essential amino acids, 1% HEPES, 1%
sodium pyruvate, 1% L-glutamine and 1% penicillin/streptomycin. As described by the
ATCC, the doubling time for these cells is >31 h. When cells were confluent in T-25
flask, the monolayer was washed with PBS, then cells were removed by addition of 1.5
mL 0.25% trypsin-versene solution for 2-3 min at room temperature. For routine
passaging, cells were transferred (1:3 split) to a new T-25 flask every 3 days.
Felis catus Whole Fetus (Fcwf-4) Cornell University Cells.
A second source of Felis catus whole fetus cells were provided by Dr. Edward J.
Dubovi, Cornell University College of Veterinary Medicine, Ithaca, NY, designated Fcwf4 CU, and maintained in the same medium as the Fcwf-4 ATCC cells. When cells were
confluent, the monolayer was washed with PBS, then cells were removed by addition of
2 mL 0.25% trypsin-versene solution for 1-2 min at room temperature. For routine
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passaging, approximately 3.3x10 cells were transferred (1:3 split) to a new T-75 flask
in a total of 20 mL complete media every 2-3 days.
Generation and Maintenance of Fcwf-4 CU IRN Cells.
To generate the Fcwf-4 CU IFNαR null (IRN) cell line, a modified Crispr-Cas
protocol, based on the GeCKO system (Shalem et al., 2014) was used to disrupt the
type I IFN alpha receptor 2 (IFNαR2) in Fcwf-4 CU parental cells. Guide DNAs were
designed using Benchling (Benchling, Inc.) to target the second and third exons
(felis_catus_6.2; range = cgrC2: 11959183-11979720) of the feline ifnar2 gene
(Accession NM_001278859.1). Single guide DNA sequences are listed in Appendix B
(Primer Index 2). For each exon target, guide DNAs were phosphorylated and
annealed by combining 10 uM of the forward and reverse guide DNA oligos, 1x T4 DNA
ligase buffer containing ATP, T4 PNK ligase (NEB; M0201S) and nuclease-free H2O in
a total reaction volume of 10 μL. The reactions were then incubated at 37oC for 30 min;
95oC for 5 min; 95-25oC ramping down at 5oC intervals holding at each temperature for
5 min. In parallel, the lentiCrisprV2-puroR+ plasmid (Addgene #52961) was linearized
with BsmBI (NEB), the 13 kb band was extracted from an agarose gel then column
purified using a SV gel and PCR clean-up system (Promega). Annealed and
phosphorylated oligo sets were diluted 1:200 in nuclease-free H2O then inserted into the
linearized lentiCrisprV2-puroR+ cassette between flaking BsmBI sites using T4 DNA
ligase (NEB) at 16oC overnight. Following transformation into Top10 E. coli and
subsequent miniprep purification (Promega), plasmid DNAs were double digested with
AgeI (NEB) and KpnI (NEB) to reveal a fragment of 621 bp confirming proper insertion
of guide DNA sequences; plasmids were confirmed by sequencing using the U6
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universal forward primer 5'-GGG CAG GAA GAG GGC CTA T-3'. To disrupt the ifnar2
gene, transducing particles (TPs) carrying the lentiCrisprV2-puroR+ plasmids, encoding
guide DNA, cas9 endonuclease and puromycin resistance cassettes, were generated.
Briefly, 3.3 μg each of lentiCrisprV2-puroR+ (empty [EV] or carrying guide DNA
sequences), psPax2 (lentiviral packaging plasmid) and pHEF-VSV-G (vesicular
stomatitis virus glycoprotein) plasmids (generously supplied by Edward M. Campbell,
Department of Microbiology and Immunology, Loyola University Chicago, Stritch School
of Medicine, Maywood, IL) were co-transfected into a 10 cm dish containing 5x106 HEK293T/17 cells using polyethylenimine (PEI) (5 μg PEI / 1 μg DNA) in antibiotic-free
DMEM 10% FCS for 24 h followed by replacement with complete DMEM containing
10% FCS with antibiotics. Alternatively, the 10 μg of total plasmid DNA was transfected
into 5x106 HEK-293T/17 cells using TransIT LT1 (Mirus) (3 μL LT1 / 1 μg DNA) without
media replacement in DMEM 10% FCS with antibiotics. For either method, after 48 h,
supernatants containing TPs were collected and stored at 4oC and cells were
replenished with 10 mL DMEM containing 5% FCS with antibiotics. After an additional
24-hour incubation (72 hours total) at 37oC and 5% CO2, supernatants were collected
and combined with the previously collected lot. Total supernatants were centrifuged
1000 xg at 4oC for 10 min to remove cell debris, then centrifuged overnight (16+ hours)
at 5,000 xg and 4oC. To concentrate, supernatants were poured off and pellets were
suspended in 1/10 – 1/100th the original volume with EMEM (-FCS). A minimal volume
of concentrated TPs was added to parental Fcwf-4 CU cells for 1 hour at 37oC and 5%
CO2 followed by addition of EMEM 10% FCS and incubation for 48 h. Transduced cells
were positively-selected by replacing media with EMEM containing 10% FCS and 10
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µg/mL puromycin (InvivoGen) for 96 h. Puromycin-selected cells were grown as a
heterologous population designated Fcwf-4 CU 2.2 (for the guide DNA sequence
specific for the second target on the second ifnar2 exon). A clone of the Fcwf-4 CU 2.2
cells, confirmed for reduction in responsiveness to type I IFN (see CHAPTER THREE:
EXPERIMENTAL RESULTS), was isolated and designated Fcwf-4 CU IRN (Interferon
alpha Receptor Null). Briefly, >10,000 Fcwf-4 CU 2.2 cells were sorted using a FACS
Aria Cell Sorter (BD) into a 96-well plate at 1 cell/well. Clones were grown over several
weeks and expanded into 24- then 6-well plates in EMEM containing 10% FCS and 10
µg/mL puromycin. Clones that were positive for permissively to FIPV Black infection
were evaluated for IFN responsiveness (see CHAPTER THREE: EXPERIMENTAL
RESULTS). The Fcwf-4 CU IRN cell line was isolated in this manner and confirmed to
be both permissive to FIPV Black infection and have low IFN-responsiveness. The
sequence of the IFNαR mRNA expressed in the Fcwf-4 CU IRN cell line was
determined by sequencing 15 PCR clones of the region (Appendix D). Briefly, total
RNA was isolated from Fcwf-4 CU or IRN cell monolayers and cDNA was generated
with random hexamer primers via the RevertAID First-Strand cDNA Synthesis kit
(Thermo Fisher). The full IFNαR region was amplified from cDNA using the F IFNaR2
Full FWD and F IFNaR2 Full REV primer set (Appendix B; Primer Index 1) in a
thermocycler set at 92oC for 2 min; 35 cycles at 92oC for 1 min, 50oC for 1 min and 68oC
for 100 min; and 68oC for 7 min. The resulting 1600 bp band was gel extracted from a
0.8% SeaPlaque GTGTM Agarose (Lonza) gel and column purified using an SV gel and
PCR clean-up system (Promega) prior to insertion into TA cloning pCR-XL-TOPO®
plasmids using the TOPO® XL PCR Cloning Kit (Life Technologies). 15 plasmids for
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each cell type were then transformed into Top10 E. coli and purified by MiniPrep
(Promega) and sequenced using M13 FWD, M13 REV, f IFNaR2 SEQ 1 FWD and f
IFNaR2 SEQ 1 REV sequencing primers (Appendix B; Primer Index 1). Consensus
sequences were compared using Clone Manager 9 (Sci-Ed Software) revealing a 14nucleotide deletion in the cas9 target region of the IFNαR Fcwf-4 CU IRN cells resulting
in a truncated protein sequence. These cells were maintained in the same medium as
the parental Fcwf-4 CU cells. For routine passaging, confluent monolayers were
washed with PBS, cells were removed by addition of 2 mL 0.25% trypsin-versene
solution for 1-2 min at room temperature, and approximately 3.3x106 cells were
transferred (1:3 split) to a new T-75 flask in a total of 20 mL complete media every 2-3
days.
Feline Airway Epithelial (AK-D) Cells.
AK-D cells were purchased from the American Type Culture Collection (ATCC)
(ATCC® CCL-150TM) and maintained in Dulbecco’s Modified Eagle Medium (DMEM;
Gibco, #12100-046) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals,
#S11150), supplemented with 2.2 g/L of sodium bicarbonate (Sigma, #S5761), 1% nonessential amino acids (HyClone, #SH30238.01), 1% HEPES (HyClone, #SH30237.01),
1% sodium pyruvate (Corning, #25-000-CI), 1% L-glutamine (HyClone, #SH30034.01),
and 1% penicillin/ streptomycin (Corning, #30-002-CI). When cells grew to a confluent
monolayer, the medium was removed, and the monolayer was rinsed with PBS. The
cells were removed by addition of 2 mL of 0.25% trypsin (Gibco, #15090-046) in
versene solution (0.48 mM EDTA in PBS) for 1-2 min at room temperature. For routine
passaging cells were transferred (1:5 split) to a new T-75 flask every 3 days.
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Generation and Maintenance of AK-D 2.2 (IFNαR-disrupted) Population.
A heterologous population of AK-D cells with reduced responsiveness to type I
interferon, termed AK-D 2.2, were recovered after transduction with Crispr/Cas guide
RNAs targeting the second exon of the interferon alpha receptor using the same
protocol as the Fcwf-4 CU IRN cells, however a clone was not obtained. Briefly,
concentrated TPs were diluted 3:1 in DMEM containing 10% FCS and applied to
parental AK-D cells for 48 h followed by selection in DMEM containing 10% FCS and 10
µg/mL puromycin (InvivoGen) for 96 h. Puromycin-selected cells were grown as a
heterologous population designated AK-D 2.2 cells and verified for permissively to FIPV
Black infection and reduced IFNα responsiveness. AK-D 2.2 cells were maintained in
the same media as the parental AK-D cells. For routine passaging, cells were
transferred (1:5 split) to a new T-75 flask every 3 days after a PBS wash and disruption
with 0.25% trypsin-versene.
Felis catus Bone Marrow-derived Macrophages (fBMDMs).
For generation and culture of feline bone marrow-derived macrophages, feline
femurs were harvested by Cornell University Veterinary Biobank from specific
pathogen-free cats euthanized according to IACUC approved protocols, and total bone
marrow content was collected. Red blood cells and fatty tissue were removed by lysis in
ACK lysis buffer and straining through a 0.70 𝜇m filter (Falcon). The remaining cells,
predominantly hematopoietic stem cells, were cryopreserved at 5.0x107 cells/mL in 90%
FBS and 10% DMSO. Feline bone marrow derived macrophages (fBMDMs) were
differentiated as previously reported (Gow et al., 2013) with slight modification. Briefly,
5.0x107 bone marrow cells were plated in 100 x 26 mm petri dishes (VWR, #25387-030)
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in DMEM (Corning, #10-017-CV) supplemented with 20% FBS, 10,000 IU/mL
recombinant human (rh) M-CSF (PeproTech, #300-25) and 50 𝜇M 𝛽-mercaptoethanol
then incubated at 37oC and 5% CO2. At day 3, supernatant was removed, clarified of
cells, diluted 1:2 with fresh DMEM supplemented with 20% FCS and 10,000 IU/mL rhMCSF, and returned to cells. fBMDMs were recovered on day 6 by gentle aspiration in
PBS following 30 min, 4oC incubation in PBS.
Mycoplasma Detection and Removal from Tissue Culture.
All cells used in this study were monitored for mycoplasma contamination using a
PCR-based assay. Cell culture supernatants were routinely collected after 3 days of
culture and then heat-inactivated at 95oC for 10 min. PCR amplification for mycoplasma
detection was performed using a forward primer: 5’- GGC GAA TGG GTG AGT AAC
ACG -3’ and a reverse primer: 5’- CGG ATA ACG CTT GCG ACC TAT G -3’.
Thermocycler settings were as follows: initial denaturation at 95°C for 10 min; 35 cycles
consisting of denaturation at 95°C for 45 sec, annealing at 60°C for 45 sec, and
extension at 72°C for 60 sec; and a final extension at 72°C for 10 min. The PCR
products were analyzed on 1% (w/v) agarose gel. DNA fragments were visualized with
a UV transilluminator after being stained with ethidium bromide. If mycoplasma was
detected, the cells were treated for 7 days with 0.5 μg/mL of mycoplasma removal agent
(Bio-Rad, #BUF035). All results shown here are from mycoplasma negative cells.
FIPV PLP2 Functional Assays
Transcleavage Assay.
FIPV PLP2 protease activity (targeting and cleavage of the LXGG motif) was
determined using a transcleavage assay. Briefly, 2x105 HEK 293T cells/mL were plated
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in 12-well plates 24 h prior to transfection. 500 ng of plasmids encoding recFIPVPLP2(V5) wild-type, catalytic mutant or empty vector were combined with 25 ng of
plasmid expressing nsp2/nsp3-GFP substrate and co-transfected into cells using
TransIT LT1 (Mirus) (3 μL LT1 / 1 μg DNA). After 16-18 h, cells were lysed in 100 μL
I𝜅B lysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 12.5 mM Na pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na orthovanadate, 1 mg/mL leupeptin, 1 mM PMSF) on ice then centrifuged at 14,000 xg for 10
min at 4oC to pellet nuclei. Lysate supernatants were separated using a 10% SDSPAGE gel then transferred to a PVDF membrane using a semi-dry transfer apparatus
(Bio-Rad). Membranes were blocked overnight in 5% milk-TBST at 4oC then incubated
with primary antibody diluted in 5% milk-TBST for 1 hour at room temperature: to detect
the nsp3-GFP cleavage product, a 1:2500 dilution of rabbit-anti GFP (ThermoFisher
Scientific) was used; to determine PLP2 expression, a 1:5000 dilution of mouse-anti-V5
tag (Bio-Rad) was applied; a 1:5000 dilution of mouse-anti β-actin (Bio-Rad) was used
to determine equivalence in protein loading. Membranes were washed three times for
15 min in TBST buffer, then incubated with donkey anti-rabbit-HRP (1:2500) or goatanti-mouse-HRP (1:2500) secondary antibody (SouthernBiotech) for 1 h at room
temperature. Three more 15 min washes in TBST were performed prior to addition of
Western Lightning® Plus-ECL (PerkinElmer, Inc.) chemiluminescent substrate and
visualization on a FluorChemTM E (Protein Simple) imaging system. Band sizes were
determined relative to PageRulerTM Prestained protein ladder (Thermo Fisher).
Deubiquitinase (DUB) and DeISGylase Assays.
The ability of FIPV PLP2 to deconjugate ubiquitin or ISG15 molecules from total
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proteins was determined using DUB or DeISGylase assays. Briefly, 2x10 HEK 293T
cells/mL were plated in 12-well plates 24 h prior to assay. Cells were co-transfected with
500 ng of FLAG-ubiquitin (Flag-Ub) for DUB assay or 500 ng myc-ISG15 and 250 ng
each of pUbcH8, pUbe1L, pHerc5 for DeISGylase assay, along with 250, 500 or 1000
ng of plasmid encoding recFIPV-PLP2(V5) wild-type, catalytic mutant or empty vector.
At 16-18 h, cells were lysed in 100 μL I𝜅B lysis buffer on ice then centrifuged at 14,000
xg for 10 min at 4oC to pellet nuclei. Lysate supernatants were separated using a 10%
SDS-PAGE gel, transferred to a PVDF membrane using a semi-dry transfer apparatus
(Bio-Rad) and blocked overnight in 5% milk-TBST at 4oC. Primary antibodies were
diluted in 5% milk-TBST as follows: mouse-anti-FLAG (SigmaAldrich) at 1:2500 (DUB
assay), mouse-anti-myc (Developmental Studies Data Bank, University of Iowa) at
1:250 (DeISGylase assay), and mouse-anti-V5 tag (Bio-Rad) at 1:2500 or a 1:5000
dilution of mouse-anti β-actin (Bio-Rad). Antibody dilutions were applied to membranes
for 1 hour at room temperature, which were then washed three times for 15 min in TBST
buffer and incubated in a 1:5000 dilution of goat-anti-mouse-HRP secondary antibody
(SouthernBiotech) for 1 h at room temperature. Three more 15 min washes in TBST
were performed prior to addition of Western Lightning® Plus-ECL (PerkinElmer, Inc.)
chemiluminescent substrate and visualization on a FluorChemTM E (Protein Simple)
imaging system. Deconjugation is visualized by a reduction in the relative intensities of
the protein smear. Band sizes were determined relative to PageRulerTM Prestained
protein ladder (Thermo Fisher).
IFN Antagonism Assay.
To determine if recFIPC-PLP2 is a type I IFN antagonist, the following assay was
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performed as previously described (Niemeyer et al., 2018) with modification. Briefly,
2x105 HEK-293T cells/mL were transfected with plasmids encoding Renilla (RL) and
Firefly (FF) luciferases (luc) along with WT or catalytic mutant rec-FIPV-PLP2. An IFN-β
promoter (p125-luc) controls FF luc gene expression, while RL luciferase gene
expression is determined by a constitutive herpes simplex thymidine-kinase (TK)
promoter. Stimulation of the IFN-β promoter triggered by overexpressed, constitutivelyactive MDA5 leads to an auto-activation of the IFN pathway and increased FF luc.
Plasmid amounts for a given 24-well plate format are as follows: pRL-TK (5 ng), p125luc (250 ng), pEF- BOS-MDA5-3xFLAG His10 (100 ng) and 100 to 200 ng of PLP2expressing plasmids. Cells were lysed at 18 hpt and 20 μL of luc-containing lysate was
transferred to white-opaque 96-well plates and used for assessment of luc activity using
a luminometer (Veritas). Relative IFN promotion is determined by calculating the ratio of
ifn(FF)/luc(RL). Each condition was performed in triplicate in at least three experiments.
Plaque Assay
The plaque assay technique was established using AK-D, AK-D 2.2 and Fcwf-4 CU
cells. 6.5 x 105 cells per well were plated in 6-well plates or 3.0-x105 cells per well were
plated in 12-well plates. Cells were washed in PBS, then infected with 300 μL of 10-fold
serial dilutions of viral samples in FCS-free media for 1 h at 37oC. Cells were overlaid
with a 0.5% Oxoid agar (Oxoid LTD, #LP0028)-DMEM containing 1% FBS mixture.
Plates were incubated at 37oC for 48 h (or the indicated time) and fixed using 3.7%
formaldehyde-PBS solution for 30 min. Viral plaques were visualized by staining with
0.1% crystal violet for 30 min and photographed. We note plaques were clearly evident
when we used Oxoid agar, but not if we used Noble agar.
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Virus Growth Kinetics
We analyzed the growth kinetics of type I FIPV Black in four cell lines: AK-D, AK-D 2.2,
Fcwf-4 CU, and Fcwf-4 ATCC. Type II FCoV titers were evaluated in Fcwf-4 CU cells.
For all cell types, 1.5 x 105 cells were plated in 24-well plates or 3.0 x 105 cells in 12well plates. After incubating for 24 h, cells were infected with FIPV in serum-free media
at a multiplicity of infection (MOI) of 0.1 at 37oC. After a 1 h incubation, the infectious
media were replaced with fresh media containing 2% FBS. At the indicated time points,
cell-free supernatants and/or infected cells were harvested and used for titration by
plaque assay on AK-D (FIPV Black) or Fcwf-4 CU (type II FCoVs) cells.
Evaluating Virus Titers from Cell-free and Cell-associated Samples
We compared the cell-free and cell-associated growth kinetics of FIPV in several cell
lines: AK-D, AK-D 2.2, Fcwf-4 CU and Fcwf-4 ATCC cells. For all cell types, 1.2 x 106
cells were plated in a 60 mm2 dish, 1.5 x 105 cells were plated in 24-well plates or 3.0 x
105 cells in 12-well plates in DMEM or EMEM containing 10% FBS. After incubating for
24 h, cells were infected with FIPV Black in serum-free media at a multiplicity of
infection (MOI) = 0.1 at 37oC. After a 1 h incubation, the infectious media were replaced
with fresh complete media. Cell supernatants and infected cells were harvested at
indicated time points and used to prepare cell-free and cell-associated samples,
respectively, for titration by plaque assay on Fcwf-4 CU cells as described above. The
supernatant was collected from the cultures at the times indicated and subjected to
centrifugation at 2,200 xg for 10 min at 4oC to remove any dead cells. This cell free
supernatant was aliquoted and frozen at -80oC until use. To prepare the cell-associated
sample, 0.5 mL of medium was added to the infected cells, and the entire plate was
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frozen at -80 C. The infected cells were then subjected to two additional rounds of
freezing and thawing (37oC for 1-2 min). After the third thaw, the cells and medium were
transferred to a centrifuge tube and centrifuged at 2,200-3,000 xg for 10 min at 4oC to
remove cell debris. The supernatant containing the viruses released from the cells
during the freeze-thaw process was designated the cell-associated virus sample. Cellassociated samples were stored at -80oC. To determine FIPV titers, plaque assays were
performed on Fcwf-4 CU cells as described above.
Type I Interferon Responsiveness Assay
To determine feline cell responsiveness to type I interferon, quantification of ISG54
transcript production by RT-qPCR following stimulation with feline IFN was performed.
Cells (1.0 x 105 in a 24-well plate) were treated with 10, 100, or 1000 U/mL of purified
feline IFN-alpha (PBL Assay Science, #15100-1) for 6 h. To determine ISG54 and feline
β-actin mRNA production, total RNA was extracted using a RNeasy Mini Kit (Qiagen)
and an equal amount of RNA (1000 ng) was used for cDNA synthesis using RT2 HT
First-Strand Kit (Qiagen, #330401). qPCR was performed with specific primers
(Appendix B; Primer Index 1) for feline 𝛽-actin transcript (FWD 5’- CAA CCG TGA
GAA GAT GAC TCA GA -3’; REV 5’- CCC AGA GTC CAT GAC AAT ACC A -3’)
(Kessler et al., 2009) or ISG54 transcript (FWD 5’- CCT GAG CTG CAG CCT TTC AGA
ACA G -3'; REV 5'- CAC GTG AAA TGG CAT TTA AGT TGC CGC AG -3') using RT2
SYBR Green qPCR Mastermix (Qiagen, #330502). A Bio-Rad CFX96 thermocycler was
set as follows: one step at 95°C (10 min); 40 cycles of 95°C (15 s), 60°C (1 min), and
plate read; one step at 95°C (10 s); and a melt curve from 65°C to 95°C at increments
of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are representative of three
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independent experiments. The levels of mRNA are reported relative to β-actin mRNA
and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].
Immunofluorescence Detection of FIPV Nucleocapsid Protein
Monolayers of 1.0 x 105 AK-D and Fcwf-4 CU cells were cultured in 8-well chamber
slides (Nalge Nunc International, #177445) at 37oC for 24 h. Cells were infected with
FIPV Black at a MOI of 0.1 for 1 h at 37oC. At times indicated, the infected cells were
fixed with 3.7% formaldehyde-PBS solution for 30 min, permeabilized with 0.1% Triton
X-100 in PBS for 10 min, and then incubated with blocking solution containing 5%
normal goat serum and 0.1% Triton X-100 in PBS at 4oC overnight. For
immunofluorescence staining of FIPV Black-infected cells, the cells were incubated with
mouse monoclonal anti-FIPV nucleocapsid (CCV2-2) (Poncelet et al., 2008) (Bio-Rad,
#MCA2594B) as a primary antibody at a dilution of 1:500 at room temperature for 1 h.
Cells were then incubated with a secondary antibody, Alexa Fluor 568-conjugated goat
anti-mouse IgG (Thermo Fisher Scientific, #A11004) at a dilution of 1:1000 in the
presence of Hoechst33342 (Thermo Fisher Scientific, #H1399) at a dilution of 1:1000
for nucleus stain. After 30 min incubation with the secondary antibody at room
temperature, the cells were then washed with PBS, mounted, and examined under a
fluorescence microscope.
Morphologic Staining
Feline bone marrow-derived macrophages, Fcwf-4 CU, or Fcwf-4 ATCC cells, grown for
24 h in 100 x 26 mm petri dishes (VWR, #25387-030), were washed with PBS,
incubated in PBS for 30 min at 4oC, then collected with gentle pipetting. Using a
Cytospin (Shandon), 200 𝜇L of cells (10,000 cells/mL) suspended in PBS supplemented
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with 2% BSA were spun onto glass coverslips (pre-treated with 2% BSA in PBS) at 115
xg for 6 min. Cells were dried, rinsed in PBS, then fixed in absolute methanol for 1 min.
Wright-Giemsa (Thermo Fisher Scientific, #9990710) staining was performed per the
manufacturer’s instructions using a 3 min primary stain and a 2 min counter stain, and
washed with 1 mL rinse solution. Slides were dried and imaged under oil immersion at
100x magnification.
Cloning and Expression of Feline TMPRSS2 in Fcwf-4 CU IRN Cells
A dsDNA gBlocks® (IDT) fragment containing the coding sequence of feline TMPRSS2
variant 1 (GenBank accession # XM_023238709.1) was designed with several
modifications for cloning into the pLVX-Puro vector. The 5’ end was designed to contain
a pLVX complementarity region (5’-TAC TAG AGG ATC ACC GGA CTC AGA T-3’)
followed by an XhoI cleavage site and a Kozak consensus sequence (5’-ACC ATG G3’). The 3’ end contains a spacer sequence (5’-GGT-3’) followed by an in-frame V5 tag
coding region (5’-GGT AAG CCT ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT
ACG-3’), translation termination sequence (5’-TAG-3’), BamHI cleavage site and a
pLVX complementarity region (5’-ACC GGA TCT AGA TAA CTG ATC ATA A-3’). pLVXPuro vector was double-digested with XhoI (NEB) and BamHI (NEB) and the feline
TMPRSS2 gBlocks fragment was inserted using NEBuilder® HiFi DNA Assembly (NEB)
using a 1:5 vector to insert ratio as per the manufacturer’s instructions. The assembled
plasmid was transformed into Top10 E. coli, purified by MaxiPrep (Promega) and
sequenced using CMV FWD, fTMPR2 SEQ F1, and fTMPR2 SEQ F2 sequencing
primers (Appendix B; Primer Index 1). Transducing particles (TPs) carrying the pLVXfTMPRSS2(V5)-puroR+ plasmids, encoding lentivirus 5’ LTR, psi (𝜓) packaging signal,
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rev-response element (RRE) and feline TMPRSS2(V5) were generated under the
direction of Dr. Michael Hantak (Loyola University Chicago). Briefly, 3.3 μg each of
pLVX-fTMPRSS2(V5)-puroR+, psPax2 (lentiviral packaging plasmid) and pHEF-VSV-G
(vesicular stomatitis virus glycoprotein) plasmids (generously supplied by Edward M.
Campbell, Loyola University Chicago) were co-transfected into 10 cm dishes containing
5x106 HEK-293T/17 cells using polyethylenimine (PEI) (5 μg PEI / 1 μg DNA) in
antibiotic-free DMEM 10% FCS for 24 h followed by replacement with complete DMEM
containing 10% FCS with antibiotics. After 48 h, supernatants containing TPs were
collected and stored at 4oC and cells were replenished with 10 mL DMEM containing
5% FCS with antibiotics. After an additional 24-hour incubation (72 hours total) at 37oC
and 5% CO2, supernatants were collected and combined with the previously collected
lot. Total supernatants were centrifuged 1000 xg at 4oC for 10 min to remove cell debris,
then centrifuged overnight (16+ hours) at 5,000 xg and 4oC. To concentrate,
supernatants were poured off and pellets were suspended in 1/10 – 1/100th the original
volume with EMEM (-FCS). For expression of feline TMPRSS2(V5), transducing
particles were diluted 1:5 in serum-free EMEM and a minimal volume was incubated
with Fcwf-4 CU IRN cells for 1 hour at 37oC and 5% CO2 followed by addition of EMEM
containing 6.25% FCS. After 48 hours, cells were lysed in either lysis buffer A (4%
sodium dodecyl sulfate, 3% dithiothreitol, 40% glycerol, and 0.065 M Tris-HCl pH 6.8 in
H2O) for evaluation of TMPRSS2(V5) by western blot, or lysed in RLT buffer (Qiagen)
for evaluation of TMPRSS2 mRNA levels by qPCR. For western blot, lysates were
sonicated, and 50,000 cell-equivalents were loaded and electrophoretically separated
through 7-15% acrylamide Mini-PROTEAN® TGXTM precast SDS-PAGE gels (Bio-Rad)
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in 1x Running Buffer (0.19 M glycine, 0.025 M trizma base, and 1% sodium dodecyl
sulfate in H2O). The acrylamide gels, methanol-activated Immun-Blot® PVDF
membranes (Bio-Rad) and filter paper (Bio-Rad) were soaked for 10 min in semi-dry
transfer buffer (48 mM trizma base, 39 mM glycine, 1.3 mM sodium dodecyl sulfate and
20% methanol in H2O at pH 9.2) and proteins were transferred from acrylamide gels to
the PVDF membranes using a semi-dry Trans-Blot® TurboTM transfer system (Bio-Rad).
Membranes were blocked at 4oC overnight in 5% milk in TBST (0.02 M trizma base,
0.15 M NaCl and 1% Tween 20 in H2O) followed by 90 min room temperature
incubation in primary antibodies specific for TMPRSS2(V5) tag (murine monoclonal IgG;
Genscript) or 𝛽-actin (murine monoclonal IgG; Genscript) diluted 1:2500 and 1:5000,
respectively, in 5% milk-TBST. The membranes were washed three times for 15 min
each in TBST followed incubation for 1 hour at room temperature in goat-anti-mouseHRP (SouthernBiotech) secondary antibody diluted 1:5000 in 5% milk-TBST. Three
more 15 min washes in TBST were performed prior to addition of Western Lightning®
Plus-ECL (PerkinElmer, Inc.) chemiluminescent substrate and visualization on a
FluorChemTM E (Protein Simple) imaging system. Band sizes were determined relative
to PageRulerTM Prestained protein ladder (Thermo Fisher). For detection of feline
TMPRSS2 mRNA transcript levels, quantitative PCRs were performed. Briefly, total
RNA was extracted from RLT lysates using a RNeasy Mini Kit (Qiagen) and an equal
amount of RNA (500 ng) was used for cDNA synthesis using RT2 HT First-Strand Kit
(Qiagen, #330401). qPCR was performed with specific primers for feline TMPRSS2
(feline tmprss2 FWD / feline tmprss2 REV) or feline 𝛽-actin transcript (f𝛽-Actin FWD /
f𝛽-Actin Actin REV) (Kessler et al., 2009) (Appendix B; Primer Index 1) using RT2
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SYBR Green qPCR Mastermix (Qiagen, #330502). A Bio-Rad CFX96 thermocycler was
set as follows: one step at 95°C (10 min); 40 cycles of 95°C (15 s), 58°C (1 min), and
plate read; one step at 95°C (10 s); and a melt curve from 65°C to 95°C at increments
of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are representative of three
independent experiments. The levels of mRNA are reported relative to 𝛽-actin mRNA
and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].
Determining IFNαR2 Expression and Amplicon Melt Temperature
Expression and amplicon melt temperature of feline ifnar gene exons 1-4 were
determined by qPCR. Briefly, confluent monolayers of Fcwf-4 CU and Fcwf-4 CU IRN
cells were grown overnight in complete EMEM, lysed in RLT (Qiagen) and total RNA
was isolated using the RNeasy RNA isolation kit (Qiagen). Equivalent amounts of RNA
were used to generate cDNA using RevertAID cDNA synthesis kit (ThermoFisher).
Feline 𝛽-actin (primers: f𝛽-Actin FWD / f𝛽-Actin REV) and IFNαR2 exon 1-4 (primers:
Fel ifnar mRNA Exon1-4 RT FWD / Fel ifnar mRNA Exon1-4 RT REV) transcript levels
were determined by qPCR using Sybr Green Master Mix (Qiagen) (Appendix B;
Primer Index 1). qPCRs were performed in a CFX96 thermocycler (Bio-Rad) using the
following settings: 95oC for 10 min; 40 cycles of 95oC for 15 s, 58oC for 1 min and SYBR
read; 95oC for 10 s; melt curve from 65°C to 95°C at 0.5°C/0.5 s. For qPCR, samples
were evaluated in triplicate and data represent three independent experiments. The
levels of mRNA are reported relative to 𝛽-actin mRNA and expressed as 2−ΔCT [ΔCT =
CT(gene of interest) −CT(β-actin)]. Melt temperatures were determined by plotting the change in
fluorescence with temperature [-d(RFU)/dT] versus temperature (oC) then calculating
the point at which the largest change in fluorescence occurs (Krenke et al., 2005).
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Detecting FIPV N gene in FIPV-infected Fcwf-4 CU IRN Cells Expressing
TMPRSS2
To determine effects of TMPRSS2 on FIPV replication, Fcwf-4 CU IRN cells were
transduced with increasing dilutions of lentiviruses expressing TMPRSS2 then infected
with FIPV Black. N gene expression was determined by qPCR. Briefly, 24-well Cell-Bind
plates (Corning) were seeded with 0.5 mL Fcwf-4 CU IRN cells at 3.0 x105 cells/mL in
complete EMEM and incubated overnight at 37oC and 5% CO2. Media was replaced
with 100 uL EMEM (-FCS) (mock), or cells were transduced with 100 uL fTMPRSS2(V5)
lentivirus TPs left undiluted, or diluted 1:20, 1:10, 1:5 and 1:2.5 in EMEM (-FCS). After 1
h incubation, 400 uL EMEM (6.25 % FCS) was added to each well (without media
replacement) to give 500 uL and 5% FCS. Cells were incubated for 48 h to allow
expression of TMPRSS2 then infected with FIPV Black at MOI of 0.1 or left uninfected
(mock; mock expressing TMPRSS2). After an additional 18 h infection, cells were lysed
in RLT (Qiagen) and RNA was isolated using RNeasy Mini Kit (Qiagen). Equivalent
amounts of RNA were used to generate cDNA using the RevertAID cDNA Synthesis Kit
(ThermoFisher). FIPV Black N gene (primers: FIPV-N-qpcr-F / FIPV-N-qpcr-R) and 𝛽actin (primers: f𝛽-Actin FWD / f𝛽-Actin REV) transcript levels were determined by qPCR
using Sybr Green Master Mix (Qiagen) (Appendix B; Primer Index 1). qPCRs were
performed in a CFX96 thermocycler (Bio-Rad) set to: 95oC for 10 min; 40 cycles of 95oC
for 15 s, 58oC for 1 min and SYBR read; 95oC for 10 s; and a melt curve from 65°C to
95°C at increments of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are
representative of three independent experiments. The levels of mRNA are reported
relative to 𝛽-actin mRNA and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].
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Reverse Genetics Methods
Genomic RNA Isolation from FCoV Virions.
Genomic RNA (gRNA) was isolated from 600 μL cell-free supernatants
containing FCoV virions at concentrations greater than 1.0x105 PFU/mL. 100 μL aliquots
of supernatant were mixed with TriReagent (MRC, Inc.) at a ratio of 1:10 in 1.5 mL
eppitubes. The mixture was incubated for 5 min at room temperature to dissociate the
nucleoprotein complexes. 0.25 mL of chloroform (Sigma-Aldrich) was added per 0.75
mL of TriReagent used in the initial homogenization, the mixtures were shaken
vigorously by hand for 1 min, incubated at room temperature for 15 min then centrifuged
at 12,000 xg for 10 min at 4oC for phase separation. The top aqueous layers containing
RNA were extracted into new RNase-free 1.5 mL eppitubes and 5 μg of glycogen was
added (1 μL at 5 mg/mL). Room temperature 200 proof isopropanol (Sigma-Aldrich)
was added at a 1:1 ratio and the six tubes were inverted to mix, incubated at room
temperature for 10 min then centrifuged 12,000 xg for 60 min at 4oC. The supernatants
were discarded, the pellets were washed in 1.25 mL 75% ethanol then centrifuged
7,500 xg for 5 min at 4oC. The RNA was washed in 75% ethanol three times total. The
final ethanol washes were discarded, and the pellets were allowed to air dry. To
dissolve, 10-20 μL RNase-free water was added directly to the pellets and tubes were
incubated at 55oC for 15 min. The six dissolved pellets were then combined, and
concentrations were determined by spectrophotometer (NanoDrop).
Deep-sequencing, Cloning and Modification of a Lab Strain of FIPV Black.
The FIPV Black (TN406) strain used as the backbone for the reverse genetics
system was kindly provided by Dr. Fred Scott, Cornell University College of Veterinary
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Medicine, Ithaca, NY. The genomic sequence of this specific FIPV Black laboratory
strain was determined by deep sequencing. Briefly, AK-D cells were infected with FIPV
Black for 24 hours, the cell monolayer and supernatant were freeze-thawed by
alternating -80oC and 37oC incubations, then centrifuged for 10 min at 2,000 xg and 4oC
to remove cell debris. The supernatant was sent to the Veterinary Diagnostic Laboratory
(Department of Diagnostic Medicine and Pathology, College of Veterinary Medicine,
Kansas State University) and subject to Ion Torrent Next Generation Sequencing. The
resulting sequencing reads were aligned to a reference FIPV Black genome (GenBank
Accession #EU186072.1) and a consensus sequence of this laboratory strain of FIPV
Black was generated (Appendix C). The concept for the contiguous cDNA FIPV Black
reverse genetics system was based on the previously described method for generating
murine hepatitis virus (Yount et al., 2002) and involves sub-cloning cDNA segments of
the coronavirus genome onto individual plasmids, ligation and transcription of the fulllength cDNA into genomic RNA followed by electroporation into cells. Based on the
deep-sequenced genome of the FIPV Black lab strain, seven contiguous cDNA
segments (A-G) (Table 8), comprising the entire genome, were designed, amplified
using specific primer sets from genomic RNA and sub-cloned onto individual plasmids.
Each cDNA fragment contains unique restriction sites, which overlap only with the
adjacent fragment and ensures that the seven excised fragments ligate in a specific A to
G order and reflect a complete cDNA version the original FIPV genomic sequence. To
generate the seven cDNA plasmids, 1.5 μg of FIPV Black genomic RNA was used as a
template for cDNA synthesis with random hexamer primers via the RevertAID FirstStrand cDNA Synthesis kit (Thermo Fisher) as per the manufacturer’s specifications.
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Using the resulting cDNA as a template, PCR reactions were set up using the ExpandTM
Long Range dNTPack (Roche via Sigma-Aldrich) kit and segment-specific primer sets
(Appendix B; Primer Index 3) were included to amplify cDNA segments B-F using the
following specifications: 0.2 mM dNTP mix, 0.2 uM forward primer, 0.2 uM reverse
primer, 3.75% DMSO, 1x reaction buffer, 1.5 U enzyme mix and 2 μL cDNA per 50 μL
reaction. The amplified cDNA segments were gel extracted from a 0.8% SeaPlaque
GTGTM Agarose (Lonza) gel and column purified using an SV gel and PCR clean-up
system (Promega) prior to insertion into TA cloning pCR-XL-TOPO® plasmids using the
TOPO® XL PCR Cloning Kit (Life Technologies). Plasmids were then transformed into
Top10 E. coli and purified by MaxiPrep (Promega). cDNA segments A and G were
individually synthesized and cloned into pUC57(AmpR+) vectors by BioBasic Inc.
(Markham, ON, Canada). The A segment sequence was modified from the genomic
FIPV Black sequence in the following ways: a T7 polymerase promoter sequence 5’TAA TAC GAC TCA CTA TAG-3’ was added at position -21 relative to the start of the
FIPV Black genome and a natural BsmBI cut site was removed at position 3806 (GAG
to GAA). The G segment sequence was modified to include a stretch of 21 consecutive
adenine nucleotides at the 3’ end. Additionally, the nucleocapsid (N) gene sequence
was amplified from the FIPV Black total cDNA using specific primers (Appendix B;
Primer Index 3) and cloned into pcDNA-3.1 using NEBuilder® HiFi DNA Assembly
(NEB) as per the manufacturer’s specifications. Large-scale preparations of the cDNA
plasmids A-G, and N gene were obtained using a MaxiPrep kit (Promega) then
sequenced (Appendix B; Primer Index 4) prior to long-term storage at -80oC.
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Assembly of Full-length FIPV Black Infectious Clone cDNA.
The method of assembling the full-length infectious clone of the FIPV Black
sequenced laboratory strain was based on the previously described reverse genetics
method for murine hepatitis virus (Yount et al., 2002). Similarly, our design for the
reverse genetics system for FIPV involves ligation of the seven contiguous cDNA
fragments at specific junctions in order to generate the full-length cDNA infectious
clone. First, each of the plasmid DNAs containing specific cDNA segments of the FIPV
genome, (FIPV plasmids A-G) was grown to a high concentration, isolated by Maxiprep
(Promega), and 40 μg was digested with BsmBI, or double digested with BsmBI and
BamHI, or SfiI according to the manufacturer’s specifications (NEB) (Table 8) FIPV
cDNA plasmids D and G were singly digested with BsmBI resulting in desired fragment
sizes of 2,339 and 4,385 bp respectively, while the FIPV Black A plasmid was doubledigested with BsmBI and BamHI resulting in a desired fragment size of 4,810 bp. FIPV
plasmids B, C, E and F were double digested with BsmBI and SfiI resulting in desired
fragment sizes of 4,064 bp for B plasmid, 4,609 bp for C plasmid, 4,762 bp for E
plasmid and 4,272 bp for F plasmid. The SfiI cut site is located on the pCR-XL-TOPO®
vector and was included to allow clearer band separation when purifying the fragments.
Additionally, 40 μg of the N gene plasmid (pcDNA-3.1 encoding the FIPV Black
nucleocapsid gene) was linearized by DraIII digestion. The digests were then diluted in
6x loading dye (Ambion) and run through a 0.8% SeaPlaque GTGTM (Lonza) low-melt
agarose gel in TAE (tris-acetate-EDTA) buffer. The desired bands (FIPV Fragments AG and linearized N plasmid) were visualized on a DarkReader transilluminator (Clare
Chemical Research) to prevent UV-induced nucleotide cross-linking, cut from the
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agarose gel, purified using an SV gel and PCR clean-up system (Promega), and eluted
in 120 μL nuclease-free H2O. To remove excess agarose, the fragments were further
purified by addition of chloroform at a ratio of 1:1. The chloroform-DNA solutions were
mixed by vortex for 1 min, centrifuged 5 min at 15,000 rpm (21,130 xg) and the top
aqueous layers containing DNA were recovered and placed into new 0.6 mL eppitubes.
The concentration of each purified cDNA fragment was determined, and aliquots were
stored at -80oC. To generate the full-length infectious clone cDNA, molar equivalents
(0.02-0.05 pmol) of each fragment were combined, totaling approximately 6 μg DNA,
and ligated using 6,000 U of T4 DNA Ligase (NEB) and 1x T4 ligase buffer (50 mM TrisHCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT) in a 200 μL reaction for 16-24 hours at
16oC. The full-length ligation product (~29.2 Kb) was purified using phenol-chloroformisoamyl alcohol extraction then precipitated with isopropanol. Briefly, 20 μL (1:10) of 3M
NaOAc at pH 5.2 and 220 μL (1:2) phenol-chloroform-isoamyl alcohol (25:24:1 ratio) at
pH 8.0 were added to the 200 μL ligation reaction. The solution was shaken vigorously
by hand for 1 min and centrifuged at room temperature for 2 min at 14,000 rpm (18,407
xg) for phase separation. The top aqueous phase containing DNA was extracted into a
new tube, followed by addition of room temperature 200 proof isopropanol (1:1 ratio)
and inversion to mix. The DNA was allowed to precipitate for 10 min at room
temperature before centrifuging at 14,000 (18,407 xg) for 10 min at room temperature.
The pellet was washed two times in 500 μL of 75% ethanol (chilled in -80oC) and once
in 500 μL 95% ethanol (chilled in -80oC) with pelleting at 14,000 (18,407 xg) for 3 min in
between washes. The pellet was allowed to air dry until translucent and 11.5 μL
nuclease-free H2O was added. To dissolve the pellet, the tube was held at room
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temperature for 1 hour with intermittent flicking. The dissolved pellet was used
immediately for in vitro transcription without storage.
Full-length Ligation Junction PCR.
To determine if ligation of the seven cDNA fragments was contiguous, PCRs
across each junction were performed. Briefly, molar equivalents of purified fragments AG were ligated overnight at 16oC using T4 Ligase (NEB). Using 10 ng of ligation product
as template, PCRs were performed using Expand Long-Range Taq Polymerase (Roche
via Sigma) to amplify each junction using junction-specific primers (AB, A5/B1R [761
bp]; BC, B5/C1R [903 bp]; CD, C6/D1R [900 bp]; DE, D3/E1R [730 bp]; EF, E7/F1R
[1057 bp]; FG, F6/G1R[1154 bp]) (Appendix B; Primer Index 4). Reactions were
performed in an Eppendorf thermocycler set at 92oC (2 min); 25 cycles at 92oC (10 s),
52 or 55oC (15 s), and 66oC (80 s); and held at 66oC for 7 min. PCR products were
diluted in 6x loading dye (NEB) and electrophoretically separated through a 0.9%
agarose gel. Bands were visualized under UV due to intercalation of ethidium bromide.
In Vitro Transcription and RNA Electroporation.
Full-length mRNA copies of the FIPV infectious clone cDNA and additional
mRNA copies of the FIPV N gene were synthesized using the mMessage mMachine T7
(Ambion) in vitro transcription kit as per the manufacturer’s specifications with the
following modifications. To generate full-length infectious clone mRNAs, the 11.5 μL
purified cDNA ligation (see above) was combined with 3.5 μL of 30 mM GTP (2.1 mM
final), 25 μL 2x NTP/CAP (1x final), 5 μL 10x reaction buffer (1x final) and 5 μL T7
polymerase/enzyme mix. N gene transcripts were generated by combining 500 ng
purified linearized N gene plasmid with 12.5 μL 2x NTP/Cap (1x final), 2.5 μL 10x
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reaction buffer (1x final), 2.5 μL T7 polymerase/enzyme mix and nuclease-free H2O in a
25 μL reaction. The reactions were incubated at 40oC for 25 min, 37oC for 50 min,
40.5oC for 25 min then held at 4oC in the thermocycler. During the in vitro transcription
incubation time, Fcwf-4 CU cells were prepared for electroporation. Briefly, Fcwf-4 CU
cells were grown to confluence in T-75 flasks (Corning) in complete EMEM over 24-48
hours prior to electroporation. The Fcwf-4 CU cells were washed in 10 mL 1x PBS,
dissociated from the plate with 2 mL 0.25% trypsin-versene at 37oC for 2 min then
diluted 1:10 in complete EMEM. The cells were pelleted at 4oC for 7 min at 760 rpm
(104 xg), washed twice in 10 mL cold 1x PBS with centrifuge cycles at 4oC for 7 min at
760 rpm (104 xg) to pellet in between, and counted on a hemocytometer using a 1:10
dilution of cells in 0.4% trypan blue-PBS. Washed and pelleted Fcwf-4 CU cells were
suspended to 1x107 cells/mL in cold Opti-MEM® I (Gibco, #11058-021) and held on ice.
Completed in vitro transcription reactions were used directly for electroporation without
additional purification. Briefly, 22 μL N gene transcript, 45 μL full-length infectious clone
transcript and 600 μL Fcwf-4 CU cells (1x107 cell/mL) were combined, in order, in a
chilled 0.4 cm gap Gene Pulser® cuvette (Bio-Rad, #1652081) and electroporated with
3 pulses of 850 V, 25 𝜇F capacitance and ∞ resistance at 5 sec intervals using a Gene
Pulser XcellTM (Bio-Rad) apparatus. As a positive control, 500 ng of purified FIPV Black
genomic RNA and 250 μg N gene transcript were combined and electroporated into 600
μL Fcwf-4 CU cells (1x107 cell/mL) using the same conditions as above. As a negative
control, 600 μL Fcwf-4 CU cells (1x107 cell/mL) with no added RNA were electroporated
using the same conditions as above. All electroporated cells were allowed to recover at
room temperature for 10 minutes then diluted in 10 mL complete EMEM and plated into
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T-75 flasks. After 3-5 hours, when the cells had settled and begun attaching to the flask,
media was gently removed and replaced with 10 mL complete EMEM. The cells were
then incubated for 24-72 hours at 37oC and 5% CO2, or until cell cytopathic effects were
observable in the positive control.
Detection of FIPV Black N gene Subgenomic RNA.
Virus nucleocapsid (N) gene subgenomic (sg) RNAs containing the FIPV Black
leader sequence were detected by reverse-transcriptase PCR (RT-PCR). Briefly, cell
monolayers containing electroporated FIPV RNA were lysed in RLT buffer (proprietary
lysis and binding buffer containing guanidinium thiocyanate) as per the manufacturer’s
instructions (Qiagen) at room temperature between 24- and 72-hours postelectroporation. Total RNA was extracted using a RNeasy Mini kit (74104, Qiagen) and
eluted in 30 μL RNase-free water. Equivalent amounts of RNA, up to 4 μg, were
converted to cDNA using the RevertAid First Strand Synthesis kit (Thermo Scientific,
K1621) using random hexamer primers. PCR to amplify N gene sgRNA was carried out
using Expand Long-Range dNTPack (Roche) with the following specifications: 0.2 mM
dNTP mix, 0.2 uM FWD primer, 0.2 uM REV primer, 3.75% DMSO, 1x reaction buffer,
1.5 U enzyme mix and 1 μL cDNA per 20 μL reaction. To amplify N gene, the following
primers were used: Forward FIPV Black Leader Primer 5’- GTG CTA GAT TTG TCT
TCG GAC ACC -3’; N Gene Reverse 5’- CAT CAG CAT GAG GTC CTG TAC CTG A 3’ (Appendix B; Primer Index 1) resulting in a 331 bp amplicon. PCR reactions were
heated to 92oC for 2 min, cycled 35 times between 92oC for 20 s, 61oC for 20 s, and
68oC for 20 s, then incubated at 68oC for 7 min for a final extension. PCR products were
electrophoretically separated on a 0.9% agarose gel and visualized under UV light.
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Generation of Figures, Graphics, Tables and Reference Management
The open source illustration program INKSCAPE (Inkscape.org) was used to create
original graphic figures. All other figures that incorporate experimental data and
statistical analyses were generated using GraphPad Prism 6 software (Graphpad.com).
Tables were created using Microsoft Word for Mac version 16.22 (Microsoft.com). All
reference materials were organized and incorporated using Mendeley software version
1.19.3 (©Mendeley Ltd.; Mendeley.com).

CHAPTER THREE
EXPERIMENTAL RESULTS
Section 1: Characterizing Replication Kinetics and Plaque Production of Serotype
I Feline Infectious Peritonitis Virus in Three Feline Cell Lines
Rationale.
It is critical that we investigate type I FIPV in laboratory cell culture in order to
understand the basic virology of natural infection, characterize type I clinical isolates,
test novel therapeutics, and develop effective feline vaccines with broader coverage.
However, this has been challenging because type I FCoVs cannot be easily adapted to
laboratory cell culture; furthermore, the receptor for type I is not known (Cham et al.,
2017; Dye et al., 2007; Hohdatsu et al., 1998), making the identification of highly
permissive cell types difficult. Select type I isolates, such as the FIPV Black strain used
in this study, have been adapted to growth in tissue culture at the cost of reduced in
vivo virulence (Black, 1980; Pedersen, 2009; Tekes et al., 2008; Thiel et al., 2014).
Feline airway epithelial (AK-D) cells propagate FIPV Black (Regan et al., 2012);
however, these cells do not represent natural tropism for FIPV. Felis catus whole fetus 4
(Fcwf-4) cells are a more physiologically-relevant feline macrophage-like cell line
(Jacobse-Geels and Horzinek, 1983), but these cells come with several technical
drawbacks for studying type I FIPV: Typical replication of serotype I FIPV in Fcwf-4 cells
takes between 15 and 96 hours to reach maximum titers, which usually range between
103 and 104 pfu/mL. Additionally, FIPV produced in these cells tends to be very cell130
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associated and requires multiple freeze-thaw cycles to release – a technique that further
reduces the final titer. Together, these factors have made investigation of type I FIPV
challenging.
As part of this study, we characterized three feline cell lines– two from the
American Type Culture Collection (ATCC) and one from Cornell University– and
evaluated the replication kinetics, efficiency of plaque formation, and responsiveness of
these cells to type I interferon in order to identify the optimal cell culture conditions for
serotype I FIPV Black. The experiments performed here were done in collaboration with
Dr. Amornrat O’Brien (Loyola University Chicago) and culminated in a co-first author
manuscript: O’Brien and Mettelman et al., 2018. In this study, we found that an Fcwf-4
cell line established at Cornell University College of Veterinary Medicine, designated
Fcwf-4 CU, propagates type I FIPV to significantly higher titers in cell-free supernatant
and with more rapid kinetics compared to commercially available Fcwf-4 cells. We show
that Fcwf-4 CU cells are less responsive to exogenous type I interferon than Fcwf-4
cells from the ATCC and are permissive to infection by both biotypes of type II FCoV.
To facilitate quantitation of FIPV Black, we established a standardized plaque assay
method using Fcwf-4 CU cells and commercially available AK-D cells and show that
both cell types permit rapid and consistent quantitation of infectious titers of type I FIPV
as well as type II FIPV and FECV from cell-free supernatants.
Results.
Type I FIPV Black replication kinetics vary between feline cell types. To
determine the optimal cell type and conditions required to grow the type I FIPV Black
strain, we evaluated virus growth kinetics using a standard infection time course. Cells
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were infected at a multiplicity of infection (MOI) of 0.1 and virus titer was determined by
plaque assay from cell-free supernatants over 96 hours. FIPV Black, a distinct type I lab
strain that replicates in feline epithelial cells, replicated as expected in AK-D cells
reaching a maximum titer >106 pfu/mL at 36 hours post-infection (hpi) (Figure 8A). In
our hands, using Fcwf-4 cells purchased from the ATCC, the replication of FIPV Black
reached a maximum titer >104 pfu/mL over 72-96 hpi (Figure 8A). Strikingly, FIPV
Black replication kinetics and maximum titer were drastically different in an Fcwf-4 cell
line established at Cornell University College of Veterinary Medicine (Fcwf-4 CU). Using
these cells, the virus reached a significantly higher maximum titer of >106 pfu/mL at 20
hpi. In other words, nearly 100 times more virus was produced from the Fcwf-4 CU cells
a full 2-3 days faster than in Fcwf-4 ATCC cells.
To address whether the differences in titer observed between AK-D, Fcwf-4 CU,
and Fcwf-4 ATCC cells were due to differences in cell-free and cell-associated virus, we
compared the cell-associated and cell-free virus titers from each cell type at the time
points around the respective maximum titers. Surprisingly, the cell-free virus titers were
higher than the cell-associated titers at all time points and in all cell types assayed
(Figure 8B). This indicates that FIPV Black virions are released into cell supernatant
during infection of cell culture and freeze-thaw cycles are not necessary to obtain high
virus titers.
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Figure 8: Fcwf-4 Cornell University (CU) Cells Produce High Titers of Cell-free
Type I FIPV With Rapid Growth Kinetics. A) Virus growth kinetics measured from
cell-free supernatants of AK-D (black), Fcwf-4 ATCC (blue), and Fcwf-4 CU (red) cells
infected with FIPV Black (MOI=0.1) over 96 hours. Arrows indicate time of peak titer
presented as plaque-forming units (pfu)/mL. Titer determined by plaque assay on AKD cells in triplicate; error bars ±SD. B) Cell-associated and cell-free virus titers were
determined following infection of Fcwf-4 CU, AK-D, and Fcwf-4 ATCC cells with FIPV
Black (MOI=0.1). Cell-free titer was determined from cell-clarified supernatants; cellassociated titer was determined from suspended cell monolayers following three
freeze-thaw cycles alternating between -80oC and 37oC. Samples were taken at hours
post-infection (hpi) just prior to, at, and following the maximum (max) virus titer for
each cell type. Titers determined by plaque assay on AK-D cells in triplicate; error
bars ±SD.
Although the maximum titers of FIPV Black were comparable between AK-D and
Fcwf-4 CU cells, the progression of cell cytopathic effects (CPE) induced by the virus
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differed. FIPV Black formed large, uniform syncytia in Fcwf-4 CU cells, while individual
cell-death-induced clearings were observed in infected AK-D cells (Figure 9A). Of note,
maximum titers from both cell types were obtained just prior to the appearance of major
CPE, allowing a visual guide to virus collection. To further demonstrate this point, Fcwf4 CU and AK-D cells infected with FIPV Black were labeled with an anti-nucleocapsid
antibody (CCV2-2) (Poncelet et al., 2008) and visualized by immunofluorescence prior
to the induction of major observable CPE. As expected, the majority of cells were
positive for virus antigen (Figure 9B) and the differences in CPE are clearly shown:
note the syncytial membrane fusion in infected Fcwf-4 CU cells and the maintenance of
distinct cell membranes in infected AK-D cells (Figure 9B). Together, these results
demonstrate the ability of the Fcwf-4 CU cells to rapidly produce high levels of type I
FIPV Black in cell-free supernatants.
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Figure 9: FIPV Black-induced Cell Cytopathic Effect Varies Between Infected Cell
Types. A) Progression of cell cytopathic effects (CPE) induced by FIPV Black over time
in Fcwf-4 and AK-D cells (MOI=0.1). Localized cell syncytia formation (black, closed
arrows) and discrete cell death (white, open arrows) indicated on brightfield images
taken at 20x magnification. B) Immunofluorescence staining of FIPV Black-infected
Fcwf-4 CU and AK-D cells (MOI=0.1) at indicated hours post-infection (hpi).
Nucleocapsid protein staining (Red; CCV2-2) indicates infected cells; nuclei stained in
blue (Hoesch3342). Images taken at 60x magnification.
AK-D and Fcwf-4 CU cells facilitate rapid and consistent plaque assays for
FIPV Black. After observing the rapid and uniform development of CPE and release of
virus into cell supernatants during infection of AK-D and Fcwf-4 CU cells, we reasoned
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that these cells would be employable in a standardized plaque assay to consistently
determine FIPV Black titer. To this end, we calculated the endpoint titer and compared
the size, uniformity, and timing of virus plaque development over time in AK-D, Fcwf-4
ATCC, and Fcwf-4 CU cells following infection with 10-fold dilutions of the same FIPV
Black virus stock initially grown on Fcwf-4 CU cells. A detailed description of the plaque
assay is provided in the Materials and Methods; we note here that Oxoid agar is critical
for visualizing clear plaques. At 2 days post-infection (dpi), FIPV Black formed
enumerable plaques on both AK-D and Fcwf-4 CU cells with the latter cells producing
more numerous and larger plaques at higher dilutions (Figure 10 top). Plaques were
not observed in Fcwf-4 ATCC cells at 2 dpi (Figure 10 top). Plaques were detected at 3
dpi (Figure 10 middle); and were clearer at 4 dpi in Fcwf-4 ATCC cells (Figure 10
bottom). Calculated titers overall were higher in Fcwf-4 CU (>107 pfu/mL) than in AK-D
cells (≥106 pfu/mL); however, we report that both cell types are useful for determining
virus titer, whereas the Fcwf-4 ATCC cells are not ideal for use in this assay.
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Figure 10: Evaluating FIPV Black Plaque Development and Titer Over Time in
Different Feline Cell Lines. Tenfold serial dilutions (10-3-10-6) of virus inoculum,
derived from 24-hour cell-free supernatant of Fcwf-4 CU cells infected with FIPV Black
at a MOI=0.1, were applied to AK-D, Fcwf-4 ATCC, and Fcwf-4 CU indicator cells.
Following Oxoid agar/media overlay, plates were incubated for 2 (top), 3 (middle), or 4
(bottom) days before cells were fixed with 3.7% formaldehyde and stained with 0.1%
crystal violet. Titers were calculated by plaque counts and are presented as plaqueforming units (pfu)/mL. ND indicates that titers were not determined.
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Fcwf-4 CU cells are distinct in morphology and IFN-responsiveness. The
apparent differences in production and kinetics of FIPV Black virus in two Fcwf-4 cell
lines led us to ask if there are morphologic or functional differences between the two cell
types. To answer this question, we first compared the single-cell morphologies of Fcwf4 ATCC, Fcwf-4 CU cells, and primary feline bone marrow-derived macrophages
(fBMDMs) by Wright-Giemsa staining. The typical morphologic characteristics of feline
macrophages (large cytoplasmic inclusions, a non-dominant nucleus, a non-ruffled cell
membrane) (Bienzle et al., 2003) were observed for the fBMDMs (Figure 11A).
Comparison of the two Fcwf-4 cell lines revealed stark differences in morphology. Fcwf4 ATCC cells were large with a smooth cell membrane and had large and abundant
cytoplasmic inclusions comparable to the fBMDMs (Figure 11A). Fcwf-4 CU cells were
more similar in size to fBMDMs; however, the Fcwf-4 CU cell line exhibited fewer
cytoplasmic inclusions and more cell membrane ruffling (Figure 11A) than either the
fBMDMs or Fcwf-4 ATCC cells. Neither Fcwf-4 cell line had a “true” macrophage
morphology further corroborating their original “macrophage-like” description (JacobseGeels and Horzinek, 1983). As macrophages are innate immune cells that restrict virus
replication through production of interferon-stimulated genes (ISGs) in response to type
I IFN, we reasoned that differences in virus replication may be due to variation in cell
IFN-responsiveness. Therefore, we asked if Fcwf-4 ATCC and CU cell lines differed in
responsiveness to exogenous type I IFN by measuring the resulting ISG54 transcript
production following treatment with IFN. Remarkably, Fcwf-4 ATCC cells produced
significantly higher ISG54 transcripts in response to IFN stimulation compared to Fcwf-4
CU cells (Figure 11B), suggesting that the Fcwf-4 CU cells are much less responsive to
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IFN. This is not to say, however, that Fcwf-4 CU cells are insensitive to IFN since they
also exhibit significant, dose-dependent ISG54 transcript production. Together, these
data highlight the distinct morphology of the Fcwf-4 CU cells and suggest that enhanced
virus replication in these cells may be due, at least in part, to reduced IFNresponsiveness.
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Figure 11: Fcwf-4 CU Cells Differ in Morphology and IFN-responsiveness From
Fcwf-4 ATCC. A) Single-cell morphology of feline bone marrow-derived macrophages
(fBMDMs), Fcwf-4 CU, and Fcwf-4 ATCC cells determined by Wright-Giemsa stain
following cytospin preparation. Images were taken at 100x. B) Interferon-stimulated
gene (ISG) 54 transcript levels from Fcwf-4 ATCC (grey) and Fcwf-4 CU (black) cell
lines stimulated with increasing concentrations of feline type I interferon (IFNα). After 6
hours, total RNA was extracted and analyzed by qPCR for ISG54 and feline betaactin. ISG54 mRNA expression was normalized to 𝛽-actin via the delta Ct method
(2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]), then presented as relative expression over
corresponding mock (basal) expression. Data are representative of three independent
experiments performed in triplicate and presented as means ±SD. Values were
analyzed by unpaired t-test. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
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Fcwf-4 CU cells replicate both biotypes of type II FCoV. Due to the high titer
and rapid kinetics of type I FIPV Black replication in the Fcwf-4 CU cells, we next
addressed whether these cells are permissive to type II FCoV infection. Fcwf-4 CU cells
were infected with type I FIPV Black or one of two type II viruses, FIPV 79-1146 or
FECV 79-1683. Cell cytopathic effects were observed over time in these cells, with the
viruses all forming similar, large syncytia (Figure 12A). Cell-free virus titers were
determined at 12 and 24 hpi. All three viruses accumulated to titers >106 pfu/mL in
supernatants by 24 hpi (Figure 12B), with FIPV 79-1146 reaching the highest titer. The
kinetics of the type II viruses were faster than the type I FIPV Black strain, producing
higher titers by 12 hpi (Figure 12B) and inducing more substantial syncytial CPE by 16
hpi (Figure 12A). Next, we asked if the Fcwf-4 CU cells could be utilized in a plaque
assay for determining the titer of type II FCoV. Indeed, both FIPV 79-1146 and FECV
79-1683 formed clear, uniform, enumerable plaques at 24 hpi (Figure 12C). Thus, we
have demonstrated that the Fcwf-4 CU cells replicate both FCoV types and biotypes to
high titers and are employable in a plaque assay to consistently determine the titers of
all viruses assayed.
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Figure 12: Fcwf-4 CU Cells and are Permissive to Both Biotypes of Type II
FCoV. A) Cell cytopathic effect at 12- and 24-hours post-infection (hpi) of Fcwf4 CU cells infected with indicated FCoV strains (MOI=0.1). B) FCoV growth
kinetics in Fcwf-4 CU cells (MOI=0.1) determined by C) plaque assay on Fcwf4 CU indicator cells. Tenfold serial dilutions of cell-free virus inoculum were
applied to cells. Following Oxoid agar/media overlay, cells were fixed in 3.7%
formaldehyde and stained using 0.1% crystal violet after 24 hours. FCoV used
were the type I strain FIPV Black and the type II strains FIPV WSU 79-1146
and FECV WSU 79-1683. Plaque assay performed in triplicate; error bars ±SD.
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Section 2: Generation of Feline Cell Lines to Study Attenuated or Clinicallyimportant FCoV Strains
Rationale.
Immunization against serotype I FIPV is likely to be the most effective
vaccination method to protect against FIP (Pedersen, 2009). To date, implementing an
effective serotype I FCoV vaccine has been unsuccessful and new strategies and
approaches are needed in order to achieve wide-spread protection. Targeted
elimination of coronavirus type I IFN antagonists resulting in a hyper interferon-inducing
(HII) phenotype has been a successful method to generate live-attenuated coronavirus
strains and successful vaccines (Deng et al., 2019b, 2017; Kindler et al., 2017). In these
studies, two conducted by our group, permissive cells deficient in type I IFN signaling
were a key component allowing for recovery and characterization of IFN antagonistdeficient viruses. The lack of the type I IFN receptor (IFNαR) allows recovery,
propagation and accurate determination of virus titer of mutant viruses produced by
reverse genetics without negative selective pressure or induction of suppressive
mutations in the viral genome. I hypothesized that feline cell lines that are i) highly
permissive to serotype I FCoV and ii) deficient in IFNαR signaling would allow for the
development and investigation of IFN antagonist-deficient FIPV viruses and could be
employed in future studies to recover vaccine candidate strains using reverse genetics.
A feline IFNαR-deficient cell type, however, is not currently available. In this section of
my dissertation, I proposed to eliminate IFN responsiveness in two serotype I FCoVpermissive cell lines: feline airway epithelial (AK-D) cells and Fcwf-4 CU cells by
employing the Crispr/Cas gene-editing system to disrupt domain 2 of the type I IFN
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receptor (IFNαR2). First, I demonstrate that a polyclonal population of Crispr/Castransduced AK-D cells (termed AK-D 2.2) display a significantly reduced response to
exogenous IFNα stimulation. Infection of AK-D 2.2 cells with serotype I FIPV induces
rapid development of cytopathic effect, while maintaining production of infectious virus.
Further, I demonstrate the utility of the AK-D 2.2 cells in determining the titer of serotype
I FIPV by plaque assay. Second, using parental Fcwf-4 CU cells, which we
demonstrated grow high titers of FIPV Black and had reduced IFN-responsiveness
(above) (O’Brien et al., 2018), I again used Crispr/Cas9 gene editing to disrupt IFNαR2
and expanded clones from the resulting total population of transductants. One isolate,
termed IFNαR2 null (IRN), was found to have significantly reduced IFN-responsiveness.
Comparison of the amino acid sequences of the parental (Fcwf-4 CU) and clone (IRN)
interferon alpha receptor indicates that the reduction in IFN-responsiveness observed in
the clone is likely due to early termination of the protein. Growth kinetics of serotype I
FIPV Black was similar in both cell lines.
As the overall goal of this dissertation is to develop tools to investigate clinicallyimportant serotype I FCoV strains, I proposed to further modify the Fcwf-4 IRN cells to
express host proteases to enhance replication efficiency of type I FCoVs. The presence
and density of specific host cell proteases are important determinants of coronavirus
entry (Millet and Whittaker, 2015) and several groups have reported that ectopic
expression of proteases, such as the transmembrane serine protease 2 (TMPRSS2),
can enhance coronavirus entry and replication (Glowacka et al., 2011; Park et al., 2016;
Regan et al., 2008). Serotype I FCoV spikes contain two protease cleavage sites, which
can be cleaved to induce membrane fusion. The S1/S2 site contains a multibasic
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cleavage sequence (RRXRR), which is processed by cell-surface proteases including
furin and furin-like proteases such as TMPRSS2. Cleavage at the S1/S2 site mediates
viral entry at the cell surface. The downstream S2’ site is cleaved within host
endosomes by cathepsin-L, allowing virus entry at this later stage. The serotype I spike
protein encoded by the TC-adapted TN406 (Black) strain used in our experiments
contains a multibasic S1/S2 cleavage (RSRR) site (Whittaker et al., 2018) and therefore
we predicted that expression of TMPRSS2 would enhance FIPV Black replication.
Indeed, using the parental Fcwf-4 IRN cells, which are already highly permissive to
FIPV Black and deficient in type I IFN signaling, I cloned and expressed feline
TMPRSS2 and demonstrate increased production of virus over time.
Together, the data presented in this section describe the generation of two feline
cell lines that are deficient in IFN-signaling and one that expresses TMPRSS2, both
characteristics that will be useful in recovery of live-attenuate type I FIPV strains and
clinical isolates from infected cats.
Results.
Evaluating the interferon response in AK-D and IFNaR2-deficient AK-D 2.2
cells. Wild type feline airway epithelial (AK-D) cells were used as the first parental cell
type to knock down the feline type I interferon receptor (IFNaR2). AK-D cells were
chosen because they are permissive to serotype I feline coronavirus and have a defined
genotype. To knock down the IFNaR2, wild type AK-D cells were transduced with
pLentiCRISPRv2 encoding a specific guide RNA targeting the second exon of the feline
ifnαr2 gene (2.2). Positive selection was performed using puromycin and cells were
cultivated as a heterogeneous population termed AK-D 2.2. As there is no available
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IFNaR-specific antibody to detect the presence of feline IFNaR2 protein, we used a
functional assay to evaluate the AK-D 2.2 cells for the IFNaR2-deficient phenotype.
Increasing concentrations of purified feline IFNa were exogenously applied to AK-D or
AK-D 2.2 cells and RNA levels of IFN stimulated gene (ISG) 54 were determined by
quantitative PCR (qPCR). ISG54 expression is prominently upregulated following
activation of the type I IFN receptor (Fensterl and Sen, 2011) and is used here to report
on the functionality of the IFNaR. As expected, wild type AK-D cells responded to
exogenous IFNa with a dose-dependent increase in ISG54 expression. The AK-D 2.2
cell population, however, produced significantly fewer ISG54 transcripts than wild type
(Figure 13), indicating a disruption of the IFN-I response-pathway. The subtle but
concentration-dependent ISG54 transcription observed from AK-D 2.2 cells may be
attributed to the presence of an additional receptor, or incomplete silencing in some
cells in the population. Nonetheless, these results indicate that the AK-D 2.2 cells have
a diminished total response to IFNa, which is likely due to disruption of the IFNαR2.
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Figure 13: AK-D 2.2 Cells Exhibit Diminished Response to Type I IFN. AK-D
(black) or AK-D 2.2 (red) cells were treated with increasing concentrations of feline
interferon alpha (IFNα). After 6 h, total RNA was extracted and analyzed by qPCR for
ISG54 and feline beta-actin. ISG54 mRNA expression was normalized to beta-actin
via the delta Ct method (2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]), then presented as relative
expression over corresponding mock (basal) expression. Data are representative of
two independent experiments performed in triplicate and presented as means ± SD.
Values were analyzed by unpaired t-test. *** P < 0.001.
Evaluating growth kinetics of serotype I FIPV Black in AK-D 2.2 cells. To
determine if knocking down the IFNaR2 had any effect on replication of FIPV Black we
evaluated the growth kinetics of FIPV Black in AK-D and AK-D 2.2 cells. We infected
cells with FIPV Black at a MOI = 0.1 and titers were evaluated over time by plaque
assays. FIPV Black achieved a maximum titer >106 plaque-forming units (PFU)/mL in all
cell types tested. The kinetics of FIPV Black were similar in AK-D and AK-D 2.2 cells
(Figure 14A), with both cell types producing peak titers at 42 hours post-infection (hpi),
suggesting that the IFNaR2 does not significantly impact virus growth in this cell type.
This is likely due to the multiple IFN antagonists expressed by FIPV, which permit
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replication in AK-D cells independent of an IFN response (Dedeurwaerder et al., 2014,
2013).
While evaluating the virus kinetics, we also observed that high virus titers were
obtained from the cell-free supernatants. This was intriguing as it has previously been
reported that FIPV is highly cell-associated and that multiple freeze-thaw cycles are
required to release infectious virus (Jacobse-Geels and Horzinek, 1983). Therefore, we
asked if FIPV Black virus titer was comparable in supernatant (cell-free) and freezethawed cell monolayers (cell-associated) in AK-D or AK-D 2.2 cells. We report that,
between 30-42 hpi when maximum virus titers are achieved, FIPV Black titers are
higher in cell-free supernatants than in the cell-associated fractions (Figure 14B) for
both cell types. These results demonstrate that high virus titers can be derived from the
supernatants alone and that further processing of cell monolayers by freeze-thaw cycles
may even be detrimental to virus titer.
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Figure 14: Characterization of Replication Kinetics and Cell Association of FIPV
Black in AK-D 2.2 Cells. Cells were infected with serotype I FIPV Black at MOI = 0.1,
and samples were collected at the indicated hours post-infection (HPI). A) Growth
kinetics of FIPV Black determined by plaque assay of infected AK-D (black) and AK-D
2.2 (red) cell supernatants. B) Cell-free (solid) and cell-associated (dashed) virus titers
were determined by plaque assay analysis from infected AK-D (black) and AK-D 2.2
(red) cells. Cell-free titer was determined from cell supernatants. Cell-associated titer
was determined from suspended cell monolayers following three freeze-thaw cycles
alternating between -80oC and 37oC. Each experiment was performed in triplicate, and
results are expressed as means ± SD.
Determining the utility of AK-D 2.2 cells in visualizing FIPV Black plaques.
Next, we asked if AK-D 2.2 cells can be used as an indicator cell type to accurately
determine FIPV-Black titers by plaque assay. An ideal indicator cell type allows a virus
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to form well-defined and easily enumerable plaques; therefore, we sought to determine
if plaque size is affected by the absence of IFNaR2 in AK-D 2.2 cells. We infected AK-D
or AK-D 2.2 cells with serotype I FIPV-Black at a MOI = 0.1 and evaluated how the
reduced IFNα response in AK-D 2.2 cells affected virus-induced cytopathic effect (CPE).
Over 48 h, we observed increased CPE in AK-D 2.2 cells compared to wild type AK-D
cells (Figure 15A), suggesting an increase in virus spread that we speculate is due to
the reduction in induced ISGs in AK-D 2.2 cells. A plaque assay utilizing AK-D 2.2 cells
resulted in large and enumerable plaques that allowed for more accurate determination
of FIPV Black titer compared to wild type AK-D cells (Figure 15B). In AK-D 2.2 cells,
plaques were more easily identified at 72 hpi, and plaque sizes were comparable to
those on Fcwf-4 CU cells at 48 hpi. It was difficult to accurately determine virus titer
using wild type AK-D cells, as the plaques were too small to count accurately at both
time points and led to an underestimation of PFU/mL. Our results highlight the utility of
the AK-D 2.2 cells in determining the titer of serotype I FIPV and indicate that this cell
line will be critical in future studies investigating IFN antagonist-mutant strains of FIPV.

151
A.
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Figure 15: AK-D 2.2 Cells Can Be Used to Determine Serotype I FIPV Titer. A)
Representative images of AK-D (top row) and AK-D 2.2 (bottom row) of uninfected
(Mock) cells or cells infected with FIPV Black (MOI = 0.1) taken at indicated hours
post-infection (HPI). Mock images were taken at 24 h post-plating. B) Fcwf-4 CU cells
were infected with MOI = 0.1 serotype I FIPV Black and supernatants were collected at
24 HPI after which plaque assay analysis was performed on AK-D, AK-D 2.2, or Fcwf4 CU indicator cells. Images were taken at 48 (top) and 72 (bottom) HPI. (A-B) Images
are representative of three independent experiments.
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Evaluating the IFN-responsiveness and FIPV Black replication kinetics in a
clone of Fcwf-4 2.2 Poly cells. In addition to disrupting IFN signaling in AK-D cells, I
also targeted the IFNαR2 in the feline macrophage cell line, Fcwf-4 CU. These cells are
a more physiologically relevant cell type in which to study FIPV and grow Black to high,
cell-free titers (O’Brien et al., 2018). To knock down the IFNaR2, wild type Fcwf-4 CU
cells were transduced with pLentiCRISPRv2 targeting the second exon of the feline
ifnαr2 gene (2.2), the same sequence targeted in AK-D cells. Positive transductants
were selected using puromycin and cells were cultivated as a heterogeneous population
termed Fcwf-4 2.2 Poly (polyclonal). To evaluate the IFN-responsiveness of the 2.2 Poly
cells, cultures were treated with 1000 U of feline type I IFN for 6 hours and evaluated for
expression of ISG54. Compared to the parental Fcwf-4 CU cells and a population
transduced with an empty pLevtiCRISPRv2 (EV), the Fcwf-4 2.2 Poly cells had reduced
ISG54 production suggesting positive disruption of the ifnar2 gene (Figure 16A).
Further, FIPV Black replication kinetics were similar in parental and 2.2 Poly cells
(Figure 16B). As this polyclonal population of cells had reduced IFN-responsiveness
and no negative impact on virus replication, I decided to isolate and evaluate several
clonal cell lines to decrease genetic variability. A total population of Fcwf-4 CU 2.2 Poly
cells were sorted into a 96-well plate at 1-2 cells per well then grown over 30 days.
Three clones, CL1-3, were evaluated for IFN-responsiveness and, as before, by first
stimulating with 1000 U of IFN then evaluating the ISG54 response (Figure 16C). Clone
3 had the most subtle ISG54 response, which was further demonstrated using
increasing concentrations of IFN stimulation (Figure 16D). The Fcwf-4 CU 2.2 Clone 3
cells were termed “IRN” for IFNα Receptor Null. FIPV Black replication kinetics were
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similar in the parental Fcwf-4 CU and Fcwf-4 IRN clonal cell line as determined by
plaque assay measuring infectious particles (Figure 16E) and by qPCR measuring
production of N gene transcript (Figure 16F). Cell cytopathic effects induced by the
virus were also similar between the Fcwf-4 CU and IRN cell lines, although CPE was
more robust late in infection, possibly due to slightly higher virus titers observed at 30
hpi (Figure 16G). Together, these results describe the successful generation and
isolation of an IFNα response-deficient Fcwf-4 CU cell line, which will be highly useful in
the recovery and study of IFN-antagonist mutant FCoVs in future studies.
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Figure 16: Fcwf-4 IRN Cells Have Reduced IFN-responsiveness and Replicate
FIPV Black to High Titer. A, C, D) Fcwf-4 CU (CU), empty vector-transduced (EV),
Fcwf-4 CU 2.2 Poly, Clones CL1 and CL2 or Fcwf-4 CU IRN cells treated with 0, 100 or
1000 U feline IFNα for 6 h and ISG54 and 𝛽-actin detected by qPCR. B, E) FIPV Black
growth kinetics (MOI=0.1) in given cell type over time. >2 replicate plaque assays done
at each time using Fcwf-4 CU indicator cells. Values reported as mean plaque forming
units (PFU) / mL. F-G) N gene expression by qPCR (F) and CPE (outlined) (G) taken
over time during FIPV Black infection (MOI = 0.1) of Fcwf-4 CU or IRN cells. mRNA
expression normalized to 𝛽-actin and presented as relative expression over mock. Data
represent >2 independent experiments in triplicate. Mean ± SD analyzed by unpaired ttests. * P < 0.05; ** P < 0.01; *** P < 0.001; non-significant (ns).
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Determining how IFN signaling is disrupted in Fcwf-4 IRN cells. The
Crispr/Cas gene editing system targets and cleaves a specific sequence leading to nonhomologous repair and in/del mutations that can lead to disruption in gene transcription,
point mutations or early termination of the protein. To determine how the IFNaR gene
was disrupted in the Fcwf-4 IRN cell line, I first isolated total RNA from these cells and
compared the expression of IFNaR2 by qPCR. In these experiments, the expression of
IFNaR2 was actually higher than the parental cells (Figure 17A) indicating that the
disruption did not occur at the level of transcription. I also compared the melting
temperatures of the amplicons produced during qPCR (Krenke et al., 2005) and found
that they differed, on average, by 1oC (Figure 17B) suggesting a possible difference in
the nucleotide composition. To determine what the difference in sequence was, I cloned
and sequenced the IFNaR2 mRNAs produced in Fcwf-4 CU and IRN cells (Appendix
D). From the sequencing, I found that the IRN IFNaR mRNA encoded a 14-nucleotide
deletion at the intended Cas9 cleavage site (Figure 17C), which translated to a frameshift and an early termination at residue 27 (Figure 17C) resulting in a shortened, nonfunctional IFNaR.
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Figure 17: Fcwf-4 IRN Cells Encode a Shortened, Null Mutant IFNαR Protein. A)
Feline IFNαR2 exon 1-4 expression determined from total RNAs collected from Fcwf-4
CU and Fcwf-4 CU IRN confluent monolayers. mRNA expression normalized to 𝛽-actin
(2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]) and presented as such. Data represent two
independent experiments in triplicate. Mean ± SD analyzed by unpaired t-tests. ** P <
0.01. B) Melt curves and maximum melt temperatures of IFNαR2 exon 1-4 amplicons
produced during qPCR of RNAs obtained from Fcwf-4 CU or Fcwf-4 CU IRN cells. Melt
temps determined by plotting change in fluorescence with temperature [-d(RFU)/dT]
versus temperature (oC) then calculating the point at which the largest change in
fluorescence occurs (Krenke et al., 2005). C) Amino acid sequence alignment of the
IFNαR2 region targeted by Crispr/Cas9 in Fcwf-4 CU and Fcwf-4 CU IRN cells.
Disruption of the IFNαR2 in the Fcwf-4 CU IRN cells due to a 14 nt deletion resulting in
a nonsense mutation, a shortened protein and a null phenotype. Nucleotide site
targeted by Cas9 cleavage indicated by arrow; asterisk indicates termination codon;
blue highlights indicate positional differences between the amino acid sequences.
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Expression of feline TMPRSS2 improves FIPV Black replication. Host-cell
proteases are critical to coronavirus entry and replication. As the goal of this dissertation
is to develop a number of tools to aid in investigating feline coronavirus, I determined if
of a host protease, TMPRSS2, may enhance FCoV replication. The feline TMPRSS2
protein carrying a C-terminal V5 tag was cloned into a pLVX lentivirus backbone vector
and termed pLVX-fTMPRSS2(V5). To demonstrate subcellular localization and to
visualize expression, HEK 293T cells were transfected with the pLVX-fTMPRSS2(V5).
The V5 antibody was detected by immunofluorescence within the cell cytoplasm and at
the cell surface (Figure 18A) and both the full-length (55 kDa) and the cleavage product
(>25 kDa), indicating an active protein, were detected from these cells by western blot
(Figure 18 B, left). Fcwf-4 CU IRN cells that were transduced with pLVXfTMPRSS2(V5) lentivirus also had detectable levels of the full-length and active forms
of feline TMPRSS2 (Figure 18 B, right) demonstrating that expression of an active
feline protease was achievable in this cell line. Therefore, I next sought to determine if
TMPRSS2 had an impact on replication of FCoV. Fcwf-4 CU IRN cells were transduced
with increasing dilutions of pLVX-fTMPRSS2(V5) lentivirus for 48 hours then infected
with FIPV Black at 0.1 multiplicity of infection (MOI) for 18 hours. Expression of
TMPRSS2 at dilutions below 1:20 (Figure 18C) resulted in significant increases in FIPV
N gene transcript (Figure 18D) compared to cells that did not express TMPRSS2,
suggesting that addition of a feline protease can enhance virus replication. Interestingly,
N gene expression was reduced at lower dilutions of TMPRSS2 (1:2.5) suggesting that
expression of these proteases needs to be carefully titrated and too much protein can
result in reduced titers. It should be noted that uninfected Fcwf-4 CU IRN cells that were
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transduced with the 1:2.5 dilution of lentivirus had significant morphologic differences
and were more detached from the plate compared to cells transduced with higher
dilutions (data not shown) indicating that the lower N gene expression observed at
higher expression of TMPRSS2 likely impacts the ability of the virus to enter cells.
Together, these data describe the successful generation of two IFNαR-null cell
lines by Crispr/Cas, the isolation of an Fcwf-4 CU IFNαR-null clone and, further,
demonstrate that expression of a feline protease in these cells can enhance replication
of serotype I FIPV.
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Figure 18: Feline TMPRSS2 Improves FIPV Black Replication in Fcwf-4 IRN Cells.
A) Immunofluorescence detection of feline TMPRSS2 (V5) in HEK 293T cells. 200 ng of
pLVX-fTMPRSS2(V5) or pLVX (mock) was transfected into HEK 293T/17 cells for 18 h.
Cells were fixed with 3.7% PFA, permeabilized with 0.1% Triton X-100, blocked in 5%
NGS / 0.3% Triton X-100 and stained with mouse-anti-V5 (1:500). 1:1000 goat-antimouse AlexaFlor568 (TRITC) was used to visualize TMPRSS2(V5); Hoesch 3342
(1:1000) was used to stain nuclei. B) Detection of feline TMPRSS2(V5) by western blot
following transfection of HEK 293T cells (left) or transduction of Fcwf-4 CU IRN cells
with pLVX lentiviruses encoding TMPRSS2(V5) (right). The full length (< 55 kDa) and
cleavage product (> 25 kDa) of TMPRSS2 are indicated. Feline 𝛽-actin used to visualize
protein loading. C-D) The impact of feline TMPRSS2 expression on FIPV replication
evaluated in Fcwf-4 CU IRN cells. Indicated dilutions of pLVX-fTMPRSS2(V5) or Mock
(empty) transducing particles were applied to Fcwf-4 CU IRN cells for 48 hours prior to
infection with FIPV Black (MOI = 0.1). RNA was isolated after 18 h infection and qPCRs
were performed to detect TMPRSS2 (C), N gene (D), and 𝛽-actin transcripts. mRNA
expression normalized to 𝛽-actin (2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]) and presented as
such. Data represent two independent experiments in triplicate. Mean ± SD analyzed by
unpaired t-tests. ** P < 0.01; *** P < 0.001; non-significant (ns).
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Section 3: Progress Toward Developing an Infectious Clone Reverse Genetics
System of Serotype I FIPV Black
Rationale.
One consideration for serotype I FIPV vaccine design is the strength of the innate
immune response to immunization. A strong innate immune response, characterized by
high levels of type I interferon (IFN), typically results in robust adaptive responses and
development of immune memory (Hoebe et al., 2004; Siegrist, 2013). Coronaviruses
including FCoV, however, prevent or subvert innate signaling using a number of virusencoded type I IFN antagonists (Dedeurwaerder et al., 2014; Deng et al., 2017; Rose
and Weiss, 2009; Totura and Baric, 2012) that limit development of an appropriate
inflammatory response (Channappanavar et al., 2016). In the case of FIPV infection, a
large, unregulated inflammatory response is mounted, which ultimately leads to the
immune-mediated pathology observed in FIP. The adaptive responses, including
cytotoxic T cell and humoral B cell stimulation/recruitment are generally weak and do
not typically result in long-lasting immune memory (Tang et al., 2011). As a further
complication, antibodies that are produced against the spike and envelope proteins of
FIPV mediate antibody-dependent enhancement of disease (Corapi et al., 1992; Olsen
et al., 1992). Although it is not known how ADE affects circulating FCoV, it remains a
significant concern for vaccine development (Huisman et al., 2009).
Strong cytotoxic T cell responses during FIPV infection are associated with
positive disease outcomes (de Groot-Mijnes et al., 2005; Pedersen, 2014a; Satoh et al.,
2011) as are increased levels of IL-12, IL-21, IL-10 and type II IFN gamma
(Dedeurwaerder et al., 2013; Kipar et al., 2006; Kipar and Meli, 2014). One group even
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argued that a lack of IL-12, which functions to promote T cell differentiation and
activation, may be the major determinant for progression to FIP (Kipar et al., 2006).
Importantly, type I IFN signaling has been shown to enhance cytotoxic T cell responses
through promotion of IL-12, IL-21, MHC-I, and IFN-𝛾 [reviewed in (Meager, 2006;
Tough, 2012)] as well as promote memory T cell development [reviewed in (Huber and
Farrar, 2011)]. Thus, enhancing the type I IFN response early during FIPV infection may
lead to development of long-lasting T cell responses, which may effectively clear
subsequent infections.
Several groups have shown that the elimination of coronavirus IFN antagonists,
therefore stimulating production of type I IFN, has been a successful method of
generating attenuated coronavirus strains (Deng et al., 2019b, 2017; Haijema et al.,
2004; Kindler et al., 2017). Our group and others have demonstrated that functional
elimination of the conserved endoribonuclease (EndoU) in mouse hepatitis virus (MHV)
leads to the stimulation of multiple IFN-I signaling pathways, rapid cellular apoptosis in
macrophages, and complete protection of mice against lethal challenge. Therefore, an
EndoU FIPV mutant virus that stimulates high type I IFN and causes apoptosis in
macrophages may be considered a vaccine candidate. The FIPV group-specific regions
ORF7 and ORF3 have also been implicated in innate immune antagonism, and are
thought to act on interferon stimulated genes (ISGs) rather than type I IFN signaling
directly (Dedeurwaerder et al., 2014, 2013). Removal of these group-specific regions or
individual proteins from serotype II FIPV leads to reduced virus replication in
macrophage-like cells. Haijema and colleagues demonstrated that individual deletion of
ORF3, or to a lesser extent ORF7, was attenuating to a serotype II FIPV and led to
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protection against a second challenge without ADE (Haijema et al., 2004). These
studies suggest that elimination of one set of the group-specific genes can be used to
attenuate the more dominant serotype I FIPV. Thus, deletion of a set of group-specific
genes may enhance the attenuation phenotype of an EndoU-mutant FIPV, thereby
producing strong innate and adaptive T cell responses.
To facilitate investigation of FCoV interferon antagonists for attenuation studies, I
designed a reverse genetics system based on a sequenced laboratory strain of the
model type I feline coronavirus FIPV Black. Similar to the MHV, SARS- and MERS-CoV
systems (Scobey et al., 2013; Yount et al., 2003, 2002), our approach utilizes
contiguous cDNA plasmids to produce full-length copies of the FIPV genomic RNA. The
cDNA plasmids can be prepared and purified to high concentration while maintaining
sequence fidelity and allow more straightforward mutagenesis. Together, this system
facilitates genetic manipulation of targeted genes and allows for production of infectious
virions with a defined genotype. The FIPV Black reverse genetics system described
here complements previously-established systems for feline coronavirus (Tekes et al.,
2008).
Results.
Designing, constructing and evaluating a contiguous plasmid reverse
genetics system of FIPV Black. The reverse genetics system described here was
developed based on the genomic sequence of an in-lab strain of FIPV Black generously
provided by Fred Scott (Cornell University). To determine the genomic sequence of the
FIPV Black laboratory strain, cell-free and cell-associated fractions obtained from
infected AK-D cells were combined and sent to the Kansas State Veterinary Diagnostic
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Laboratory for deep-sequencing. A consensus sequence of our in-lab FIPV Black was
generated by aligning the deep-sequencing reads to a known FIPV Black genome
(EU186072.1). The resulting genomic sequence of the in-lab FIPV Black genome was
then used as a template off of which the reverse genetics system was design and from
here will simply be referred to as FIPV Black. The design of the FIPV Black contiguous
cDNA plasmid reverse genetics system, based on work from Yount and colleagues
(Yount et al., 2002), is diagrammed in Figure 19.
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Figure 19: FIPV Black Infectious Clone Reverse Genetics Schematic. (1) RNA
genome of lab-seq FIPV Black sub-cloned on 7 cDNAs, each containing two unique
terminal restriction sites. A T7 promoter was added to the 5’ end of A frag and a poly-A
tail was added to the 3’ end of G frag; (2) Large-scale plasmid preps digested to release
frags, which were gel isolated, column purified, and chloroform extracted. Molar
equivalents of frags ligated using T4. (3) Ligation product and linear plasmid encoding
the Black nucleocapsid (N) gene in vitro transcribed using T7 into full-length, capped
mRNAs and (4) electroporated into Fcwf-4 CUs. (5) After 24-72 h, CPE visualized. RNA
isolated for detection of subgenomic (sg) RNA by RT-PCR, or virus recovered.
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First, the consensus FIPV Black genome was divided into seven sections (A-G)
in silico (Table 8). For segments B-F, PCR fragments were amplified from total cDNA,
generated using isolated FIPV Black gRNA as a template, using specific primer sets
(Appendix B; Primer Index 3). These primers appended two terminal BsmBI sites on
each segment that produce unique 4 nt overhangs upon digestion and only base-pair
with the next contiguous fragment (Table 8). PCRs were performed using a high-fidelity
Taq Polymerase (Roche), which appends a T/A residue on the terminal ends of each
segment and allows insertion of each segment into pCR-XL-TOPO® using TA cloning.
The A and G segments could not be PCR amplified (without mutation) due to the
complexity of the 5’ and 3’ ends of the gRNA, which contain low GC%, multiple
repeating nucleotide stretches and secondary structures. Instead, these segments were
synthesized by BioBasic, Inc and inserted into pUC57 vectors. The sequence of the A
segment was modified at the 5’ end to encode an in-frame T7 RNA transcription
promoter sequence (5’- TAA TAC GAC TCA CTA TAG -3’) upstream of the genomic
sequence, and a natural BsmBI site was eliminates at position 3,806. The G segment
was modified to carry a 21-nt poly-A tail. All other segments were unmodified and largescale DNA preparations were purified and sequenced to confirm sequence fidelity
(Appendix B; Primer Index 4). Thus, each of these seven cDNA subclones encodes a
specific cDNA segment of the FIPV Black gRNA. The sequence of the FIPV Black
nucleocapsid protein was also amplified and cloned onto pCDNA-3.1 with a 5’ T7
promoter sequence.

166
cDNA
Clone

Cloning
Plasmid

Genome
Location

Restriction
Enzymes

A

pUC57
(AmpR+)

1–
4,810

BamHI / BsmBI

B

pCR-XL-TOPO®
(KanR+)

4,811 –
8,875

C

pCR-XL-TOPO®
(KanR+)

D

5’ Restriction
Junction

3’ Restriction
Junction

Frag Size
(Kb)

5’-G_GATCCAGTTT
CCTAG_GTCAAA-3’

5’-A_AGACTGAGACG
TTCTG_ACTCTCG-3’

4.810

BsmBI / SfiI
(vector)

5’-CGTCTCA_AGACA
GCAGAGTTCTG_T-3’

5’-A_TTACTGAGACG
TAATG_ACTCTGC-3’

4.064

8,876 –
13,485

BsmBI / SfiI
(vector)

5’-CGTCTCA_TTACC
GCAGAGTAATG_G-3’

5’-G_CATCTGAGACG
CGTAG_ACTCTGC-3’

4.609

pCR-XL-TOPO®
(KanR+)

13,486 –
15,825

BsmBI

5’-CGTCTCG_CATCA
GCAGAGCGTAG_T-3’

5’-CGTCTCA_TAATG
GCAGAGTATTA_C-3’

2.339

E

pCR-XL-TOPO®
(KanR+)

15,826 –
20,588

BsmBI / SfiI
(vector)

5’-CGTCTCA_TAATG
GCAGAGTATTA_C-3’

5’-A_CTGTGGAGACG
TGACA_CCTCTGC-3’

4.762

F

pCR-XL-TOPO®
(KanR+)

20,589 –
24,861

BsmBI / SfiI
(vector)

5’-A_CTGTGGAGACG
TGACAC_CTCTGC-3’

5’-G_CCATTGAGACG
CGGTA_ACTCTGC-3’

4.272

G

pUC57
(AmpR+)

24,862 –
29,198

BsmBI

5’-CGTCTCG_CCATT
GCAGAGCGGTA_A-3’

5’-A_AAAAAGAGACG
TTTTT_TCTCTGC-3’

4.341

Table 8: FIPV cDNA Sub-cloning, Fragments and Restriction Digest Junctions.
Genome Location: the genome locations given are based on the genome of the Baker
Lab strain of FIPV Black, which was sequenced by Kansas State. Restriction Junction:
the (_) indicates the enzyme cleavage site; bold sequences indicate unique overhangs
produced following enzyme digestion.
Following subcloning, the seven cDNA segments were excised from the cloning
vectors using restriction enzyme digest (Table 8) and purified by separation through a
low-melt agarose gel, cutting out the appropriate cDNA fragment and cleaning on a
DNA-binding column. In addition to BsmBI, cDNA clones B, C, E and F were also
digested with SfiI, which cleaves the cloning vector into smaller fragments allowing
better visualization of the intended cDNA fragments on an agarose gel. The plasmid
encoding the N gene was linearized by digestion with DraIII. The seven eluted
segments of cDNA, now referred to as “A-G Fragment”, and the linearized N gene were
further purified by chloroform extraction in order to concentrate the DNA and remove
excess agarose gel. The size and purity of each cDNA fragment was confirmed by
separation on an agarose gel (Figure 20A).
Next, to generate a full-length cDNA copy of the FIPV Black genome, molar
equivalents of each fragment were combined and ligated overnight using T4 Ligase. In
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order to confirm that fragments aligned in the proper order, PCRs were performed to
amplify each junction using junction-specific primers (AB, A5/B1R; BC, B5/C1R; CD,
C6/D1R; DE, D3/E1R; EF, E7/F1R; FG, F6/G1R) (Appendix B; Primer Index 4) using
the full-length cDNA as template. The PCR products of each junction were successfully
amplified (Figure 20B) and the size of full-length cDNA was confirmed (Figure 20C,
second lane). Once confirmed, the ligation product was extracted using phenolchloroform-isoamyl alcohol, precipitated using isopropanol and washed with ethanol.
In the third, fourth steps of the reverse genetics process (Figure 19), the purified
ligation product and the linearized N gene DNAs were in vitro transcribed using T7
polymerase into 5’-capped mRNAs encoding the FIPV Black infectious clone (ic) or the
N gene (Figure 20C). These mRNAs can be directly co-electroporated into Fcwf-4 cells
to produce infectious virus and are detectable visually by CPE development and by
amplifying subgenomic RNA by RT-PCR.

168

Figure 20: Experimental Evaluation of FIPV Reverse Genetics Steps. A) cDNA
frags (A-G) electrophoretically separated on an agarose gel observed using ethidium
bromide under UV. B) PCR amplification of full-length ic cDNA ligation junctions
visualized on an agarose gel under UV. C) Agarose gel depicting the full-length cDNA
ligation (LIGATION), and the in vitro transcribed N gene (NG TSC.) and the full-length
infectious clone (IC FV TSC.) RNAs. D) Prototypic “syncytial” and “melted” cell
cytopathic effects (CPE) observed after 24 h electroporation of Fcwf-4 CU cells with
purified genomic (g) RNA from FIPV Black. E) Determining the optimal electroporation
voltage needed to introduce gRNA and N gene transcript into Fcwf-4 CU cells. 600 uL
Fcwf-4 CU cells at 1x107 cells/mL in Opti MEM pulsed three times at indicated voltage
(V) and plated in 10 cm dishes. Brightfield images taken at 24-48 h at 40x magnification.
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To determine the optimal electroporation conditions needed to introduce RNA
into Fcwf-4 CU cells, I used purified gRNA isolated from lab-stocks of FIPV Black. Fcwf4 CU cells were washed twice in PBS and diluted to 1x107 cells/mL in OptiMEM. In a
cuvette, 600 uL of Fcwf-4 CU cells were added to 500 ng of FIPV Black gRNA and 250
ng of in vitro transcribed N gene RNA. Cells and RNA were pulsed three times at
increasing voltages (450-1200 V), with constant 25 μF capacitance and ∞ resistance,
then plated into 100 cm dishes for 24 and 48 hours. Cells electroporated at all voltages
developed CPE by 48 hours-post electroporation (hpe) (Figure 20E), however, optimal
conditions were achieved at 850 V as cells were healthy, and CPE was the most robust
(Figure 20E). Two types of CPE were observed including the classic syncytial formation
and a “melted cell” phenotype (Figure 20E) and were used as first indicators of
successful generation of infectious FIPV Black.
The use of IFNα signaling-deficient cells is critical to recovery IFN-antagonistdeficient FIPV Black mutant viruses. As this is the primary future use of this reverse
genetics system, it was important to determine if the IFNαR-deficient cell line, Fcwf-4
CU IRN cells, could also be used to successfully recover wild-type FIPV Black from
electroporated gRNA. Indeed, substantial CPE was observed over 44 hpe in Fcwf-4 CU
IRN cells electroporated with gRNA and N gene RNAs (Figure 21B). Interestingly, the
CPE was more robust in the IRN cells compared to the CU cells (Figure 21A),
corroborating previous results obtained during traditional infection (Figure 16 E-G).
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A.

Fcwf-4 CU at 850V

B.

Fcwf-4 IRN at 850V

Figure 21: FIPV gRNA Electroporation Produces Infectious Virus in Fcwf-4 CU and
IRN Cells. A-B) FIPV Black gRNA (500 ng) was combined with N gene transcript (250
ng) and electroporated into 6x106 Fcwf-4 CU (A) or Fcwf-4 CU IRN (B) cells at 850 V,
25 μF C and ∞ R. Images taken at indicated hours post-electroporation (hpe). Arrows
indicate CPE development. Mock cells electroporated without RNA.
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Together, these data demonstrate that all steps of the reverse genetics process
have been successfully optimized and describe the successful and reproducible
generation of FIPV Black from electroporated gRNA in both Fcwf-4 CU and Fcwf-4 CU
IRN cells as a positive control.
Generation and detection of a wild-type infectious clone FIPV Black. To
determine if this reverse genetics system could produce infectious virus, a full-length,
mRNA infectious clone (ic) of the FIPV Black lab strain was constructed by digestion
and ligation of fragments A-G and subsequent in vitro transcription. The icFIPV mRNA
and N gene transcripts were co-electroporated into Fcwf-4 CU cells using optimized
electroporation conditions. Fcwf-4 CU cells electroporated with 500 ng of purified FIPV
Black gRNA and 250 ng N gene transcript was used as a positive control; Fcwf-4 CU
cells electroporated without RNA (mock) were used as a negative control. The
development of syncytial CPE was observed at 24 hpe in cells electroporated with both
the icFIPV and FIPV gRNA (Figure 22A) suggesting that virus was produced in both
cases. These syncytia were not observed in the mock-electroporated cells indicating
that this cell morphology was not a side-effect of electroporation and was a result of
virus replication. The detection of subgenomic (sg) RNAs, which are only produced
during active CoV replication, was used in order to confirm the presence of FIPV. Mock,
icFIPV- and FIPV gRNA-electroporated Fcwf-4 CU cells with were lysed at 24 or 48 hpe
(depending on CPE development in the positive control) and I used RT-PCR to
determine if L-containing subgenomic N gene mRNA was present. Indeed, sgRNA was
detectable in both the positive control and the icFIPV (331 bp) (Figure 22B) confirming
successful generation of an ic of FIPV Black using our reverse genetics system.
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gRNA icFIPV

20.0 5.0 -

1.5 -

0.5 0.4 0.3 0.2 .075 Figure 22: FIPV Infectious Clone Produces Syncytial CPE and N gene
Subgenomic RNA. A) Development of syncytial cell cytopathic effect (black arrows) at
24 hours post-electroporation (hpe) of Fcwf-4 CU cells with mock (0 ng RNA), genomic
(g) RNA (500 ng + 250 ng N gene transcript) or infectious clone (ic) RNA (total
transcription product with 350 ng N gene transcript), respectively. Representative
brightfield images taken at 60 x magnification. B) Detection of nucleocapsid (N) gene
subgenomic (sg) RNA by RT-PCR. Total RNA was isolated from Fcwf-4 CU cells
electroporated with mock, gRNA, or icFIPV RNA, as in (A), at 24-48 hpe. cDNA was
generated using random hexamer primers. RT-PCRs using primers specific to the
leader sequence (forward) and the N gene (reverse) were run using the cDNAs from
each cell type as templates. The products were separated on an agarose gel and
visualized with ethidium bromide under UV. Positive amplicons present as a 331 bp
band. Image representative of > 3 experiments.

CHAPTER FOUR
DISCUSSION
Summary and Implications
Overview.
A number of issues related to the growth and characterization of serotype I feline
coronavirus have slowed investigation of these important animal pathogens and
hindered the development of effective vaccines. The goal of the research presented in
this dissertation was to begin to establish a “tool box” containing protocols, reagents,
cell lines and genetic techniques to facilitate the study of clinically relevant and mutant
serotype I feline coronaviruses. In the first section, colleagues and I identified and
characterized the growth kinetics of FIPV Black in a new, physiologically-relevant feline
cell line, termed Fcwf-4 CU, and found that these cells were capable of rapidly
producing high titers of cell-free virus. In the next section, I successfully disrupted IFN
signaling in these Fcwf-4 CU cells and a second cell line, AK-D, using Crispr/Cas
demonstrating that advanced genetic manipulations could be successfully performed in
either cell type. A clonal cell line, termed Fcwf-4 CU IRN was isolated and found to be
both IFN insensitive and also permit growth of high titers of FIPV Black. Expression of
feline TMPRSS2 in these cells also increased FIPV replication indicating that these cells
may be useful for isolation of serotype I strains directly from animal tissues and further
highlights the importance of having a genetically plastic cell line. Finally, using the
sequence of a laboratory strain of FIPV Black, I generated an infectious clone reverse
173

174
genetics system using seven contiguous cDNA plasmids and demonstrated successful
detection of a wild-type FIPV Black produced in this system. In future experiments, the
Fcwf-4 CU IRN cells will be used to recover and characterize IFN-antagonist-mutant
FCoV strains exhibiting a hyper-interferon inducing phenotype for use as live-attenuated
vaccine development.
Characterizing Replication Kinetics and Plaque Production of Serotype I FIPV in
Three Cell Lines.
Summary. Investigating type I feline coronaviruses (FCoVs) in tissue culture is
critical for understanding the basic virology, pathogenesis, and virus-host interactome of
these important veterinary pathogens. This has been a perennial challenge as type I
FCoV strains do not easily adapt to cell culture and viruses that do adapt, lose
pathogenicity. We characterized the replication kinetics and plaque formation of a model
type I strain FIPV Black (TN406) in Fcwf-4 cells established at Cornell University (Fcwf4 CU). We determined that maximum virus titers (>107 pfu/mL) were recoverable from
infected Fcwf-4 CU cell-free supernatant at 20 hours post-infection. Type I FIPV Black
and both biotypes of type II FCoV formed uniform and enumerable plaques on Fcwf-4
CU cells. Therefore, these cells were employable in a standardized plaque assay.
Finally, we determined that the Fcwf-4 CU cells were morphologically distinct from feline
bone marrow-derived macrophages and were less sensitive to exogenous type I
interferon than were Fcwf-4 cells purchased from ATCC.
Implications. Since the isolation of the FIPV Black strain in 1980 (Black, 1980) it
has remained a predominant model of type I FIPV because it is cultivatable in
commercially available Fcwf-4 cells. However, different groups have reported major
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variations in the growth kinetics, maximum obtainable titer, and techniques for recovery
of this virus from tissue culture (Jacobse-Geels and Horzinek, 1983; Pedersen et al.,
1984; Tekes et al., 2012, 2008; Thiel et al., 2014). For example, maximal titers
measured by determining the TCID50 can range between >103 (Jacobse-Geels and
Horzinek, 1983) and 104 TCID50/mL (Takano et al., 2015) at 24-48 hpi, or measured by
plaque assay between >104 (36 hpi) (Tekes et al., 2012, 2008) and >107 pfu/mL (20 hpi)
(O’Brien et al., 2018). This suggests either high variability in the Fcwf-4 cell lines used
or co-adaptation between a particular virus and Fcwf-4 cell line used during laboratory
cultivation. Indeed, we report significant differences in FIPV Black replication properties
between an Fcwf-4 cell line that was newly purchased from the ATCC, and the Fcwf-4
cells that were established at Cornell University (CU). The enhanced rate of FIPV Black
virus growth and increased maximum titer (>107 pfu/mL by 20 hpi) obtained from
infected Fcwf-4 CU cells, however, may not be due to co-adaptation with our particular
strain of FIPV Black, as these cells also replicated both biotypes of serotype II viruses.
Instead, the Fcwf-4 CU cells may be highly susceptible to FCoV infection in general and
therefore may be particularly useful in generating highly-permissive cell types to isolate
and grow clinical type I FCoVs. The increased infectibility of Fcwf-4 CU cells could be
due to any number of cellular factors including increased abundance of specific entry
co-factors (e.g. DC-SIGN) or host proteases, which have been shown to enhance
coronavirus entry (Millet and Whittaker, 2015; Regan et al., 2010). However, as
infection by both serotype I and serotype II viruses were enhanced, it is tempting to
speculate that the reduced IFN-responsiveness of the Fcwf-4 CU cells relative to the
Fcwf-4 ATCC cells may also significantly enhance infection in the former. Further, these
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Fcwf-4 CU cells may express a higher density of the yet unknown serotype I virus
receptor (Cham et al., 2017; Dye et al., 2007) and therefore may be critical in identifying
the receptor or other cellular characteristics that allow for enhanced type I virus
replication.
FIPV Black infection of Fcwf-4 cells has also been reported to be highly cellassociated (Jacobse-Geels and Horzinek, 1983; Pedersen et al., 1984), requiring
suspension and freeze-thaw cycling to release infectious virus. In contrast, we found
significantly higher titers of virus in cell-free supernatants and speculate that multiple
freeze-thaw cycles may actually decrease virus titer by damaging the virus envelope.
The release of virus into cell supernatants and the uniform CPE observed in AK-D and
Fcwf-4 CU cells were critical in establishing a standardized plaque assay using either
cell type. Further, we report that the stage of CPE development can be used as an
indicator of when maximal virus titers can be recovered. These findings are an
important step in standardizing how the FCoV field measures and reports serotype I
virus titer and may reduce the overall variability in the literature.
One possible explanation for the varied reports on FIPV Black replication kinetics
and maximum titer could be that laboratory lines of Fcwf-4 cells have deviated from the
original ATCC stock. The Fcwf-4 cells deposited with the ATCC in the 1980’s were
characterized as “macrophage-like” (Jacobse-Geels and Horzinek, 1983), which hints
that these original cells were not terminally differentiated and may further develop
distinct characteristics under different growth conditions. Further, as per the ATCC,
Fcwf-4 cells grow as a “dual population” of adherent and suspended cells that need to
be pelleted during routine passaging (ATCC personal communication) – a technique
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that, if not followed, may significantly impact the characteristics of these cells in culture
over time. Subtle changes in Fcwf-4 characteristics and morphology is likely what
occurred at Cornell University to produce the Fcwf-4 CU cell line, given that Fcwf-4 cells
were obtained from the ATCC and then passaged for many years. To our knowledge,
O’Brien and Mettelman et al. (2018) is the first report describing the phenotypic
differences between the original Fcwf-4 cells available from the ATCC and a distinct
lineage that was derived from the original cells.
Finally, as these Fcwf-4 CU cells are “macrophage-like” they represent a more
physiologically relevant cell type in which to propagate serotype I FIPV strains, not just
tissue culture (TC)-adapted strains. One of the major issues in serotype I FCoV
research is attempting to extrapolate information about clinical viruses from studies
using TC-adapted strains, which harbor many genetic mutations. The majority of type I
FIPV strains that grow well in tissue culture, including the Black strain used here, have
lost in vivo pathogenicity due to TC adaptation posing the question of biologic relevance
when investigating such strains. It is likely that forcing serotype I FCoVs to grow in suboptimal conditions selects for adapted virus genotypes at the cost of virulence traits
such as the sequence of S and the presence of accessory genes 3c and 7b. These
specific gene regions have been shown to be altered or lost during TC adaptation and
demonstrate that the genetic cost of TC adaptation is loss of virulence (Pedersen,
2014a; Thiel et al., 2014). The characterization of the Fcwf-4 CU cells is an important
step away from forcing viruses to adapt to sub-optimal conditions as these cells are
highly permissive to serotype I FIPV. Future studies will be needed to determine if the
Fcwf-4 CU cells can replicate new clinical isolates of type I FIPV without forcing genetic
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mutations and allow propagation and investigation of more clinically relevant viruses in
lab without the use of live animals.
Many challenges are still associated with the growth of type I FCoV in tissue
culture, including the lack of a known cell-entry receptor and no highly-permissive cell
type that rapidly grows clinical samples of these viruses. However, our studies with the
Fcwf-4 CU cell line demonstrate that rapid, high titers of type I FIPV Black can be
recovered from cell-free supernatants and enumerated using a standardized plaque
assay. It is our hope that the Fcwf-4 CU cells will alleviate some of the technical
hardships associated with the growth of type I FCoV and expedite investigation of a
wider range of type I FCoV strains. The Fcwf-4 CU cells, due to their distinct growth
kinetics and enhanced replication of FIPV Black virus, will be deposited at the ATCC to
facilitate their distribution to the research community.
Generation of Feline Cell Lines to Study Attenuated or Clinically-important FCoV
Strains.
Summary and implications. The development of live-attenuated serotype I
FCoV vaccine strains may be possible through mutation of encoded IFN antagonists.
Generating and subsequent characterization of these so-called “hyper interferoninducing” (HII) FCoVs requires cell lines that lack IFN signaling in order to avoid
selective pressures and determine the mechanism(s) behind the virus attenuation. To
my knowledge, such IFN-nonresponsive feline cell lines were not available and studies
using gene-modifying tools such as Crispr/Cas had not been performed in feline cells
permissive to FCoVs. In the previous section, my colleagues and I characterized the
growth kinetics of FIPV Black in AK-D and Fcwf-4 CU cells and demonstrated that rapid
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growth of wild-type serotype I FIPV could be achieved given the right cell type and
conditions. However, these cells still produced IFN upon stimulation suggesting that
neither cell line would not be appropriate for recovery of HII viruses by reverse genetics.
Previous studies from our lab using mouse hepatitis virus (MHV), a model murine
coronavirus, strongly imply that production of IFN antagonist-deficient CoVs by reverse
genetics absolutely requires the use of an IFN-nonresponsive cell type (Deng et al.,
2017). In these studies, we determined by deep-sequencing that mutant MHV strains
produced in IFN-responsive cells acquired additional mutations that suppressed the
original IFN antagonist mutation. This phenomenon likely occurred in response to
selection imposed by the antiviral activity of type I interferon, which selected against the
attenuated HII phenotype. Cells lacking the type I IFN response allowed for recovery of
“clean” mutant viruses that contained only the desired mutation. Subsequent
characterization of novel MHV IFN antagonists, as well as the relevant mechanisms
underlying their activities, were undertaken using IFNαR-/- cells, highlighting the need of
such cell lines in investigating attenuated feline coronavirus strains.
Building on this idea, the goal of this section of my research was to genetically
modify AK-D and Fcwf-4 CU cells to generate feline cell lines that are i) highly
permissive to serotype I FCoV and ii) deficient in IFNαR signaling. I predict that feline
cells with these two characteristics will allow for future investigation of not only IFN
antagonist-deficient HII viruses, but also isolation of clinically-important FIPV strains. To
this end, I first disrupted the type I interferon alpha receptor domain 2 (IFNαR2) in two
feline cell lines, AK-D and Fcwf-4 CU using the Crispr/Cas gene editing system,
referring to the total population of positive transductants as AK-D 2.2 and Fcwf-4 2.2
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Poly, respectively. Both populations of total positive transductants had diminished IFNresponsiveness and replicated FIPV Black to high titers. Although I was unable to
isolate clone of the AK-D 2.2, I showed that the polyclonal population of these cells
produced higher FIPV Black virus titers from cell-free compared to cell-associated
fractions of infected cells and were employable in a standardized plaque assay, a
technique that will be useful in future studies for determining the titers of HII mutant
FCoV strains without the negative impact of IFN on virus growth. From the Fcwf-4 2.2
Poly cell line, I isolated a clonal cell line, termed Fcwf-4 CU IRN, which I determined to
have significantly diminished IFN-responsiveness. Further, I sequenced the IFNαR from
these cells and determined that the “null” phenotype was likely due to a 14-nucleotide
deletion in the Crispr/Cas-targeted region of the IFNαR mRNA, which led to early
termination in the second exon and a shortened protein product. Replication of FIPV
Black in this cell line was comparable to kinetics of the same virus in Fcwf-4 CU cells
and rapidly produced high titers of cell-free virus.
Interestingly, isolation of clones that both maintained the reduced IFNresponsiveness phenotype and remained permissive to FIPV Black was difficult in Fcwf4 2.2 Poly- and ultimately unsuccessful in AK-D 2.2 cells. For both cell populations, the
majority of isolated clones were non-permissive to FIPV Black infection regardless of
the degree of IFN-responsiveness. This suggests that, within a given population of AKD or Fcwf-4 cells, a portion of cells are non-permissive to FIPV, or can become nonpermissive in different culture or selection conditions such as those used in the
Crispr/Cas protocol. Further, this supports the speculation that continuous passage and
inadvertent selection of Fcwf-4 cells in tissue culture may alter expression of host
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proteases, entry co-factors, or virus receptor over time and that infectability of these
cells can change.
FIPV Black replication in parental and IFNαR-null (IRN) cells was relatively
equivalent and only slightly higher virus titers were observed in IFN-unresponsive cells.
Initially, I expected that virus growth would be significantly enhanced in the AK-D 2.2
and Fcwf-4 CU IRN cells as these cells are not stimulated to express high levels of
ISGs in response to IFN signaling. However, the observed growth kinetic results are
consistent with the function of the IFN antagonists encoded on the FIPV genome, which
allow replication of the virus in the wild-type cells without significant triggering of the IFN
response. In future studies, it will be very intriguing to compare the replication kinetics of
WT FIPV to HII mutants in Fcwf-4 CU and IRN cells. Here, I would expect to see
significantly reduced titers of HII viruses and production of type I IFN in the wild-type CU
cells, but equivalent titers and no IFN production in the IRN cells. This will be a highly
critical set of experiments moving forward and requires the Fcwf-4 CU IRN to
demonstrate that IFN is responsible for difference in virus replication.
TMPRSS2, a transmembrane serine protease, has been shown to mediate or
enhance cell-surface entry of a number of coronaviruses including HCoV 229E (Bertram
et al., 2013; Shirato et al., 2017), MERS-CoV (Park et al., 2016; Shirato et al., 2013)
and SARS-CoV (Glowacka et al., 2011; Reinke et al., 2017). To further demonstrate the
utility of the clonal Fcwf-4 CU IRN cell line in investigation of type I FCoVs, I transduced
these cells with feline TMPRSS2, and observed a significant, though modest, increase
FIPV Black replication as detected by an increase in N gene expression. This is an
important observation as it demonstrates that Fcwf-4 CU IRN cells can be transduced to
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express functional proteins, and that addition of host factors is a viable way of
enhancing serotype I FIPV infection in these cells. It should be noted that the TCadapted Black strain used here contains a polybasic TMPRSS2 S1/S2 cleavage site
(RSRR). Interestingly, the N gene expression dropped when expression of TMPRSS2
was further increased and significantly altered the morphology of the cells in culture
causing cell rounding and detachment from the surface, which may have prevented
efficient access to these cells by the virus. The increased presence of active TMPRSS2
could also be affecting the virus entry/exit by over-processing of the spike protein. The
pre-fusion form of the CoV spike must be processed at the appropriate spatiotemporal
stage of infection in order to mediate efficient membrane fusion, and it is possible that
excess TMPRSS2 may have pre-maturely cleaved S leading to reduced replication
efficiency. Ultimately, a stable, inducible cell line is needed to temporally control
TMPRSS2 expression. As Fcwf-4 CU cells have been shown to be amenable to genetic
modification by Crispr/Cas, inserting a Tet-On inducible TMPRSS2 should not be too
technically challenging.
Coronavirus S-mediated membrane fusion and subsequent entry into host cells
has been shown to occur at both the cell surface and within endosomes depending on
the availability of host proteases (Belouzard et al., 2012; Millet and Whittaker, 2015)
(Figure 23, top). For feline coronaviruses, cleavage of spike at the S1/S2 site by
transmembrane serine proteases (e.g. furin; TMPRSS2) typically mediates entry at the
cell-surface, while cleavage at the S2’ site by cathepsins typically mediates entry within
endosomes. The route of FCoV entry can differ between serotypes. Most all serotype II
viruses do not contain an S1/S2 site and rely on the S2’ for mediating membrane fusion,
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while most serotype I FCoV spikes contain both the S1/S2 and the S2’ and can enter by
either route (Belouzard et al., 2012; Whittaker et al., 2018). For FIPV Black, we consider
that the presence of a trypsin-like protease (e.g. TMPRSS2) at the cell surface can
functionally replace the usual endogenous protease to promote virus replication.
Importantly, entry of serotype I FCoV can be further impacted by tissue culture
adaptation. de Haan and colleagues demonstrated that the spike protein encoded on a
Fcwf-4 TC-adapted serotype I FCoV strain, FIPV-UCD1, had reduced cleavage at the
S1/S2 site, but exhibited increased binding to heparan sulfate (de Haan et al., 2008).
Interestingly, the serotype I FCoV clinical isolate, FECV-UCD, contains a full furin
cleavage site at S1/S2 and did not bind heparan sulfate, resulting in no replication of
this virus in Fcwf-4 cells. This suggests that tissue culture-adapted strains may forfeit
the S1/S2 cleavage site in favor of binding to heparan sulfate, which may be a more
abundant entry receptor on Fcwf-4 cells compared to the yet unknown natural receptor
in these cells (Figure 23, left).
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Coronavirus Entry

TC-Adapted Serotype I FIPV (Proposed)

Serotype I FIPV Clinical Strain (Proposed)

Figure 23: Dual Mechanisms of CoV Entry. Serotype I FIPV entry likely occurs within
endosomes (cathepsin cleaves S2’) or at the cell surface (furin cleaves S1/S2) (top).
TC-adapted S loses S1/S2 cleavage in favor of heparan binding (left). Expressing host
factors, like TMPRSS2, may promote natural receptor usage and cell-surface entry,
limiting S mutation and aiding in recovery of clinical serotype I strains (right).
The concept that TC-adaptation can alter the preferred virus entry pathway may
be common amongst lab-adapted CoV strains. A recent study by Shirato et al. showed
that clinical isolates of HCoV 229E, much like serotype I FCoV clinical strains, favored
TMPRSS2-mediated cell-surface entry while high passage, TC-adapted strains
preferentially adopted cathepsin-mediated entry in endosomes (Shirato et al., 2017).
These results have a major impact on the recovery of clinical serotype I FCoV. If
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serotype I FCoV growth in Fcwf-4 cells positively selects for the use of heparan sulfate
as an entry receptor, and by extension the loss of the furin/TMPRSS2 site, then this
may explain why tissue culture-adapted strains lose pathogenicity. Cell-surface level
entry, mediated by S1/S2 cleavage by furin or TMPRSS2, has been shown to be
involved in pathogenicity and spread of coronaviruses in vivo (Park et al., 2016; Shirato
et al., 2013) possibly by increasing the kinetics of virus entry (Earnest et al., 2017).
Therefore, the loss of the S1/S2 cleavage site in tissue culture-adapted strains may
significantly contribute to both the loss of pathogenicity of tissue culture-adapted strains
and the inability to cultivate true clinical isolates without several rounds of passage.
Interestingly, serotype II FCoVs do not contain an S1/S2 cleavage site, do not
apparently utilize heparan sulfate, and use feline aminopeptidase N (fAPN) - a different
entry receptor than serotype I FCoV (Hohdatsu et al., 1998). As such, tissue culture
adaptation of serotype II FIPV strains does not typically correspond with a loss in
pathogenicity (Tekes et al., 2012; Thiel et al., 2014) suggesting that maintenance of the
natural receptor/entry route may allow recovery of pathogenic type I strains. Thus,
increasing the expression of S1/S2-targeting host enzymes such as furin or TMPRSS2
along with expression of other host factors that have been shown to enhance entry at
the surface-level including tetraspanins, as has been shown with other coronaviruses
(Earnest et al., 2017; Hantak et al., 2019), may lead to more efficient recovery of clinical
type I FIPV strains (Figure 23, right). Other host proteases, such as cathepsins, have
been shown to be important for FCoV entry within endosomes (Regan et al., 2008) and
could also be expressed in Fcwf-4 CU or Fcwf-4 CU IRN cells using a similar system
described here for TMPRSS2.
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Together, the results in this section describe the successful disruption of the
IFNαR in two feline cell lines and suggest that overexpression of feline proteases, in at
least one of these cell lines, may be useful for enhancing infection of serotype I FCoVs.
Importantly these data also demonstrate the genetic malleability of the Fcwf-4 CU cells
and, to my knowledge, represent the first genetically-modified Fcwf-4 cell line. Thus,
both the AK-D 2.2 and the Fcwf-4 CU IRN cells will be useful in future studies
evaluating feline viruses that lack interferon antagonists and may be an important tool in
isolating serotype I clinical strains from infected cats.
Progress Toward Developing an Infectious Clone Reverse Genetics System of
Serotype I FIPV Black.
Summary. In this final section, I worked to establish a reverse genetics system
based on a deep-sequenced laboratory strain of the model type I FCoV, FIPV Black.
Using this FIPV Black sequence as a template, the genome was subcloned as seven
cDNA segments (A-G) into cloning vectors. I demonstrated that each fragment could be
excised from the vector, purified and ligated into a full-length cDNA version of the
genomic RNA and, using in vitro transcription, that mRNAs of the full-length icFIPV and
nucleocapsid gene could be produced. Using purified WT gRNA isolated from FIPV
Black virions, I optimized the electroporation protocol and established the positive
control conditions necessary to reproducibly recover infectious virus from Fcwf-4 CU or
IRN cells electroporated with gRNA. Electroporation of Fcwf-4 cells with WT gRNA or
icFIPV resulted in the development of CPE over 24-48 hours. Finally, sgRNA, a positive
indicator of ongoing virus replication, was detectable by RT-PCR from these cells
further demonstrating that viable FIPV was produced from our reverse genetics system.
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Implications. One of the major challenges with developing the FIPV Black
reverse genetics system was the high degree of sequence variability within the S and
7b regions observed following deep-sequencing. These two regions, which are critical
for virus replication and cell tropism, varied greatly within the sequenced population of
viruses obtained from the same supernatant and resulted in stretches of “n” reads
denoting the lack of consensus. This suggested that the in-lab FIPV Black strain was
likely a quasispecies populated by several dominant strains. Initially, this complicated
the reverse genetics design as the system must be based on a single, consensus
genome derived by giving the most abundant nucleotide at any given position. In
addition to the “n” reads in S and 7b, it was also difficult to determine if the consensus
generated for the rest of the genome represented a viable virus strain or a sequence
mix between dominant sub-strains. To overcome this, I compared deep-sequencing
results of two independent FIPV Black stocks, obtained from different sequencing
facilities (Kansas State and University of Chicago) with a published sequence
(EU186072.1) to construct a consensus genome that represented the population.
Ultimately, this FIPV Black genome (Appendix C) resulted in detectable replication of
infectious clone FIPV Black as determined by the presence of CPE and N gene sgRNA
following electroporation.
Additional challenges were confronted when attempting to propagate the
infectious clone FIPV Black strain. Unlike the positive control gRNA, syncytia induced
by icFIPV did not progress after 48 hpe. Further, passage of supernatants containing
icFIPV did not cause CPE nor produce sgRNAs in new Fcwf-4 CU cells. This lack of
second-round infectivity suggests that the icFIPV may harbor a sub-optimal genomic
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sequence preventing the de novo construction of infectious virions. Indeed, there are
numerous possible sequence or assembly defects that could lead to non-infectious
virions, several of which we addressed. First, we can detect the presence of
subgenomic nucleocapsid mRNA, the production of which requires both the translation
of the replicase polyprotein and the activity of the nonstructural proteins encoded on
pp1a and pp1ab. This suggests that the defect is likely not within the 5’ UTR, as this
structure directs translation, nor the components of the replicase polyprotein necessary
to produce subgenomic mRNA transcripts. Second, the electroporated material
produces syncytia, a process mediated by spike-receptor engagement. This suggests
that, at the very least, the spike protein is produced, engages a receptor and is able to
mediate membrane fusion. However, it does not necessarily rule out the possibility that
the spike sequence is sub-optimal or mediates low-efficiency fusion, which may impact
virus entry. To determine if the spike sequence was limiting the infectivity of the ic
virions, I replaced our ic S with the S sequence obtained from the published serotype I
sequence (EU186072.1), which was shown to be infectious (Tekes et al., 2008).
However, this sequence did not produce infectious, passable virus (data not shown)
and we concluded that the spike was likely not the issue. Finally, we looked at the 7b
accessory region to determine if variability in this region could be contributing to the
infection defect. Indeed, after deep-sequencing we observed a large amount of
variability in the 7b accessory protein region resulting in an approximately 35 nt stretch
of “n” residues indicating the lack of consensus. In our ic genome, this region was
deleted entirely. While the loss of the 7b protein is commonly observed with TC-adapted
FCoV strains (Thiel et al., 2014) and likely not the direct cause of the defect, the ORF7
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sequence directly precedes the 3’ UTR region, which is critical for efficient initiation of
subgenomic mRNA. Thus, if the sequence of 7b is not correct in the consensus, it may
impose changes to the loop-structure of the downstream 3’ UTR thereby affecting the
efficiency of subgenomic mRNA transcription. To attempt to answer this question, we
replaced the 7b sequence of our infectious clone with the published 7b sequence
(EU186072.1). Again, this did not solve the problem and no infectious virions were
produced (data not shown) allowing us to conclude that the 7b region is likely not the
issue.
Thus, I speculate that a possible defect preventing the production of infectious
virions may be housed within the E and/or M structural proteins, which influence the
formation of the virions but do not impact the production of sgRNAs or syncytia
formation. The M protein is the main structural component of the coronavirus outer
membrane and, along with the E protein, directs the formation of the mature virion (de
Haan and Rottier, 2005). If one or both of these proteins have an incorrect sequence or
are not produced at high enough levels, this may impact the formation of infectious
virus. Future experiments are needed to detect production of E and M sgRNAs by RTPCR and to attempt to visualize the completely-formed, mature virions by electron
microscopy. Ultimately, the genomes of several “Baker-Lab strain” FIPV populations
need to be compared following multiple rounds of plaque purification to determine the
most common genomic RNA sequences and eliminate variability arising from the viral
quasispecies. In parallel, individual syncytia could be isolated after icFIPV
electroporation and deep-sequenced to determine if these infected cells contain a more
optimal genomic sequence. Together, these experiments are the most direct means of
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rectifying the issues with the consensus sequence and may help produce a fullyinfectious virus by reverse genetics.
Interestingly, a recent study by Ehmann and colleges offers a different
perspective on the inability of our icFIPV to passage. This group constructed the firstever reverse genetics system for a field strain of serotype I FECV (Ehmann et al.,
2018). During production of this FECV, however, they also found that virions obtained
directly from electroporated cells could not be passaged, even though they were
observable by EM and produced sgRNAs. Interestingly, infectious virus could only be
recovered following direct injection of concentrated electroporated cell-supernatant into
live felines. I speculate that infection efficiency of the icFECV was enhanced in vivo due
to the presence of high concentrations of host cell proteases or other infectionenhancing cell surface molecules not present in tissue culture. Intriguingly, this same
phenomenon was observed during generation of another coronavirus, porcine epidemic
diarrhea virus (PEDV), by reverse genetics. Like the Ehmann study, icPEDV could only
be recovered following in vivo injection, in this case of porcine intestine (Beall et al.,
2016). Thus, several groups have demonstrated that production of some CoV strains by
reverse genetics might require additional factors present in whole animal tissue in order
to replicate. The observations made by these two groups may, in part, explain the lack
of passage in my FIPV Black system – although injection of live cats is outside the
scope of our current research protocol. In future studies, Fcwf-4 CU IRN cells
expressing additional feline proteases, like TMPRSS2, may provide a compromise to in
vivo injection and may facilitate recovery of FIPV Black by reverse genetics.
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The goal of the reverse genetics system described above was to have a platform
on which to generate live-attenuated serotype I FIPV strains by non-functional mutation
of interferon antagonists. Investigation of interferon antagonists encoded by
alphacoronaviruses, including FCoVs, have been limited to studies involving groupspecific accessory proteins (Cruz et al., 2013, 2011; Dedeurwaerder et al., 2014). Early
work using recombinant FCoV demonstrated that attenuation of serotype II FIPV (strain
79-1146) could be achieved through single deletion of group-specific protein clusters
3abc or 7ab, respectively (Haijema et al., 2004). Cats vaccinated with these mutant
serotype II strains generated protective humoral immunity and survived subsequent
challenge with homotypic strains. Although this group did not evaluate IFN production in
these animals, both accessory regions 3abc and 7ab have since been shown to be
involved in IFN antagonism (Dedeurwaerder, 2014; Dedeurwaerder et al., 2014, 2013).
Further investigation of FCoV nonstructural proteins (e.g. PLP2 or EndoU), as has been
described extensively in betacoronaviruses (Deng et al., 2019b, 2017; Frieman et al.,
2009; Kindler et al., 2017; Mielech et al., 2014; Niemeyer et al., 2013; Sun et al., 2012),
may also result in the discovery of new FCoV IFN antagonists. It is tempting to
speculate that combined deletion of individual accessory regions with mutation in
nonstructural protein IFN antagonists (e.g. PLP2 or EndoU) may lead to a HII virus
phenotype and, ultimately, stimulation of immune memory.
Final Thoughts
As this research program progresses, it is my hope that the tools described in this
dissertation will aid in the generation, recovery and characterization of IFN antagonistdeficient serotype I feline coronaviruses and stand as a successful means of creating
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live-attenuated vaccine strains. To this end, we have recently begun a dual
collaboration with the Tekes group at Justus-Liebig University (Giessen, Germany), and
the Whittaker group at Cornell University (Ithaca, NY). Our combined research efforts
aim to produce serotype I FIPV HII viruses using an established serotype I FIPV reverse
genetics system in the Tekes lab (Tekes et al., 2008), to characterize these strains in
our lab using the tools and techniques described in this dissertation and, finally, to
evaluate attenuated strains as vaccine candidates in the Whittaker lab who have
capacity to do experimental work on felines. Together, we hope to develop a successful
means to prevent this highly pathogenic feline illness.

APPENDIX A
ANTIBODIES USED TO DETECT FELINE CORONAVIRUS
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Antibody Detection of FIPV Black Nsp15, dsRNA and N Gene Production. A-B)
Affinity-purified rabbit-anti-FIPV nsp15 (EndoU) polyclonal antibodies were generated
by GenScript against a purified H227A catalytic mutant FIPV Black nsp15 protein
immunogen. This antibody is effective at detecting FIPV Black nsp15 by
immunofluorescence or by western blot. A) Immunofluorescence detection of FIPV
Black nsp15 (FITC) and double-stranded (ds) RNA (TRITC) following 18 h infection
(MOI = 0.1) in Fcwf-4 CU cells. Composite image shows localization of nsp15 to
replication complexes. Images representative of two independent experiments. B-C)
Western blot analysis of FIPV Black (B) nsp15 or (C) N protein from Fcwf-4 CU cell
lysates following 16 h mock or FIPV Black infection (MOI = 0.1). The black arrows
indicate the ~40 kDa nsp15 protein and the ~42 kDa N protein. The CCV2-2
biotinylated monoclonal antibody (Bio-Rad) detects FIPV N protein and has been
previously described (Poncelet et al., 2008).
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PRIMER INDICIES
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ASSAY

qPCR

RT-PCR

PCR TA
Cloning

PCR

SEQ

PRIMER NAME

SEQUENCE (5' - 3')

GC %

Tm (ºC)

NOTES

FIPV-N-qpcr-F
FIPV-N-qpcr-R
f𝛽-Actin FWD
f𝛽-Actin REV
F ISG54 FWD
F ISG54 REV
F IFN Beta FWD

ACCAGCCAATTCCTAGAACAG
GAACGGGATTTTCTTTGCCTC
CAACCGTGAGAAGATGACTCAGA
CCCAGAGTCCATGACAATACCA
CCTGAGCTGCAGCCTTTCAGAACAG
CACGTGAAATGGCATTTAAGTTGCCGCAG
CCAGAAGGAGGAAGCCATATT

47.6
47.6
47.8
50
56
48.3
47.6

62
61.7
63.7
63.5
68.6
69.9
61.6

FIPV Black
N Gene

F IFN Beta REV

TCTCAACAGTGGTCTCATTCC

47.6

61.6

Fel IFNaT FWD
Fel IFNaT REV
F IFNa11 FWD
F IFNa11 REV
Fel tmprss2 FWD
Fel tmprss2 REV
Fel tmprss2 V5 FWD
Fel tmprss2 V5 REV
Fel ifnar mRNA
Exon2 qPCR FWD
Fel ifnar mRNA
Exon2 qPCR REV
FIPV Black Leader
Fwd
N Gene Rev
Fel ifnar mRNA
Exon1-4 RT FWD
Fel ifnar mRNA
Exon1-4 RT REV

CACGTGACGAACCAGAAGAT
GATCAAGTCCCGTGCAGAAT
CACGTGACGAACCAGAAGAT
GATCAAGTCCCGTGCAGAAT
TGTCTACAACAACCTGGTCAC
CCACCAGATGTGACTCTTCATAG
GTGTATGGAAATGTGACCGTATTTA
TAGAATCGAGACCGAGGAGAG

50
50
50
50
47.6
47.8
36
52.4

61.9
62.2
61.9
62.2
62
62
61.5
61.8

CAGAATACTTCCTGGATTAGAC

40.9

57.8

AGTACAAGATTCGTCTGACA

40

58.5

GTGCTAGATTTGTCTTCGGACACC

50

64.8

CATCAGCATGAGGTCCTGTACCTGA

52

67.1

AAGATGCTTTGGAGCCAGAATA

40.9

62.3

CCAGGAAGAAATCGCTGATACA

45.4

62.2

F IFNaR2 Full FWD

ATATCTATTTCCTTTCAGATGTG

30.4

56.6

F IFNaR2 Full REV

TCATCTCATTATATAACCATCCCTG

36

60.1

Myco Fwd
Myco Rev

GGCGAATGGGTGAGTAACACG
CGGATAACGCTTGCGACCTATG

57.1
54.5

64.9
64.8

U6 – Fwd

GGGCAGGAAGAGGGCCTA

66.7

65.1

GACAAGCTGATTCCAAACACAAAC

41.7

63.1

TTCATCTGAATCCTCTAGGT

40

57.6

CGCAAATGGGCGGTAGGCGTG
GAATAGTTTCTATTCTAGCCAC
GTTGCAACAGCAAGTATGTCTAC
GTAAAACGACGGCCAGT
CACACAGGAAACAGCTATGACCAT

66.7
36.4
43.5
52.9
45.8

69.8
56.4
61.9
59.4
64.8

F IFNaR2 Seq 1
FWD
F IFNaR2 Seq 2
REV
CMV Fwd
fTMPR2 SEQ F1
fTMPR2 SEQ F2
M13 Fwd
M13 Rev

Primer Index 1: PCR Primers.

Fel 𝛽-Actin
Fel ISG54
Fel IFN-𝛽
(Kessler et al.,
2009)
Fel IFN-α;
all subtypes
Fel IFN-α11
Fel TMPRSS2
TMPRSS2 V5
Tag
Fel IFNαR
exon 2 mRNA
L-containing
sgRNA
N gene sgRNA
Fel IFNaR2
exon1-4
Fel IFNaR2
exon1-4
Fel IFNaR2 full
mRNA
Fel IFNaR2 full
mRNA
Mycoplasma
Detection
Seq sgDNA;
LentiCrisprV2
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PRIMER NAME

SEQUENCE (5' - 3')

GC %

Tm (ºC)

Exon2 sg1F

CACCGCGTGGTGTGTATCGGCCTCA

64

66.7

Exon2 sg1R

AAACTGAGGCCGATACACACCACGC

56

63.2

Exon2 sg2F

CACCGTGTGTATCGGCCTCATGGT

58.3

63

Exon2 sg2R

AAACACCATGAGGCCGATACACAC

50

59.5

Exon3 sg1F

CACCGCTTCCGGCTTATCTTGTCA

54.2

61.3

Exon3 sg1R

AAACTGACAAGATAAGCCGGAAGC

45.8

57.6

NOTES

These primers
generated the Fcwf4 CU IRN and AK-D
2.2 cells

Primer Index 2: IFNαR2 Single Guide DNA Primers.

NAME

SEQUENCE (5' - 3')

GC %

Tm (ºC)

B-Fwd
B-Rev
C-Fwd
C-Rev
D-Fwd
D-Rev

CGTCTCAAGACACTGTGAATCAAAAGCGTGTGTCTG

GTAAGGCACCAATGTGGTATAGGCCTCCGC

47.2
51.5
48.8
50
53.5
56.7

64
63.8
67.2
61.8
68.9
65.2

D-a mutF

CAGAATTCGCCCTTCGTCTCGCATCAAGCCCTGCATTGTT

52.5

69

D-a mutR

AACAATGCAGGGCTTGATGCGAGACGAAGGGCGAATTCTG

52.5

69

E-Fwd
New
E-Rev
F-Fwd
F-Rev
F-a mutF

CGCTGCTGAAACCGTGAAAGCAAAGGAGGAATC

51.5

65.2

CGTCTCCACAGTAGGGTAGGTAACCGCCTAGAATAG

52.8

64.5

CCTACTGTGAGAGACGGCCCGAATTGTGGATG
GAATTCGCCCTTCCTACTGTGGAGACGGCCCGAATTGTGG

56.2
50
57.5

65.6
64.2
69.6

F-a mutR

CCACAATTCGGGCCGTCTCCACAGTAGGAAGGGCGAATTC

57.5

69.6

FIPV-N-F

CTTGGACCGAGCTCGGATCCACCATGGCCACACAGGGACAACG

62.8

72.6

FIPV-N-R

GCGGGCCCTCTAGACTCGAGTTAGTTCGTAACCTCATC

55.3

66.8

CGTCTCAGTAATCAGCCTCTCCCATTGAACCAG
CGTCTCATTACCGCATGGCTTGTTATGCTCATTTGGGTAAGGC
CGTCTCAGATGCTACAAGTAATGTGGGGTCAGTGAC
CGTCTCAGCATCAAGCCCTGCATTGTTAGATCAGCGCACTGTC

CGTCTCAATGGCGTTTAACTCGTCAAGTACAGCG

Primer Index 3: Reverse Genetics Cloning Primers.

NOTES

Incorrect "A" at 7 nt
Circular mutagenic
primers to remove
"A" introduced by
D-Fwd on D clone
in pCR-XL-TOPO

Circular mutagenic
primers to eliminate
"A" introduced by
F-Fwd on F clone
in pCR-XL-TOPO
Gibson Assembly
primers; insertion
into pcDNA 3.1/V5His B
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CLONE

A

B

C

D

E

F

G

PRIMER NAME
A1a
A1b
A1
A2
A3
A4
A5
B1R
B1
B2
B3
B4
B5
C1R
C1
C2
C3
C4
C5
C6
D1R
D1
D2
D3
E1R
E1
E2
E3
E4
E5
E6
E7
F1R
F1
F2
F3
F3-1
F4
F5
F6
G1 REV
G1
G2 REV
G2
G3
G4
G5
G6

SEQUENCE (5' - 3')
CTTAAACCTGTTCTCCTTACCGAACC
GGACTGGTTTTAAGACTGCTTGTTG
GATGTAGTGGCATCACTCTGCAC
TCGCCGCTGCTGTTACTAAGG
GTGGCAACGTCACAACTGACGAC
GGTTGCCGATGGTGAAGACTTTG
CGATTACTGTGTGGATGGTATGG
ACAGTTCCTTTGAGTTGCTCACCAT
GTGTTAGAGGTACGGTGGCTATC
GGCATGTAGTGGTAGTGTTCAAGC
GAATGTTCCGAAGGGTTTTACAGG
GAATCAGTGTCAGCAAAGAACGG
GAGCACGCTAGTGGTAACATGG
CAGACTGTAGTGTTGAGTTAACACTGAC
GCACCACTTGGAATTAGGTAATGG
GCTACTGCACACAATTTTGTCTGGG
CCACTGTGCAGTCTAAACTTACAG
CCAGCTGCCTCAGCTACAAGAC
CTCTCAAATGGTGCCGGTAATGG
CGGTAATGTTGCACGTAAGGATC
ACCTGGTTTCACTGTCTGGTAT
TGCCACACGTAACGCTACCGTAG
CATTGGTGCGTTTAAGGCCACC
GTCTATCACACCGTATGTGTGTAGC
TACCAGGAGGACCTTGGATAGTT
GCACAGTTAATGCTTTGCCTGAAG
GCATTCTCTGTGTCATGTGTGACAG
GCGACTATTTCGACGGCTTGTC
GTACCCAGAGTTCTCAATTGTCTG
GCAAAGCGCAAACTTGGACTCAC
CCACCATTGGTGGTATGCATCTTC
CGACGCAGACTTCAGTGTTACAG
CAATGACAGATTTTAACAGCCACATG
CTGTGCTGGTTATGCTAAGAACG
CAGGTTGTTCTATTGCGACTCAC
CAACTATGCCAAGGGCACAGCTG
GATGGTGCTATGATAACAACTATGCC
GGCAATACACATTGCCGTAGCTTG
CCATTGGTAACATCACACTAGCAC
CCTCAGATGAGTGATTTCGTGC
GACGGTTGTTGTCACAATTCCATC
GATGGAATTGTGACAACAACCGTC
GCATGGCGTGCAGGTAGTACTAT
ATAGTACTACCTGCACGCCATGC
CTACCCTTAGATGGTACACCAACGG
GAGTCTTCTGGGTTGCAAGGGATG
ACCTTCTGAAGTGGCTAAGGATCAG
CAGATCTTAGCACTACCGCTTGG

Primer Index 4: Reverse Genetics cDNA Segment Sequencing.

GC %
46.2
44
52.2
57.1
56.5
52.2
47.8
44
52.2
50
45.8
47.8
54.4
42.9
45.8
48
45.8
59.1
52.2
47.8
45.5
56.5
54.5
48
47.8
45.8
48
54.5
45.8
52.2
50
52.2
38.5
47.8
47.8
56.5
42.3
50
45.8
50
45.8
45.8
52.2
52.2
52
54.2
48
52.2

Tm (ºC)
57.2
56.4
57.8
59.6
60.7
58.6
58
58.8
56.7
57.9
56.1
56.4
57.8
57
58.6
56.3
55.5
60
58.1
56
55.8
58.4
59.3
57
56.8
57.1
58
58.3
57.9
59.6
58.2
57.7
55.1
56
58.5
60.8
55.7
58.8
55.9
55.8
56.6
56.6
59
59
59.3
59.7
58.2
57.3

APPENDIX C
FIPV BLACK LABORATORY SEQUENCE

200
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ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES

Feline infectious peritonitis virus Baker Laboratory
Strain (Origin: AK-D Cells; Consensus)
Bases 1 to 29198
Robert C. Mettelman, Susan C. Baker
Generating biologic and genetic research tools to
investigate serotype I feline coronaviruses
Ph.D. Dissertation; Loyola University Chicago; 2019
(1..29198)

[A_SEGMENT]
5'UTR.
PP1AB.
PP1A.

1..4810
1..311
312..20407
312..12407

[B_SEGMENT]

4811..8875

[C_SEGMENT]

8876..13485

[D_SEGMENT]

13486..15825

[E_SEGMNENT]
SPIKE.

15826..20588
20404..24792

[F_SEGMENT]
ORF3ABC.

20589..24861
24293..25819

[G_SEGMENT]
24862..29198
ENVELOPE.
25820..26068
MEMBRANE.
26079..26870
NUCLEOCAPSID.
26883..28016
7A.
28021..28326
7B.
28331..28905
3'UTR
28906..29198
ORIGIN
1
61
121
181
241
301
361
421
481
541
601
661
721
781

acttttaaag
gtgctagatt
gccatagaag
ttgagagaac
ggcggttccg
ccgccaggag
acgtgcctag
gttttgaggg
aggatcacta
ttaccgaacc
ttgaggactt
acatgtgtgg
atgaggatgt
atgaaaaacc

taaagtgagt
tgtcttcgga
acaagcgttg
gacgcgccag
cccgtcgtag
aatgagttcc
ccttcctttc
ctatgttttc
cgtcattggt
ttccgtcatg
tgaccttaaa
tgctgatgga
tatcatttat
tttgtgtcaa

gtagctgggc
caccaactcg
attatttcat
ggttccgtcc
ttgggtagac
aaacaattta
cgtgacgtgc
gtgcctgaat
gttctgggta
ttgcaaggct
atcgcccgta
aaacctgtca
gaaggggaag
caaactcttc

tataactctt
aactaaacga
ccagtttggc
ctgtttggta
cgggttccgt
agatcctcgt
tgcaggacat
actgtcgtga
acggaataag
tcattgttag
ctggaaatgg
ttgatggcga
agtatcattg
tcacaattag

catttacttt
aatatttgtc
aatcactcct
agtcgtctag
cctgtgatct
taatgaggac
taagtactgc
cctagttgat
tgatcttaaa
agccaattgc
cgccatatat
atttagggat
tgcttggtta
ggaaatccaa

aactagcctt
tctctatgaa
aggaacgggg
tattagctgc
ccatcgccgg
caccaagtca
taccgcaacg
tgcgatcgta
cctgttctcc
aatggcgttc
gtggaccaat
tacttcggtg
actgtgcgcg
tacaacctgg

202
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
2101
2161
2221
2281
2341
2401
2461
2521
2581
2641
2701
2761
2821
2881
2941
3001
3061
3121
3181
3241
3301
3361
3421
3481
3541
3601
3661
3721
3781
3841
3901
3961
4021
4081
4141

acatcccaca
actctaaggt
ttatgggcaa
ctcttaagtg
ctgcttgttg
gtgacgccgt
tactccaata
ctgttaatga
ctgagagtac
atgatgcagt
gtagtgctag
ttgtcgatgc
aaatctatga
ctgtgtttgt
ttgtgaaagc
gctttgtgct
ttaaaatact
ttggtgccac
aggtagagga
tttacaagag
atgtttttaa
ccaagagtaa
ctgctgttac
gagcacttaa
cagtttgtct
agggttttct
ttcaggccat
tatggtatag
tgctaggtaa
cagttaacta
cattttccac
ctgtagttga
gtggcaacgt
ttgaacctaa
aagatgatca
tgggtggtgg
ctgttacacg
aaaaagtcat
ctatctccga
aaggttattt
tgatttcaca
tggaagacac
cttcaactgc
aacaagtttc
aactctcctc
ccgttgatga
atcttaatgg
gttaccagct
gtgacgttat
cgggggatgc
cacttagtgc
agctcacacc
acatgtgtga
aacaaacgcc
caacacagag
tgggaattaa

taaattgcca
tgttctttct
tggagatagt
tccttgtggc
tggtcttctt
tgtcactagc
tgctggtgat
gactgtctgc
ttcacttgtc
ccatgattgt
cctacttttt
ttggaaagtt
tgtagtggca
ggtttcatct
ctttgacgtt
tggttctaaa
cggtaagaga
tgttaatgtg
tgttgtcaca
tggagaatac
agccgcgcga
gatggtggtc
taaggttaat
ggatggtgaa
taaaaaccat
tgacaccttc
taaaaacatt
atgtatgcca
tggtgttaaa
cagcaaactg
ctttaaaaca
atatggtgaa
cacaactgac
agacaatggc
tttttatcca
tgacaagtca
tgtcaggcta
tggtaccaaa
gacacttgac
tatttatgac
gtacgatctt
ctctttgatt
tgatgccgaa
tcttgtagag
agtagaggaa
acaggaagct
taaaatcatc
gcaagctttt
gcctttcgtg
agaatacctt
taagtgcggc
tcttaggaat
gtttgctagc
tatgtcacaa
tggtcattat
accttgtaaa

aattgtgcta
gaggagtata
cttaacaagt
gccgaaagta
ggcaaagtta
atgagtgctg
gtggaaaatg
accactgatt
tcatgctcca
attatcacgg
aagaaaacac
attgaggaac
tcactctgca
aatagcgtta
ttcacacagg
tacttgcttt
cagaaaggtc
acaccacaga
ccaggtgaag
tattttatga
gtgccgtctt
aaaattggaa
gacttacttg
aacatcttgg
gtcggtttat
aatcatctta
ctttgtcctg
gcctgctctg
gtgatttgtg
tgtgatacag
ccatctagca
gcattctctt
gactggtcag
gatgtaattg
tatggttctg
gtttcgtttt
gaatttgagt
tataagttta
aaaatttttg
acatgcggtg
aacacagctg
tctgacaacg
tacgtttcac
gaaagtagtg
aaaattgaag
gaacaaccaa
cttaaacaac
gatttcttta
aatttctgtt
ttggaaacga
tgtggtgtta
gagtttaaat
gtggaaggtt
ttcattgtga
atgattgaag
cataagtttt

ttagagaagt
gaaaactcta
gttttgacag
gtggtgttgg
aaggtgtcac
gcaagggtgt
tctctgtttg
ttgaaggcga
ttaagagagc
gaaagttgga
cctggtttgt
tgctttgttc
cttccacctt
agagtctcgt
caattacaat
ttaacaacgc
ttgatagtgc
ggaccgaggc
gtcatattgt
tggcaagccc
ataacattgt
catcatttga
ttgagtttag
ttgaggcata
gggacattat
atgatttgga
accttctgct
atgtgtctat
atggctgtca
ctcgtaaaga
gcttcatcga
ttaagactgc
atcccatttt
ttattgctgg
gcatggttgt
cagacaatgt
ttgacaatga
taggtaccac
acacgcttgc
gatttgacat
ctgatgacaa
aagatgttga
ccgtggttgc
ttttaactcc
tttctgctaa
aaccttcctt
aagataataa
aacacgattt
atgcagctat
tgctcaatga
aagagatagt
atggtgtctg
caggtgtttt
cacctactat
attgcattca
acacatccac

agcaccacca
tgacatcttc
cctccacttc
tgattggact
attaggtgct
aaaattcttt
gaaagtgatt
attgaacgcc
tttcatcaca
tcttagtact
gcaaaagtgt
tcttaaactt
tactattatg
tgacaagtgt
tgcaggtgtg
acttgtcaag
attttttgcc
tgctaacatt
catcgttggc
tgattcagtc
ttatgatgtg
atttgatggt
acaaggaaag
ctttaagaaa
aaaacgagat
ggatgtcaag
tgaattggac
tttgggtaat
tagctttgct
cattgaaatt
catgaaagat
aagtgtgcct
gttagaaccc
atacaccttt
gcagaaaatg
taatgttaga
ggttgtaaca
ttgggaagag
tgaacagggt
taataaccca
gagcgactct
acaaattgaa
cgatggtgaa
tgttgcaaac
gaatgatcca
ggcacccttt
ttgttggata
gtgggatgat
aactttgaag
ttatagtaca
tttagaacga
tggtgactgt
tgttcatgat
gcatgcagtt
cgattactgt
tttgtttctt

gtcaagaaga
ggctcaccat
attgctgcta
ggttttaaga
gttaagccag
gctaatagtg
aaaactttca
ttcattagac
ggggaagttg
aacctgtttg
ggtgcaattt
acatacaagc
gactacaaac
gtcaaaattc
gaggctaaat
cttgtcagtg
actaatttga
agcctgaata
gatatggctt
cttgttagta
aatgatgaca
gacctcgccg
ctttatttca
tacaaaatgc
tctgacagga
gatacaaaaa
tttggtgcaa
gttaaaatca
aaccgcctaa
ggtggtatac
gccatttact
gtaactaata
gcagattatg
tacaaggatg
tataacaagt
gagatagaat
caggtgcttg
tttgaagatt
gtagaacttg
gatggtgtta
gatgcaagcg
gaggatagtg
gactttgttg
cctgatgggc
tgggctgctg
aggacaacaa
aatgcttgct
tttaagaaag
caaggtgatt
gctagagtca
actgtgttta
aagcaaatta
agaattgaaa
tacacaggtt
gtggatggta
aatgcaaatg

203
4201
4261
4321
4381
4441
4501
4561
4621
4681
4741
4801
4861
4921
4981
5041
5101
5161
5221
5281
5341
5401
5461
5521
5581
5641
5701
5761
5821
5881
5941
6001
6061
6121
6181
6241
6301
6361
6421
6481
6541
6601
6661
6721
6781
6841
6901
6961
7021
7081
7141
7201
7261
7321
7381
7441
7501

taatgacaac
tagaagaatg
cattttacca
acgctgctaa
caggtggtaa
ctggtaatgc
gaccacgtaa
ccaggtgtga
tggaagtttc
tttacactga
aggtaacgga
gtgagcaact
gtgtgtcaga
atggctttcc
ttgtaacaca
caatttgttt
tgtgggattc
caggcttaaa
tgatgtcaag
aagttgaaac
aaacttgtgt
ctatcacttc
gttacactgg
tggtcgatgc
ttgctagtaa
aagaaccaaa
gtaaagaaaa
aatatgctga
ttaaatattt
taaaaccacc
gacaattgaa
tatatcattt
gtagtgttca
ttttgtgcaa
tgtcatggga
tattcttggc
agtaccttaa
tcgtcaactt
ttctcgcact
aaattgctag
tgtatgtcca
attgtgactc
gtaatagcat
ttgaatgttc
atgatgtaaa
atgacttcat
tttatttttc
atttgtctgt
ccttcaatgt
ttgatgttac
taattacaga
gtgtttccgc
aggttttaac
gttctacagc
ttacgtttaa
tgtcagcaaa

tgaatctaaa
tcaaagtcct
aggagattta
tggtgatctt
gttaacaaaa
tgtgcttttt
tggtgacagt
cggtaagata
attgcagtgt
ccaagagaga
agacactgtg
caaaggaact
tgtcggtgaa
aaatgcagcg
taacaacttc
agcattacag
gtttctcacg
gaaaggacaa
tgatagtgta
tttcaccgga
tcatggtgtg
tttaataggt
tttgaactca
tgagaaagcc
ttttgttgct
cacggctcgt
attgctagct
cgtgttcttt
attggttgtt
acacgtattt
cagaccagcc
cttctatttg
agcatatagt
ggcgtgtctg
ttataagtca
tgtttttggt
cctgtggtta
tgaatcaatc
taaacacatt
gcagacgcgc
tgctaatggt
ttatgggttt
taagcaaact
cgaagggttt
acataagaag
tgtttacagc
acaattaatt
agactttaag
tgatgtctca
attttccact
ccgatctttt
tatggacatc
acaacgtggt
acaaaaggtt
cgctgtgggt
gaacggttca

actatggttg
aaagatctta
gatgttttga
aagcacatgg
cgctctaaag
gaaaacgtac
agagttgaag
ctaacaccac
ctacttaaaa
attaccatag
aatcaaaagc
gttattatta
aaagttgtta
gcttttagcg
attgttcata
agacttaaac
cgtaaaactg
cctggtgatg
gtcactgtca
tctgtggtag
agtgtcaatg
cctgtagtag
cgtggccatt
taccattttg
aacacaccta
gtttttattg
attgagagtg
atgactggtg
tttatgtgtc
agaaacttgg
ctgtggcgtt
tttgtcagca
aattctagtt
gcatcttatg
gacccactat
aacaattatg
tcctattttg
tctgttgaat
ttcctaccat
attcctatac
actggtaaac
gatcacacat
gtttatgcta
tacaggttct
tatagtagtc
ccatcagggt
ggtaggccta
ggagcacttt
gaatgtaaaa
tttgagatgg
aataatttct
ggtaagtgca
aaaagtgttg
ttagttaaaa
tcagatgaag
ggtttctttg

aactacctgt
tactaccctt
ttaactttct
gtggcgttgc
aatatcttaa
ttgagcatct
gtaaactctg
ttatcagtgt
ctgtcacaga
aaaatttctt
gtgtgtctgt
aagacaaaga
aggcattgga
ccagttccca
agcaaactga
ctacatggaa
ctggatttgt
ctgagctgac
cacatacaac
cagcacccct
ttaaagtgac
gagatatcat
acacctacta
agaaaagtct
aagaggagat
aggttgaaga
gtgtagatta
ataaaattct
ttagaaaatc
gtgctaaagt
acataaaact
taccagtagt
ttgtaaagtc
atgaattggc
ggaatagagt
ttagatgcct
gttatgttaa
ttgtaatcat
gcaacaaccc
aggttgtggt
tctgcaaaaa
tcatttgtga
ctgataggtc
atgttggtga
aggaggtgct
cttctctttc
ttaagattgt
tcaatgccaa
acctagagga
cagttaataa
ggccatcgaa
tgacttttga
tatggttaag
catttgtaga
atttgccata
atgtactcaa

gcccgtaaag
ctataaagcg
tgaacctgat
taaagctatt
atccaacaaa
tagtgtgttg
taatgtctac
tggtatcttt
tagagattta
caatggtact
agcacttgat
tgtcaccaac
tgttgattgg
tgatgcttat
taataattgt
gtttcctggt
ccacatgcta
tttacataag
tgcatgtgat
tctggtctat
aagtgttaga
tgatgcaact
cgataatcgt
tttacaggtt
tgtgcctacg
aagtcctaaa
tacaatcaca
taggtttctc
taagatgcct
tagaacattg
agtactactt
gcataaattg
agaagtttgt
agattttgat
tatacaattg
tcttatgtat
gtatagctgg
agttgtggtt
gtcatgtaag
taacggttca
gcataacttt
tgagattgtg
ataccaggaa
agaattcacg
caagacaatg
tagtgttaga
taatagtgat
gaagaatgtt
ttgttataag
tgctcataga
gatcaagcct
tgctaagatt
tcaagatttt
ggagggtgtg
tgagcgattc
acagcttaaa

gataagtgcg
ggaaaagtct
gtcgttgtta
gatgtattca
tcaatagctc
aatgctgtag
aaagcaattg
aaagtcaaac
aatgtctttg
atccctgtca
aaaacttatg
cagttgccaa
aatgcttact
aaatttgatg
tgggttaatg
gttaaaagtt
tatcacattt
cttggtgcgt
aagtgtgcaa
ggcactgatg
ggtacggtgg
ggttatatct
aatggtttaa
acaacatcta
aatctagtta
aatatagttc
acactcggta
cttgaagtct
aaagttaaag
aattatgtaa
ttaatagcct
gcatgtagtg
ggtaattcta
catctccagg
tcgtatttta
tttgtctccc
tttttgcatg
tttaaggcag
acatgttcta
atgaagactg
tattgtaaga
cgtgatctaa
gtcacaaaag
gcatatgact
ttcctgcttg
aacgtctgtg
ttgcttgaag
attaagaatt
gcgtgtaacc
ttcggtgttt
ggctcttctg
gtcaatgcaa
tctgcactta
aacttttcac
actgaatcag
caacttttct
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7561
7621
7681
7741
7801
7861
7921
7981
8041
8101
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8221
8281
8341
8401
8461
8521
8581
8641
8701
8761
8821
8881
8941
9001
9061
9121
9181
9241
9301
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9421
9481
9541
9601
9661
9721
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9841
9901
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10081
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10381
10441
10501
10561
10621
10681
10741
10801
10861

ggtgtctcgt
agtcttatat
aatcatttga
ttaaagctaa
ctgtttttga
ttggtagatc
atcatacggg
cgtgcactac
ttgagggtgc
gtaacatggt
aggctacaac
gtggtgacaa
ccacactggg
ccacatctgg
atggtgttct
ttgttacatt
ttgtttatgc
atgcggggtt
taatggtatt
tctttgaagg
tagacatgcg
atgctaacag
gcatggcttg
acatgcttta
aaatggcaca
atgtccttaa
gtgatacatc
tttctatagc
atcttgtgct
tgaggccagg
acggtgtgaa
ggtcagtagg
aattaggtaa
aagatcaacc
catttttgta
cgctagaatc
acgcttttaa
ttgttagact
atgagttcac
aagtgaaatc
tagaattttt
tagctattac
tctttatgtc
acatgacctg
cagttgatat
ctataagatt
tgatgtttaa
ttttgttatg
ttgttgtctt
cttttgttca
acctattctg
gtggtgttta
tgtctgcacc
gtggagaacg
cgaatgttgt
ggaattattg

ttttgtcatt
tgattctgct
tgattctatt
atatggtttt
tttaggtaat
cttagtgttc
cgccgctgta
tctaactggc
taagctttat
aaaaatacca
ctattgcaga
ctggtttgtc
attcttcaaa
tgcaatgttg
taagtttaaa
ggttgttaat
tattatctat
cattattgca
cctatatgat
tgataaattt
ttcatatgaa
ctttaacaag
ttatgctcat
cacgccaccg
gcctagcggt
tggcttgtgg
gcgtgtaatc
caaaaataat
taaggtaaat
tgagagtttt
catgagaagt
ttatgtatta
tggctctcat
tagcatgcaa
tgctgctctt
ttacaattca
catgttggcc
caataaaggt
gcctattgaa
gctattttac
catgtataca
aacacttgtg
ttttgtgatg
ttatgaaagt
gcaaggtgtc
ttttacatgc
cattgttaag
tcttgtaaac
tgtatcatat
agattttggt
ttgttattac
ccaatttacg
taagactgca
taatatcaaa
cttgcttggc
tgttggtttg

actatttgtg
gagggttatg
aactgtgtac
gtacctacat
atgagaccaa
gcaatcaatg
agtaagaatt
attggtggta
agtgaattgt
gccattatta
gtgggagagt
tatgacaaag
aatgtgttcg
gctaacatta
aagatctttg
aatgtttcct
tatttcacaa
tacttgaata
tccctaccat
gtgggtagtt
acactcgtta
tacaagtact
ttgggtaagg
acggtcagtg
gtcgttgaac
ctaggagatg
aattacgaga
gtgtttttgg
caggtcaacc
aacattctcg
cagggtacta
gaaaatggaa
gtcggttcaa
ttggagggta
attaatggtg
tgggccaaaa
gcaaaaactg
tttggaggac
gtcataaggc
cctgtgatga
cccttcacat
tctgtgttat
cctagtgtcg
ttacaggtcc
atgcttgcac
aagcagtcgt
ttactaggta
atgcttacta
aaatttgctt
tttgttaagt
ggcatccttt
gtttcaccag
tatgatgcta
atatccactg
cttttgtcta
cataatgaaa

gtctatgctc
attacatggt
ataatacata
ttgacaagtc
tccctgatgt
ctgcatttgg
cttactttga
cagtcgttta
tacctgatta
ggggttttgg
gtactgaaag
agtttggaga
cactctttaa
ttattgcatg
gtgattgcac
actttgtaac
caagaaaact
tggctccgtg
cactattcaa
ttgaatcagc
attctacatc
atactggttc
cattaatgga
ttaactcaac
cctgtattgt
aagttatttg
atgagttgtc
gtgttgtgtc
ccaacacacc
cttgttatga
tcaaaggttc
cgctctattt
atcttgaagg
ctaatgtcat
aaagatggtt
ccaatagttt
gttatagtgt
gtactatact
aaatgtatgg
ctgccattgc
ggattaaccc
tagttgctgg
ttttagctac
ttgtggaaaa
ttttctgtgt
ggttttcact
tgataggtga
tgttgataag
attacatagt
gcataagcat
actgggttaa
ctgagctcaa
tgattcttag
tgcagtctaa
aaatgcatgt
tcaatttgtg

agtctacagt
tattaagaac
caaaggcttt
ctgccctatt
gccagcgtat
cgttactaat
cacttgtgtc
ttgtgccaag
ttattatgag
tctacggttt
tcaagctggt
tggttacatt
ttctaacatg
tctggctatt
tctcctagta
ccaaaacaca
cgcataccca
gtatgttctt
acttaaggta
agctatgggt
cttagataga
aatgggagag
ttattctgtt
actacagtct
aagggtagcc
ccctagacat
tagtgtgcgt
tgccaaatat
ggaacataaa
aggctgtccc
gtttattgct
tgtgtacatg
ggagatgtat
gtcatcagat
tgttacaaac
tacggaaatt
tgaaaagttg
gtcttatggc
tgttaatctt
cattcttttt
gacatttgtt
aattaagcac
tgcacacaat
tgttaataca
tgctgtgttt
atttgcaaca
gccatggact
tcttactaca
tgtgtatgta
aatttacatg
caggtttaca
atacatgact
ttttaagttg
acttacagag
tgaatctaat
tgacgaccct

tttgcaactc
ggtgttgttc
acagtgtggt
gttttaggaa
gtagcacttg
gtgtgctatg
ttcaattctg
caaggacttg
cacgctagtg
gtaaaaacac
ttttgctttg
tgtggaagct
tctgtagtag
gcagtctgtt
gttatgatta
ttctttatga
ggtattttag
gttttgtatg
acaacaaacc
acttttgtta
attaagtcat
gctgattacc
tcaagaaatg
ggattgcgaa
tacggtaata
gtcattgcta
ttacataact
aagggtgtga
tttaaatctg
ggtagtgttt
ggtacctgtg
caccacttgg
ggcggttatg
aatgtagttg
acatcaatga
gtgtcaactg
cttgagtgta
tccttgtgtg
cagggtggta
gcattttggt
agtattattc
aaaatgttgt
tttgtctggg
actttcttac
gttacataca
actgtttttg
gatgactaca
aaagattggt
atgcagccag
gcttgcggtt
tgcatgacgt
gctaataatt
atgggcattg
atgaagtgta
tcaaaagagt
gatgtcgtcc
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11041
11101
11161
11221
11281
11341
11401
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11521
11581
11641
11701
11761
11821
11881
11941
12001
12061
12121
12181
12241
12301
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12421
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12541
12601
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12721
12781
12841
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13141
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13441
13501
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13621
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13741
13801
13861
13921
13981
14041
14101
14161
14221

ttgagaagtt
gtgatcttat
atgcagcctt
agaagaatga
agagtgagtt
ctgcagctgg
ctatgcatag
ttattgaaca
caagacttat
atgtgcacta
aagtccactt
taacttgtga
agaaagctgt
ttatggcttt
ttaagtatgt
tgcgctttta
gcttgaacac
aagctggtaa
cacctgaccc
actgtgtaaa
aatctaacac
atgtagaaca
caaccgggac
gttgctggct
atcagagtta
tactgatcca
tggtaaattc
ctacgtagtc
tcttaaagat
tgaattcggt
tgctattagg
aggtgcctgc
agctatacat
tgtagcgttt
ccaagatctt
tggatgtgct
atgtttagag
tgatttattg
gcactgggat
tcattgtgcc
tcttgtacgt
caaacagttg
gacagatctt
gttagatcag
gacagtgaaa
ctttgaggag
tgctatgaca
ggcgcaattt
caatgctaga
atttggtaag
tgctttaaca
atctggcaag
gagacagtac
tattggaaca
cgtagataat
tatgatacga

acttgcgctc
tgagtcttat
gcctagctgg
tgttagtcct
tgaacgggag
tatgtacaaa
tttacttttt
ggctcgtaac
tgttgtaaca
tgcaggtgcc
gaaggaagtt
gagaaccaca
taaagcatct
tgaatgtggt
taaatgggag
tgtagatggt
tcttagacgt
acctactgaa
tgctaaagca
aatgctctca
acaacagtac
tcctgcaatt
tcaggatcct
taataatggt
tttaaacgag
gaccatgtta
cttaagacta
aagcgttgta
tcaggtgcag
aatgttgcac
aactttgatg
aatgaatctt
gaagtgtacg
tgtgatgcta
aatggcaatt
tgcgttacat
tccgaaaatt
gcttatgatt
cgaacatacc
aattttaaca
aaagtccaca
ggtattgtgt
cttaggtttg
cgcactgtct
ccaggtcact
ggatctgagt
gattttaact
gtttataaaa
gaggttgttg
gcaagacttt
aagagaaatg
gctagagctc
caccagaagc
actaaattct
ggttgtttga
atggcttccg

attgcattct
tttgagaata
attgcctatg
caacttttga
gcttcagtgc
gaggcacgcg
ggtatgctta
ggcgtgttac
cctaatcttg
atttggtcaa
acagctgcca
aagttgcaga
gctacaattg
aagagcttta
agcaacaatg
gttaatggtc
ggtgctgttc
cacccatcta
tatgttgatg
aatggtgccg
tcttatggtg
gatggattgt
attagattct
tgtatgtgtg
tgcggggttc
gtagagcttt
attgttcccg
ctaagagcgt
ttgctgaaca
gtaaggatct
aaaagaactg
tttttgaaaa
caagacttgg
ttgtggaaaa
tttacgattt
catattattc
ttgtgaaaag
tcacggacca
accctaattg
cgttattttc
tagatggtgt
ggaatcttga
tcactgaccc
gtttctccat
ttaacaagga
tgacattgaa
attaccgtta
ttgtgtgtaa
tcaccaacta
actatgagac
ttctacccac
gtactgtggg
atttgaaatc
atggtggctg
tgggatggga
caatggtatt

ttttgtccaa
ccactatttt
aacaagctcg
aacagcttac
aaaagaagct
ccgtggacag
agaaactcga
cattgagtat
aagtgctttc
ttgttgaagt
atgaattaaa
ataatgaaat
atggtgatgc
tatatgcatt
atgtaatacc
ctgaggttaa
ttggttatat
atagtggttt
ctgttaagcg
gtaatggtat
gcgcatctgt
gccgctttaa
gtattgaaaa
atcgtacttc
tagtgcagct
tgacatctac
ttttaggaat
tatggaccat
tgacttcttt
tacaaagtac
tgaagttctt
caaggattgg
acctatagta
aggttacata
cggtgatttt
ttatatgatg
tgatatctat
taaggaaaaa
ctctgattgt
aatgaccata
gccagttgtt
tgttaaatta
cacattactt
tgcagctttg
tttctacgat
acacttcttc
caacagagtt
gtactttgat
tgataagagt
tctatcatat
aatgactcaa
aggagtgtcg
tattgctgcc
ggacaacatg
ctatccaaag
gggttctaag

gcataacaca
acagagtgtg
tgcagatcta
aaaggcgtgt
tgacaaaatg
gaagtcgaaa
catgtccagt
tataccagct
caaggttaga
taaggatgct
cataacctgg
cttgccaggt
ttatggtagc
tatagcatca
tattgaactt
atacttgtat
cggtgcaaca
gctgacattg
aggtatgcag
ggctatcaca
atgcatttat
aggtaaattc
tgaagtttgt
tatgcaaggc
cgactagaac
aataaagatg
ttagacaaac
gagcaagtct
ttgtataagg
acaatgatgg
aaagaaatac
tttgatccag
gccaacgcta
ggtattataa
gtaaaaacaa
cccttaatgg
ggtgctgatt
cttttccaaa
acaagtgatg
cctaatactg
gttactgctg
gacactatga
gtagcatcaa
agtactggtg
tttataacag
tttgcacagg
actgttttag
tgttacgatg
gctggttacc
gaggagcagg
atgaatttga
cttctttcaa
acacgtaacg
ctaaagaatt
tgcgaccgtg
cacattgggt

tgtgacctta
gcatctgctt
gaagaggcta
aatatcgcta
gcagagcagg
atagtttcag
gttaatacta
gcctcagcta
caggaaaaca
aatggcgctc
cccttgagta
aaacttaaag
ggtaaagcgc
gacagcaacc
gaggctccat
tttgtgaaaa
gttcgtctgc
tgtgcttttg
ccagttacca
aatggtgtcg
tgtagatgtc
gtccaagtac
gtcgtttgcg
accactattg
cctgtaatgg
ttgcatgtat
atgatgccta
gttataacga
aaggtcgatg
atctgtgtta
ttgtgacatt
tagaaaatga
tgcttaaatg
ctcttgataa
cgccaggttt
gaatgacttc
ataagcagta
aatactttaa
agtgcattat
catttggacc
gttaccattt
agttgactat
gccctgcatt
ttacatacca
agcgtggatt
gtggtgaagc
acatctgtca
gtggttgcat
cacttaataa
atgcgctttt
aatatgctat
caatgacgac
ctaccgtagt
tgatgcgtga
ctttgcctaa
gttgtacaca
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14701
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15301
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15541
15601
15661
15721
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15841
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16081
16141
16201
16261
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16621
16681
16741
16801
16861
16921
16981
17041
17101
17161
17221
17281
17341
17401
17461
17521
17581

tagtgatagg
ttgtacaggt
gtatgctaac
aggagtagat
tgataattgt
tttaagaaag
agattatgct
tcagaacaat
accacatgaa
cctaccttat
taagacggac
actcacaaaa
taaacactta
ggaggatggt
tactgtcttg
cggagactgt
tacaaaacat
tgttaatgat
accacaatta
tgcaattggt
tgtagaggat
aaccgtgaaa
ggttgtcgga
taacagaaat
tgaatttgtg
cactactaag
taaagctaac
gtttaatata
aaaatttaca
gggtttgtat
tgctttatgt
tcaaagaatc
tttgttttgc
agtatcaatg
tattgtttat
cacactccaa
tgtatttttg
tgtttacgag
tgtaaaaggc
tgtcaaggca
caacagtcaa
tgcgcaaggt
tattaatgtc
catgtgtgac
tggcttgcaa
gtacatacca
tgatggctta
tatggggttc
ctttgctatg
tggtgataat
tgtagtacaa
agcaagagca
atcgtggcat
gtcagacatc
ctttgttaag
tagctcacaa

ttctatcgac
ggtttttata
tcggctttta
tcaaacacct
taccgtagta
cacttctcta
gatcttggtt
gtatttatgt
ttctgttcgc
ccagaccctt
aacgtcatta
caccctaaac
cagaagactc
caagataaat
caagctgctg
ttaaggagac
aaattcatta
gttacaaaat
tcattcccgc
tctgaagatg
tataaacttg
gcaaaggagg
cctaaggaag
tctgttttca
tttgagcagt
ctggcaccgg
attttagtca
gcggaggcct
actatccaag
tatcctcaag
gaaaaggctt
agagttgatt
acagttaatg
tgtacaaact
gtaggtgacc
cctgaggact
cacaaatgtt
aataaatttt
caagttcaga
tttttagcac
aattatgtgg
agtgagtatg
aacagattta
agaaagatgt
gcaaaacctg
ccagcatatg
gctgttaaca
aggtttgagg
cgtaatgtta
attggaacta
actgaaggat
ccaccgggtg
attgttaggc
ttaatttttg
attggaaaac
tgtgtctatg

tctctaatga
taaaacctgg
acatctttca
gtaacaatgt
gcagtgtaga
tgatgatttt
atgtagcaga
ctacagctaa
aacacaccct
ctagaatttt
tgcttgaacg
ctgcatatca
taaatgctgg
tctggagtga
gcatgtgtgt
cccttttgtg
tgtctatcac
tgtttttggg
tctgtgctaa
ttgatgattt
ctaacaacgt
aatctgttaa
ttgtactcca
cgtgttttca
cagaatatgg
gtatgatttt
accaagagaa
ataccacatt
gtcctcctgg
ctagaattgt
ccaagaactt
gctatatggg
ctttgcctga
atgatctcag
cacaacaact
acaacgttgt
acagatgccc
tacctgtcaa
ttgaatctaa
ataatccaaa
cacgacgtct
attatgtcat
atgttgccat
atgataatct
aaacttgtgg
ctacgacata
tcggtacaaa
ccaatgtacc
gagcatggct
atgtaccact
gtgttgttac
agcaattcgc
gtcgtatagt
tgctatgggc
cacaaaaatg
cttgttttaa

gttagctcaa
tggtacaact
agctgtttct
tacagttaag
tgatgatttt
gtctgatgat
cattggtgcg
gtgttgggta
acagattgta
gtcagcaggt
ttatgtgtct
aagagtattt
tatacttgat
agagttctat
tgtttgtggt
cactaagtgc
accgtatgtg
cggtcttaac
tggtaatgtg
caacaaactt
taaagaatct
agctgaatat
atgggaatcc
gataaacaag
tagtgattct
tgtgttgacg
gtacaatacc
ggtgccttac
tagtggtaaa
ctatacagca
taatgttgat
ttttaaacct
agctaactgt
tgttataaat
tccagcacct
gactcagagg
agctgaaatt
ccctgagtca
ctcttctata
atggcgtaaa
actaggtctg
ttacacacag
tactagagca
tgatttctat
tttgttcaaa
tatgagtttg
ggatgttaaa
aggctaccac
aggttttgat
acagctgggc
tgaaaaaggt
gcacttgata
gcagatggtt
tggtggtctt
tgagtgtggc
acatgcatta

gtactcacag
agtggtgatg
gctaatgtta
tccatacagc
gttgtcgaat
ggtgttgttt
tttaaggcca
gaaccagatt
ggaccggatg
gtttttgtgg
ttagcaatag
tatgctcttc
tcattctctg
gccagtcttt
tcacaaactg
gcctacgacc
tgtagctata
tattactgta
tttggcctgt
gctgtttcag
ctgaaaattt
gcttatgcca
tctaagatta
gatactaaaa
atttactata
tctcataatg
atatccaagc
tatcaaatga
tcacattgtg
tgttcacatg
aaatgttcaa
aataatacca
gacattgtgg
agtagactga
agaaccttga
atgtgtaaac
gttaaaacag
aagcagtgct
aacaacaagc
gctgttttta
caaacgcaaa
acatctgata
aaggttggca
gaactcaaag
gattgttcaa
tctgacaatt
tatgccaatg
acattgtttt
gtcgaaggtg
ttttcaaatg
aatagcattg
ccactcatga
tgcgactatt
gagcttacaa
aaaatggcaa
ggatgtgatt

aggttgtaca
gtactacagc
acaagctttt
gcaagatata
actttagtta
gttacaataa
ccttatatta
ttaatgttgg
gtgattacta
atgatattgt
atgcatatcc
ttgattgggt
tcactatgtt
atgaaaagtc
tgttacgttg
atgtcatggg
atggttgtac
ctgaacacaa
acaagagtag
actggaccaa
tcgctgctga
tattaaagga
aacctccact
ttcagttagg
aaagtactag
tgagtccact
tctatcctac
tcggtaagca
ttataggttt
cagctgtgga
ggataatacc
atgcacaata
ttgtggatga
gctacaaaca
ttaacaaggg
taggacccga
tctctgctct
ttaagatgtt
aactagaggt
tctcacccta
ccgtagactc
cacagcatgc
ttctctgtgt
attcaaagat
agaatgacca
ttaagacaag
ttatctcata
gcacacgaga
cacatgtttg
gtgtggattt
aaattgtaaa
ggagaggtca
tcgacggctt
ctatgcgata
cttgctatag
acttgtacaa
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20641
20701
20761
20821
20881
20941

tccttattgc
tgaagtttgt
gtgccttgct
tattgaaaac
agctgctctt
tcgttgtgct
tgttagatgt
ttggaattgt
aacccgctca
tgcatttcac
cttttattac
taagtccaat
tgcactctat
ttggtgtcct
actccagagc
aaaaggtgac
tgataagtgt
tgcaaagcgc
cgcaacacat
taagcaagtg
tattagtggt
tgctgtgaaa
aagtactgta
cgttgaacag
tagtacaatg
tcttgaggat
tggtatgcat
agaatttatg
tccatcttct
cgttaagagc
ggcatggaga
ccaatcttcc
gtgtctcgaa
tactactaat
tgttccacat
tggtactacc
gagagattat
tgaggataaa
tggtgaaaac
gctagcgctt
atatgaatta
gtcatcagaa
agtggatggt
attgtcacat
tgttgttaat
taaaatactc
accatgatag
ggtgttacct
tataacttct
ctaccctact
gtgggacaaa
cacggtgttt
agagttggct
caagacaaag
ggtaatataa
tttaaccaga

attgacatcc
aacattcata
atatatgatt
gaagaaaaga
aaggttttca
acgacaccca
ctggagtatg
aacgtagaca
aaactgtcat
acaccagctt
gatgagagtg
gtttgcataa
agagcgtatg
caaaattttg
ttggaaaatg
ttaccaacag
attttcacaa
aaacttggac
aaatttgtgt
tgtgcttaca
tcttttgaac
ggacttagtg
ggaaacaaac
attgacagtt
gaagaagact
tatggttttg
cttcttatat
aataattctg
aagaatgtgt
ttagatctta
tggatgttgt
gagtggaatc
cggtgtaatc
gtcgttaagt
aaaatgcgtg
gtattaaaaa
gtttccgacg
tttgatttgc
acgtctaagg
ggaggttctg
attcaaagat
ggtttcctga
aatataatgc
aactcagttc
ttaaaagaaa
attagaaata
tgttaatatt
tacctcaatt
tacaaacttg
gtggagacgg
atggtaggca
actttgatgt
tattgatagc
tagaggaaaa
gttcatacca
gattttcatt

aacaatgggg
gaaatgagca
gttttgtcaa
tcaataaagc
accctgctgc
taccgtggtt
attacatggt
tgtacccaga
tagaaggttg
acgatagaag
actgtgagtt
caaaatgtaa
ttgaggacta
acacttacat
tagcttttaa
cagttgttgc
ataaaactag
tcacacctcc
tgtgggatta
ctgatcttga
gctttactac
ccattaaatt
ctgtcacatg
attatacaca
ttcttagtat
aacacgttgt
cacaagtgcg
acagtacact
gcacttatat
acgtcgtgtc
ggtgtgagaa
caggctatag
tctacaatta
atacccagtt
ttctgcattt
gatggttgcc
cagacttcag
ttatatctga
atggcttctt
ttgccatcaa
ttgagtattg
taggtattaa
atgccaatta
tagatactcc
gagaattaaa
atggtaagtt
tgcactcctt
taacacttcc
ggacatacct
cccgaattgt
ctcttacata
aagagaacat
catttatggc
ccaaccccat
tcaatttagt
agacaccgtg

ctacacaggt
tgtggctagt
acgtgtagat
tggtcgcatt
aattcatgat
ttgttatgat
acatggacaa
gttctcaatt
taatggtggt
agcatttgct
tattgatgga
cattggtggt
caatgtgttt
gttgtggcaa
tgttgttaaa
tgataagatc
tttgcctaca
cttaacaata
tgaagctgaa
tggtgaagtt
tacgaaagat
acaatatggc
gtacatctat
gggacgtact
ggatactaca
atttggagat
ccttgcaaaa
gaaaagttgt
ggacatactc
gaaagttgtg
ttcacaaatt
catgcctaca
tggtgcacaa
gtgtcaatac
aggagcagca
agatgatgcc
tgttacaggt
tttgtatgat
tacatacatt
aatcactgaa
gactgtgttt
ctacttggga
tatattttgg
caaatttaag
tgacatggtt
actaaacttt
agcactgcta
tctaacaatc
ccaaatacag
ggatggtata
aacactaaaa
aattctgatg
acctcgtatt
gtggctgtta
gtcaatctag
ttgactgcta

tctctgagca
ggtgatgcta
tggtccattg
gtacaatcac
gttggtaatc
cgtgatccta
atgaatggtt
gtctgtagat
gcattgtatg
aagcttaaac
caacctaatt
gcagtctgca
gtacaagctg
ggttttgtta
aaaggtgcct
atggtgaggg
aatgtggcct
cttagaaatc
tgtcctttct
gtaacatgtt
gcagtgctta
tttttgaatg
gtgcgcaaga
tttgaaacct
ctcttcatcc
gtttctaaaa
atgggtttgt
tgtataacat
ttagacgatt
gatgttattg
aaaaccttct
ctttacaaaa
gtgaagttac
ctcaatacca
ggtgctaatg
atattggttg
gattgtacta
ggttccacca
aatggtttca
tttagttgga
tgtacaagtg
ccatactgtg
agaaactcca
tgtcgttgta
attggattgc
ggtaatcact
ggtctgaaga
agaagttcga
aaactattct
attttgttta
atctgaacat
gtttgtggga
acagtctact
aaatctgtca
aagatggtgg
atgattttta

tgaatcatca
tcatgactag
tgtacccttt
atgtcatgag
caaaaggtat
ttaataacaa
taatgttgtt
ttgatactcg
ttaataacca
ctatgccatt
atgtaccact
agaaacatgc
gttttataat
atggcaaagc
tcgccgatct
atggacccat
ttgagctgta
taggtgttgt
caaactttac
ttgataatag
tttctaataa
atttacctgt
acggtgagta
ttaaacctcg
aaaagtatgg
ccaccattgg
tttctgttca
atgctgatga
ttgtgactat
tagattgtaa
atccacaact
tacagcgtat
ctgacggcat
ctacactatg
gtgttgctcc
ataatgatat
acctctatat
agtctataga
ttaatgagaa
ataaaagttt
ttaacacctc
acaaggctat
caatcatggc
acaacgcact
taaggaaggg
ttgttaacac
tgcccctcat
acttaatttc
aggcggttac
tagtcaaaat
accgaatgtt
tgcgcgtgat
aatggtttta
ttggaaaccg
tcaatgtgtg
tggtttccag

208
21001
21061
21121
21181
21241
21301
21361
21421
21481
21541
21601
21661
21721
21781
21841
21901
21961
22021
22081
22141
22201
22261
22321
22381
22441
22501
22561
22621
22681
22741
22801
22861
22921
22981
23041
23101
23161
23221
23281
23341
23401
23461
23521
23581
23641
23701
23761
23821
23881
23941
24001
24061
24121
24181
24241
24301

tggactgaca
aatgactgga
tattacatac
aattatacgc
aacgtttttg
ctgttatcag
gtacaatgtc
aatgacctct
gacagtgatg
aatacaaccg
aatagtagcg
tctgttgtga
ggtagggatg
agtgtcaact
aattatacag
gactcacccc
tattctgcta
ttctacaatt
gatatcatct
ctccaagcta
gctctatttt
ttacaaaatt
actttgtgtt
gttaattggc
acaactatgc
tgcactgatt
cgattagtgg
agtactactg
attaacgatg
gtcaatcaca
aatatgccgc
tctgtcatca
gtcactcatg
atattaatac
aaacctgttg
ttgttaacac
cgtcttgaat
gcaaccattg
tttgatggtc
ctattgttca
tgctctgctg
gttttacccg
ggtatggctt
gctaggctta
gctaatgcct
gctgttacaa
agtgtggtta
ttccaggcta
gatgcccaag
caaactttaa
aatgagtgcg
ttctcacttg
acagaatggg
gtgttgaaag
cgtaacatgt
gaagtgactt

catatgtcga
gttctgttga
aatttgtcaa
acttgcagtt
tgccaattga
ataaatccac
ttaggcctgt
attgccctgg
tttacacaga
catccatagc
tatctcacat
gcagacaagt
gttccgtttt
tctctattag
atgtaatggt
tcaatagaat
gcatgcttgt
ggatgcatat
tagctgaggc
acggaagtgt
ataaatatac
atgactgccc
ttgatgtgaa
gtacacagtt
caagggcaca
ataacatata
ctggccttta
gggagatttt
agatagtggg
cacaagcgaa
aattttatta
cttattcctc
ttgaaactgt
ctaaaaactt
ttgtggattg
aatacacctc
cgttgatgct
aaaagtttaa
tgagcagtct
ataaggtggt
gtacagatgt
gcattgtaga
tgggctctat
attatgttgc
ttaacaatgc
ccatttcaga
atcaacaggg
ttagcagttc
ttgaccgcct
ctcagtatgc
tgaaatcaca
tcaattctgc
aagaagtgac
atttcgatca
ttcaacctag
ttttgaacac

catctactta
agccagtatt
cagaaccacg
agcagagtgc
tggcaaaata
tttagtgcaa
accaacctgg
tgttacggct
tttaactaat
ttgttatagc
cccacttggc
cttgggtata
tgttaatggt
ttcagttgag
ggatgttaat
caagtgtcaa
taaaaatgat
tacgctacat
ccctgaacta
cgtgaatgtt
tagtttacaa
tttctcacca
cccagctgtg
cgccaccatc
gctgggtttc
tggatttcaa
ctacacatct
cactgtagtg
agctataaca
gagatcacgt
cataacatgg
ctttgctatt
ggacgatata
tactgttgca
tgccaagtat
agcttgtcaa
taatgatatg
cgccacagcc
attaccaccc
aaccagcggt
agctgatcta
tggtaataag
cacatccgct
attacaaact
cattggtaac
cggctttaac
tgaagcgctg
tattgctgaa
cattactggc
tgaagtcaag
gtcggatagg
acctgatggt
ggcatggtca
ttccattttt
aaaacctcag
tacatatacg

ggaggcacta
tcataccact
tattatacat
catagtgaat
ccagaaagct
ggacgtgttc
tccaataata
gaagttttga
gatgaccagt
agtgctaatg
aaaactattt
ctgccaccaa
tacaaatatt
cagtatggtt
ggcactggta
caattgaagc
ttacctaaaa
gtcgtgttga
gcctcacttg
accagtctat
ggtttgtata
cagcatttta
gcaggttgta
actgtctctt
aaagacatct
ggcacaggca
attagtggtg
ccatgtgatt
tctgttaatc
aggccgacat
tggaacaatg
tgtaatactg
ggtgttatca
gtgcaagccg
gtttgtaatg
acaatcgaaa
atcacagtat
acaggtggtg
aaaataggtg
cttggcactg
gtgtgtgccc
atggccatgt
gtagctgtcc
gatgtcctac
atcacactag
accatggcct
agtcaactta
atttataata
aggttggcgg
gctagtaggc
tatggtttct
ttgcttttct
ggaatatgtg
agctataaca
atgagtgatt
atgtttcaga

ttactaaggt
ggaaccagat
acaataatac
actgtgctgg
tctcttttag
ttagtaggca
gtgctgtggt
ggttcaactt
tttatttcac
ttactgattt
gttttgccaa
ctgtacgaga
ttagtttacc
tttggaccat
tcagcaggtt
atgtattacc
catttgtaac
acgacactgc
ctgatgtaca
gtgtccaagc
cttattctaa
ataattattt
agtggtcgtt
ataaagatgg
ctaatttagt
ttattagaag
atcttctcgc
taacagtgct
aaactgatct
cacactcggt
acacctcgac
gtgaaatcaa
aacctatttc
aatacattca
gcaatacaca
atgcccttaa
cagatcgtag
taaaactggg
cgaggtctgc
tggatgatga
aatattacaa
acacagcatc
ctttttccat
aggaaaatca
cacttggaaa
cagccttgac
ccagtcagtt
gattggaaaa
cacttaatgc
aactggcaat
gtggcaatgg
ttcacacagt
ttaatcatat
acacgtatat
tcgtgcaaat
atattgtggt

gtgggttaac
taattatgga
tggcggttca
ttatgctaag
taactggttt
gcctgtcctt
atttttcagt
gaactttagt
atttgaggac
ccagcctgca
tttctcacac
gtttgcattt
acctatcaag
agcttacacc
gttctattgc
agacgggttt
tatgccacag
gaagaaagaa
ctttgaaatt
aaaacagttg
tttggtggag
gcagtttgaa
agttcatgat
tgctatgata
aaaagatgaa
caccacctca
ctttaaaaat
agcagctgtg
gtttgagttt
aaccacctac
taattgtacg
atatgttaat
aacaggtaac
gattcaagtc
ttgccgtagc
ccttggtgca
tctggagctt
tggtctatac
tgttgaggat
ttacaaaaag
tggcattatg
tttaattgga
gcaggtgcag
gaaaatactt
agtttctaat
taagatccag
acagaaaaac
ggcggaagct
ttacgtgtct
ggaaaaagta
aacacaccta
tttgcttcct
ttatgcatat
ggtaactcct
tacgagttgt
tgattatatt

209
24361
24421
24481
24541
24601
24661
24721
24781
24841
24901
24961
25021
25081
25141
25201
25261
25321
25381
25441
25501
25561
25621
25681
25741
25801
25861
25921
25981
26041
26101
26161
26221
26281
26341
26401
26461
26521
26581
26641
26701
26761
26821
26881
26941
27001
27061
27121
27181
27241
27301
27361
27421
27481
27541
27601
27661

gacattaaca
gaattagaat
gaccaattag
atcgacaatc
gtaaaatggc
ttgttactgt
tgttgccact
cacattcact
ctgtacttga
ctggtagatt
cttatgccaa
acagtttacg
atcataaata
aacactctaa
gattctatag
ttcagcaccg
gtatgtgtcg
atagcatttg
gtttacttag
acgacactaa
atttatgtca
tttgtagacc
gttgttagag
gtcgtaggag
gaagaagaag
catggttatg
agcattgcta
agtactacct
taattccgat
tcgcgtgcat
ctaatacttg
ttatttggca
cagtgttaca
tcatgtggct
accaagtttc
cactttggat
ggtcttttaa
ttctaccctt
atgctgaagg
tgattgctac
ctactgccac
cacgtactga
aaatggccac
ggtctaactc
ctcttgagtc
taggtaataa
gaggccagcg
atgctgatgc
ccatgaataa
aatttgatgg
caaggtctgg
aacagtccaa
taggtgttac
ccagggatac
gtgatgtgac
tcgttgccaa

agactatcgc
tacagctcga
aacaaagagc
ttaataagac
cttggtatgt
tttgctgttt
ctctttgtag
aactaaacga
cgagttaaac
acttgtgtgt
acttcatctg
atttttgtgc
atacaaaacc
gttttatagt
tacaacaaca
ctgttctctt
gcgtcttaat
gttactatat
catacttttg
tgtttgtaca
cattatatgg
ctatgcttgt
cagttgaact
tttacaatgc
agcgtgtcta
agcgtcttct
aatgttatta
gcacgccatg
gaagcatttt
aattgcatgc
catcaatggc
tcttgctaac
atatggcaga
attatggcct
cagatatgta
gatgtatttt
tcctgagacc
agatggtaca
ttttaaaatg
acctagtaga
gggatgggct
taatttgagt
acagggacaa
tcgtggtcgg
aggatcaaaa
ggatcaacaa
taaggaactt
taaattcaaa
gccaacaaca
taagatacca
ttcccagcct
taaccagaat
tgacaagcaa
aacacctaag
aaatttctat
tggtaacgct

tgatatgctt
aatctttaat
tgacaatctt
tctcgttgac
gtggctacta
gagtactggt
tagaagacaa
tttatggaca
gccattgcat
ataggttttg
gatattgaag
taaaaactgg
taaaacagca
cactaatcaa
acatgttgtt
tgttttattt
gtttaagata
agatggaatt
gtatgttaat
tgacagagct
aggcataaat
aggcatagct
tctcaatggt
agccttttct
tgatgtttcc
tctggctcct
aactatgcat
catatgatgc
tggtttgaac
gtttttggtg
actaattcct
tggaacttca
ccacaattta
attgttctag
atgttcggct
gtgagatcta
aacgcaattc
ccaacgggtg
gctggtggtc
accatcgttt
tactatgtaa
gaacatgaaa
cgcgtcaact
aagaatggta
ttttggaaca
attggttatt
cctgagagat
gataaaattg
cttggcactc
ccacaattcc
agatctgttt
actaatgttg
aggtcacgtt
aatgccaaca
ggtgctagaa
gccaaatgct

gaacaatatt
cagacaaagt
actaccattg
ctcgaatggc
attggcttag
tgctgtggat
tttgaaaatt
ccgtcaagtc
ttgctgtaac
gtgatacttt
agtcgcctaa
tataaattac
agtactataa
catgtgattg
aatgctagta
ttagctttgt
gtttcaatga
gtgacaacaa
agtaaatttg
gcaccgttta
tacatgttcg
atacgtggcc
gtttttattt
caggcggtta
tagggcattt
gttgataatt
ggtatgttgc
ctataagacc
taaacaaaat
aacgttattg
catgtcaaac
gctggtctgt
gctggctcgt
cgcttacgat
ttagtattgc
ttcagctata
tttgtgttaa
tcactctcac
ttaccatcga
acacattggt
aatctaaagc
aattattaca
ggggagatga
atatacctct
tatgtccgag
ggaacagaca
ggttcttcta
atggagtctt
gtggaaccaa
agcttgaagt
caagaagcag
aggatacaat
ctaaatctgg
aacacacctg
gtagttcagc
accctcagat

attctaatta
taaacctcac
cacatgagct
tcaacaggat
taatagtctt
gctttggttg
atgaacctat
tattggcatc
acttaaggtg
tgaggaggct
tcatacgact
cttttgcagt
aacgtagaag
ttaataacac
ttaaaagttt
accgtagtac
cacttatagg
ccgtcttagc
aattcatctt
tgagaagttc
tgaatgatct
tagtccgtgc
atatattttc
taaacgaaat
accatcatag
atattgatat
aatttgggta
tttatgcaaa
gaagtacgtt
tgccatgaag
ctgctttgaa
aatattgatt
ttatggcatt
ttttaatgca
aggtgcagtt
tagaaggacc
tgcattgggt
tttgctttcg
gcatttgcct
tggaaaacaa
tggtgattac
tatggtgtaa
accttccaaa
ttcatacttc
agattttgtt
ggtgcgttac
tttctcaggt
ctgggttgca
caatgaatcc
gaaccgttct
gtctcaatct
tgtagccgtg
agaacgtaat
gaagaaaact
caactttggt
agctgaatgt

cacaacgcct
tgcagaaata
acagcagtat
tgaaacttat
ctgcatacca
tcttggaagt
tgaaaaggtt
tctgtggacg
ttatttaatt
gaacaaaaag
tcttaatatc
cagattgcgt
aagggttgtt
accacatgtc
tcatttagag
aaactttaaa
acctatgctt
tttaagattc
atacaataca
tcacggccct
tacgtagcat
tgacctaaca
acaggaggcc
tgatttgaaa
atgaccatgg
tgttttcaat
agactattat
ttaaggccta
ttgttaatac
gatgactcgt
cgtggtgatc
gtttttataa
aaaatgctga
tactctgagt
gtaacgtttg
aaatcatggt
agaagttatg
ggaaacctat
aaatacgtca
ttaaaagcaa
tcaacagaag
ctaaacttct
agacgtgatc
aaccccatta
cccaagggaa
cgcattgtca
acaggacctc
agggatggag
aaacctttaa
aggaacaatt
agaggaagac
cttagtaaat
caatctaagc
gcaggtaagg
gatagtgatc
gttccatcag
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27721
27781
27841
27901
27961
28021
28081
28141
28201
28261
28321
28381
28441
28501
28561
28621
28681
28741
28801
28861
28921
28981
29041
29101
29161

cgtctagcat
tcacactcac
aacagattga
cccgttctaa
acacagatgt
atgctcgttt
atccaattac
gttttaggtg
tgtcttgatt
ctgcgagtga
ttttaacatc
taccactgtg
ttggacacac
ttgagtgtga
tattcctttg
ttagttggtg
gtagaccttc
ggtagacatc
catggttatt
aaggtcttcg
aaaactggtt
aagcacgtgt
ttggcaatgc
atggaagagc
tccttttgat

actctttggc
tcacacctat
tgcttataag
gtctgctgat
gtttgatgac
tcctacatgc
tagaaaggtt
tgcctgacag
ttaacatcct
tctttctagt
atgattgttg
caacctgaca
tctttacatt
gagtattgaa
tagatgaatt
ctgtgccaaa
catttggcac
tagagtgtac
gctttaatga
acaaactcaa
tttccgagga
aataggaggt
tagatttagt
taacgtctgg
agtgataaca

agtcaatggt
tacctgccaa
caaccttctg
aagaagcctg
acacaggttg
tgtacttgta
gttactcagt
tagtctgcgt
acataaagtt
tcttctagga
tactccttgt
cccatgaaca
acaacgtatc
tgatcatatt
ttatattgta
acaaaagaga
tcagatatac
tcacagagtc
gaagctgaag
ccaacatcgt
attactggtc
acaagcaacc
aatttagaga
atctagtgat
acaaaaaaaa

ctgctgaaga
aagatgatgc
aagtggctaa
aggagttgtc
agatgattga
acagctttaa
catctgctta
gtaaattgtt
ttagcagaaa
ttttcctgct
gtgtgttttc
tccagtcctc
agatcttagc
gatttttatt
ggtgaaggaa
ttaaatgttg
catgacaggg
tactttgtga
gtttatgacc
aaaactgagt
atcgcgctgt
ctattgcata
agtttaaaga
tgtttaaaat
aaaaaaaa

agctggtgat
caaaaccagc
ggatcagagg
tgtgactctt
tgaggttacg
tcttactact
atctcacaac
tgcaactttt
tcagattact
atacattgtt
ttggctaatg
acctgggact
actaccgctt
tcgatctttc
atcaaagaat
gttgccatac
attttcaaca
agtactgccc
tgaagcaact
tataaggcaa
ctactcttgt
ttaggaagtt
tccgctatga
gtaaaattgt

caagtgaaag
caattcctag
caaagaaaat
gtagaggcat
aactaaacgc
aattggtaga
agtcagtaat
gaaaccagac
agtagtagta
aggtgcatta
gaattaaagc
tgttgcaaca
ggatctcgtg
caaccctttc
taatctcaga
atcatttgct
ccctgctagt
atacaacttg
cagaagcaag
cccgatgttt
acagaatggt
tagatttgat
cgagccaaca
ttgaaaattt

APPENDIX D
FELINE IFNAR2 SEQUENCING ALIGNMENT
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212
Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

1 MLWSQNTSWIRPHDLYPVVYLVVCIGLMVGVVSAWPDLSDESCTLKVTFRSFRLILSWELKNHSIAPTHYTLWYTVMSKP
1 MLWSQNTSWIRPHDLYPVVY----IGLMVGVVSAWPDLSDESCTLKVTFRSFRLILSWELKNHSIAPTHYTLWYTVMSKP
1 MLWSQNTSWIRPHDLYPVVY----IGL-IG--MA*

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

81 DDMKIVEHCSNITASFCDLTDVWEVLPETYIPRVDGFRGNTMLVSCISDFFLATHVSLEPPDFDIVGSTNHINVIVKFPP
77 DDMKIVEHCSNITASFCDLTDVWEVLPETYIPRVDGFRGNTMLVSCISDFFLATHVSLEPPDFDIVGSTNHINVIVKFPP

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

161 VIPKILNGELLQYYLPLVIEEQSGKIVKKHHPKLNGNIIGNVTYVIDKLIPNTNYCVSVYFKSKDMGAINRSPVKCTFLQ
157 VIPKILNGELLQYYLPLVIEEQSGKIVKKHHPKLNGNIIGNVTYVIDKLIPNTNYCVSVYFKSKDMGAINRSPVKCTFLQ

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

241 PGQETESSESAKIGGIIIMFLIAAVFISTILILKRVGYICLRNDFPKVLNFNNLSSWVFLERPPLETVAFVEVIHVNRKK
237 PGQETESSESAKIGGIIIMFLIAAVFISTILILKRVGYICLRNDFPKVLNFNNLSSWVFLERPPLETVAFVEVIHVNRKK

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

321 KVWDYNYDDESDSNDEVAPPISGGGYTMHGLTGRLLGPASASSATLEDCNQPDAEEPDQSEPEADTEPLMAAWPSPGQSE
317 KVWDYNYDDESDSNDEVAPPISGGGYTMHGLTGRLLGPASASSATLEDCNQPDAEEPDQSEPEADTEPLMAAWPSPGQSE

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

401 CCKSGAYKERGRLPQDPVSEDDDSASEGSGDKITFNVNLNSVFVRIPDDDSEVPPTSPPFLEETANLEDSDETEISFLAA
397 CCKSGAYKERGRLPQDPVSEDDDSASEESGDKITFNVNLNSVFVRIPDDDSEVPPTSPPFLEETANLEDSDETEISFLAA

Feline IFNaR Full
CU IFNaR Consensus
IRN IFNaR

481 SGEGTQPPFASPSAECPWPEDALSDKSDSSESDADIRDGYIMR
477 SGEGTQPPFASPSAECPWPEDALSDKSDSSESDADIRDGYIMR

Feline IFNαR2 Amino Acid Sequence Alignment. Amino acid sequence alignment
[CLUSTAL W (1.7)] of feline interferon alpha receptor domain 2 (IFNαR2) comparing a
published sequence (GenBank #NM_001278859.1) with the sequences determined
from Fcwf-4 CU and Fcwf-4 CU IRN cells.
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